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ABSTRACT 
Following injury, adult musculoskeletal wounds undergo a process of repair, the body’s way of 
quickly closing an area of damage. Repair is characterized by the development of granulation 
tissue (scar) which lacks the structural and functional properties of the native tissue’s 
extracellular matrix (ECM). Scar formation has been linked to the presence of inflammation, as 
injuries in environments with little inflammation (e.g. fetal) heal via regeneration, in which the 
synthesized matrix physiologically mirrors that of the tissue pre-injury. The limited ability of the 
adult body to regenerate these tissues following injury as well as resolve excessive inflammation 
associated with injury or material implantation, calls for strategies to enhance and support the 
restoration of these tissues to their natural state. Through the use of collagen-based extracellular 
matrix mimics, this thesis describes bioinspired scaffold compositions aimed at providing 
inherent cues to direct cellular behavior towards regeneration in vivo. Growth factors play a 
significant role in the overall health, function and phenotypic fate of cells in vivo and in vitro. 
We used charged glycosaminoglycans (found naturally in the ECM) to electrostatically sequester 
growth factors within the collagen matrix, preventing biomolecule degradation and presenting 
relevant factors to fibroblasts and mesenchymal stem cells. We showed that these 
glycosaminoglycans could also influence the three-dimensional delivery of charged-based gene 
vectors. While necessary to prevent infection during wound healing, inflammation, especially if 
it is prolonged, contributes to scar formation. By incorporating the anti-inflammatory matrix of 
the amniotic membrane into the collagen ECM analog, we sought to provide a biomaterial that 
would temper this inflammatory response to allow for tissue regeneration. This fetal 
environment-inspired material was studied in fibroblast, stem, and immune cell populations in 
vitro and in an in vivo animal model. Overall, this work demonstrates the effective modification 
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of scaffold composition in order to address issues of transient growth factor sequestration, gene 
delivery capacity, or immunomodulation.  
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CHAPTER 1: INTRODUCTION AND BACKGROUND: TISSUE REGENERATION, 
MIMICRY OF THE EXTRACELLULAR MATRIX, AND NATURALLY-INSPIRED 
BIOMATERIALS* 
1.1 Thesis Overview 
This thesis will focus on the manipulation of collagen-glycosaminoglycan scaffolds for the use in 
tissue regeneration applications. As a whole, this dissertation describes the use of compositional 
changes to enhance the material’s inherent bioactivity and ability to manipulate cellular activity. 
This goal can be further broken down into two different strategies: using electrostatic 
interactions via glycosaminoglycan charges to enhance growth factor and gene delivery 
(Chapters 2 & 3) and using the amniotic membrane to alter the cellular immune response within 
the scaffolds (Chapters 4, 5 & 6). 
1.2 Motivation 
1.2.1 Injuries to the tendon and tendon-bone junction 
Tendons are connective tissues which act to transmit high tensile loads from muscle to bone, 
resulting in movement. Depending on their functional role (positional vs. energy-storing), 
tendons in the body can display significantly different mechanical and structural properties. 
Positional tendons, such as the human anterior tibialis, serve to transmit muscle-generated forces 
to bones to enable locomotion [1]. They are relatively inextensible under load (max. strain: 
3.1%) [2] and show reduced injury levels as a result of over-use compared to energy-storing 
tendons [3]. Energy-storing tendons, such as the human Achilles, act like springs by stretching 
                                                 
 
* Portions of this chapter have been adapted from Rebecca Hortensius, Laura Mozdzen, and Brendan Harley, 
“Biomaterial Scaffolds for Tendon Tissue Engineering,” in: M.E. Gomes, R.L. Reis and M.T. Rodrigues (Eds.), 
Tendon Regeneration, Elsevier, 2015, pp. 349-380 & Rebecca A. Hortensius and Brendan A. C. Harley. “Naturally-
derived biomaterials for addressing inflammation in tissue regeneration.” Experimental Biology and Medicine, 
2016; 241(10):1015-24. 
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and recoiling under high loads [1]. While these tendons are highly extensible under load (max 
strain: 10.3%), they exhibit high injury rates [4].  
Injury to the tendons throughout the body is common and can present in the acute or chronic 
state. The tendons of the hand (flexor [5], extensor [5]) are often injured, cut, or even crushed 
during accidents, while shoulder (rotator cuff [6, 7], biceps tendons [8, 9]) and leg injuries 
(Achilles [10, 11], patellar [12]) are more often injured during falls and sports accidents. Hand 
injuries account for approximately 10% of all emergency room visits and hand tendons are 
injured at an annual rate of approximately 33 in every 100,000 people [5]. The nature of hand 
function is to have precise and delicate control of movement to perform various tasks, and small 
dysfunction in ability can lead to a significant social and economic loss [5]. Similarly, the annual 
rate of incidence of biceps tendon rupture is approximately 1.2 in every 100,000 people, 
occurring more frequently in men than in women. Common complications of a biceps tendon 
rupture are nerve damage, re-rupture, and ossification of the tendon [9]. Currently, the vast 
majority of these injuries require surgical intervention. 
Tears to the rotator cuff are characteristic of a separate class of tendon injury: injury at the 
insertion between tendon and bone. The native osteotendinous region (tendon-bone junction) is 
the body’s solution for connecting elastic tendon to (100-fold) stiffer bone. This osteotendinous 
interface is 100 – 250μm wide and protects the interface from failure by minimizing stress 
concentrations [13] through overlapping gradients of matrix mineral content, insoluble proteins, 
structural alignment, and biochemical signals [13-15]. Rotator cuff tears account for more than 
4.5 million physician visits and 250,000 surgeries nationally each year [16]. Surgical repair is 
accomplished via mechanical fixation with sutures or screws. This approach does not restore the 
complex structure and composition of the interface, but, rather, results in the formation of tissue 
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with inferior biomechanical properties (scar). Insufficient re-integration between the tendon and 
bone compartments is responsible for long-term joint instability and high clinical failure rates 
(11%-94%) [17]. Another major class of injuries that relies on successful tendon-to-bone healing 
is the surgical repair following an anterior cruciate ligament (ACL) tear. Commonly, a soft tissue 
graft (autograft or allograft, tendon or ligament) is fixed at each end into tunnels bored into the 
femur and tibia. Graft stabilization, mechanical strength, and eventual surgical outcomes depend 
on the integration of this graft with the anchoring bone [18-21]. 
After injury and subsequent healing (with or without surgical intervention), tendons are often 
unable to bear the same load as the original tissue. Scar tissue, which contains different 
physiochemical properties than native tendon, often replaces the complex collagen hierarchy of 
the tissue and limits its functionality. Its formation has been linked to the inflammatory phase of 
the wound healing cascade (discussed further in section 1.6). Increases in the gene expression of 
pro-inflammation (IL-1β, TNFα) and matrix degradation factors (MMP-3, MMP-13) as well as 
decreases in the expression of tendon ECM (COLI) and tendon-specific markers (SCX) have 
been shown in a canine flexor tendon model [22]. Studies in the healing process following acute 
tendon injury, in particular, show upregulation in TGF-β1 mRNA and protein expression, 
disruption in collagen fiber continuity and organization, and decreases in ultimate stress and 
modulus when compared to uninjured tendons [23, 24].  
1.2.2 Chronic wounds 
Chronic cutaneous wounds and their limited ability to heal represent a major problem in the field 
of wound care. It is estimated that more than $25 billion is spent in the US every year on the 
treatment of chronic wounds, which are most commonly present in the elderly and individuals 
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with diabetes [25, 26]. They are characterized by an extended period of inflammation, delayed 
angiogenesis, and the disruption in the transition to the normal proliferative and remodeling 
phases of wound healing (outlined in Figure 1.1A) [27].  
Tendons (e.g., patellar [28-30], Achilles [10, 31, 32]) also commonly display tendinopathies, 
characterized by pain, inflammation, and decreased functionality often as a result of overuse or 
deterioration due to chronic injury or disease [10, 28-32]. Approximately 50% of all sports 
injuries result from overuse of connective tissues such as tendons [10]. For example, Achilles 
tendinopathy accounts for 6-17% of all running injuries [32] and often has an unpredictable 
clinical outcome [31]. Patellar tendinopathy effects up to 40% of professional athletes during 
their career [33] but is also common in recreational [34] and adolescent athletes [35], often at a 
higher rate in men than in women. Many tendon injuries, such as patellar tendinopathy, are not 
limited to athletic endeavors, with risks also increasing with other conditions such as obesity 
[30]. 
1.3 A tissue regeneration approach 
The limited ability of the body to regenerate the native structure and function of tendon 
following injury as well as resolve excessive inflammation associated with a range of wounds, 
calls for strategies to enhance and support the restoration of these tissues to their natural state. 
The field of tissue engineering has modeled its therapeutic approach towards this goal on a triad 
consisting of materials, cells, and biological factors; the three major components found in every 
tissue and organ. The resident cells of every tissue in the body are supported by an environment 
of insoluble components called the extracellular matrix (ECM) and a concert of soluble 
biological factors (growth factors, cytokines, hormones). The ECM, primarily composed of 
collagen and glycosaminoglycans, is the three-dimensional microenvironment in which cells 
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reside within tissues and organs of the body. It is responsible for providing instructive signals 
which can modulate cell bioactivity via compositional, structural, and mechanical properties. 
Following tissue injury, the likelihood of complete restoration of these ECM properties is low as 
the human body’s wound healing mechanism prioritizes wound closure (repair) over tissue 
regeneration [36]. Therefore, even after months of ECM remodeling, natively repaired tissues 
exhibit disorganized matrix and decreased mechanical properties [37]. An increasingly common 
paradigm of tissue regeneration relies on the implantation of scaffold materials, cells, and/or 
soluble molecules not to replace the damaged tissue but rather to promote normal deposition of 
tissue with eventual material degradation for the restoration of native structure and function [38]. 
Tissue regeneration strategies have traditionally relied on designing biomaterials that closely 
mimic native traits of the ECM as a means to promote normal, site-specific cellular function. 
This thesis, in particular, will describe efforts to develop biomaterials that through their inherent 
properties can alter the activity of cells (either seeded on the scaffold or infiltrating from 
surrounding tissue) and biological factors. 
1.3.1 Repair versus regeneration 
The goal of achieving in vivo induced regeneration for a variety of tissues and organs following 
severe injury remains at the forefront of current tissue engineering investigations. Treatment 
options for organ injury depend significantly on the scale of the defect. Microscopic defects are 
often treated using a wide variety of soluble factors (i.e., biomolecules, hormones, and 
antibiotics). However, organ-scale defects present a significantly larger wound site, requiring 
considerably different treatment practices. These defects, created by disease or by an acute or 
chronic injury can result in millimeter or centimeter scale wounds. These wounds cannot be 
6 
 
treated with drugs because the failure encompasses a mass of tissue which includes cells, soluble 
proteins, cytokines, and the extracellular matrix. 
The adult mammalian response to severe injury is closure of the wound by contraction and scar 
tissue formation, a process termed repair. Distinct from repair, regeneration is characterized by 
synthesis of a physiological (normal, functional) replacement tissue in the wound site that is 
structurally and functionally similar to the original tissue. The contractile fibroblast phenotype, 
termed the myofibroblast, plays a critical role in determining the nature (repair or regeneration) 
of mammalian wound healing. During adult repair, myofibroblast-mediated organized wound 
contraction and scar tissue synthesis is observed [39]. During early fetal healing, differentiation 
of myofibroblasts has not yet occurred and regeneration of damaged tissue and organs occurs in 
the absence of contraction.  
The data suggest that induced organ regeneration in the adult may be encouraged by developing 
techniques to mimic early fetal healing. It has been hypothesized that biomaterial ECM analogs, 
such as those described in section 1.4, induce regeneration by establishing an environment that 
selectively inhibits wound contraction by preventing the organized contractile response and 
blocking scar synthesis, the two processes normally responsible for closing a wound following 
severe injury [39]. The transforming growth factor-β (TGF-β) family of molecules has also been 
implicated in this ontogenetic transition between (fetal) regeneration and (adult) repair response 
to injury. TGF-βs are multifunctional cytokines with widespread effects on cell growth and 
differentiation, embryogenesis, immune regulation, inflammation, and wound healing [40]. 
Deficient levels of TGF-β1 and -β2 and increased levels of TGF-β3 are observed in early 
gestational (“fetal” regenerative healing response) compared to late gestational (“adult” repair 
healing response) mice. TGF-β1 and TGF-β2 are known to promote scar, while TGF-β3 may 
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reduce scar [41, 42]. These results suggest the use of an appropriately designed active ECM 
analog along with decreased TGF-β1, -β2, and increased TGF-β3 expression may play a 
significant role in promoting regenerative repair of tissue defects [43].  
1.4 Extracellular matrix analogs 
Biomaterial analogs of the extracellular matrix are a critical element of any tissue engineering 
product towards in vitro or in vivo clinical applications. While these scaffolds are responsible for 
providing the appropriate structural, mechanical, and/or biomolecular cues necessary to promote 
cell bioactivity and regenerative potential, it is intended that they stimulate remodeling and 
resultant regenerative repair of functional tissue as a temporary construct instead of as a 
permanent implant. Given the typical dimensions of tendon defects, such scaffolds are generally 
three-dimensional, exhibit high porosity to encourage cell attachment, penetration, proliferation, 
and nutrient/waste exchange, and contain compositional features to promote cell-matrix 
attachment and subsequent interactions [44]. 
Degradable polymeric-based biomaterials (synthetic and naturally-derived polymers) have been 
adopted for tendon tissue engineering applications, with their long chain molecular structure 
providing a backbone similar to features of the native ECM. Synthetic polymers have tailorable 
material properties (fine control over size, shape, and mechanical properties), scalable 
production, and can withstand a range of processing conditions although they lack the natural 
amino acids and ligands of native ECM [44, 45]. Poly(α-hydroxyacids) are a class of synthetic 
polymer that include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their copolymer 
poly(lactic-co-glycolide) (PLGA), that have been widely used for a range of tissue engineering 
applications [44, 46]. These are FDA approved for the use as sutures, stents, and wound 
dressings and are widely used as ECM analogs in tissue engineering and drug delivery systems 
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research [47]. PLA and PGA are easily processed and their properties can be controlled through 
the alteration of polymer molecular weight and associated copolymers [48]. This class of 
polymers degrades via hydrolytic processes, releasing monomers that can be removed by natural 
pathways [49]. However, the heterogeneity of polymer degradation (when the inside of the 
material degrades faster than the outside) [49] and the acidity of the resultant byproducts [50] 
presents some concern.  
Materials such as collagen, glycosaminoglycans (GAGs), and fibrin are derived from native 
components of the ECM. Such naturally-derived constructs often can provide key features of the 
ECM (e.g., ligand sites, MMP-degradable) to support biological recognition, cell adhesion, and 
subsequent cell bioactivity [44]. Collagen is a significant constituent of the natural ECM and 
collagen-based scaffolds have been used in a variety of applications. While offering advantages 
in terms of potential bioactivity, naturally-derived polymer biomaterials often have limited 
control over available fabrication paradigms, are mechanically weak, and can suffer from batch-
to-batch variations [48]. Regardless of their limitations, collagen-based scaffolds show promise 
as bioactivity materials for tissue regeneration and will be the focus of the remainder of this 
thesis in the form of a graft copolymer of type I collagen and sulfated GAGs [39, 51]. 
1.4.1 Biomaterial composition 
The ECM composition of tendon, largely collagen (86%), GAGs/proteoglycans (1 – 5%), and 
elastin (2%), provides compositional targets for the design of tissue engineering biomaterials. 
From the standpoint of biomaterial design, the low antigenicity and immunogenicity of collagen 
and the presence of ligands and peptides that aid in the formation of cell-scaffold interactions are 
advantageous [52]. The mechanical properties and degradation rates of collagen constructs can 
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also be controlled through collagen density as well as the degree of material crosslinking [52]. 
Glycosaminoglycans are linear polysaccharides that are a significant component of tendon ECM 
[52, 53] and known to play a critical role in sequestering growth factors within the ECM [54]. 
Bioinspired strategies for functionalizing ECM analogs with GAGs to affect growth factor 
availability will be discussed later in this chapter (section 1.5) and within this thesis (Chapter 2). 
While collagen-GAG (CG) scaffolds have been widely used for a variety of tissue engineering 
applications such as skin, peripheral nerve, and cartilage regeneration [52, 55-58], they have only 
recently been adapted for tendon applications [59-62]. Other natural polymers such as gelatin 
[63], chitosan [64], alginate [65], and agarose [66] have also been investigated as potential 
materials for ECM analogs for tendon tissue engineering applications.  
1.4.2 Biomaterial structural properties 
The biological activity of any ECM analog also depends significantly on its three-dimensional 
pore microstructure. After migrating into the scaffold, cells interact with the surrounding scaffold 
environment, making use of its cell surface receptors to bind to specific ligands on the scaffold 
surface. The first critical component of ECM analog microstructure to consider is the open or 
closed-cell nature of the scaffold. An open-cell pore microstructure exhibits pore 
interconnectivity while a closed-cell microstructure exhibits membrane-like faces between 
adjacent pores, effectively sealing the environment of one pore from its neighbors. Pore 
interconnectivity is critical for scaffold bioactivity because it allows cells to migrate through the 
construct and interact with other cells in a manner similar to that observed in vivo. In order to be 
used as a template for cellular growth, pores should also be large enough to allow for nutrient 
transport and early cellular infiltration [67], while maintaining appropriate tissue-dependent 
mechanical integrity. Pore size influences the specific surface area, permeability, and mechanical 
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properties of the material [61, 68-71]. Initial cellular attachment generally increases with an 
increase in specific surface area, typically inversely related to pore size. Although initial cellular 
attachment can be increased by reducing pore size, the ultimate disadvantages of small pores 
(steric hindrance, decreased permeability) provide an important design trade-off to consider [72]. 
A wide range of studies, across a range of biomaterial chemistries, have suggested the optimal 
range of pore sizes that balances these parameters, in addition to cell bioactivity, is 200-400µm 
[72].  
Beyond pore size, the microstructural alignment of biomaterial substrates (two-dimensional) and 
shape and alignment of pores (three-dimensional biomaterials) is often a critical design feature to 
consider in biomaterial fabrication. A range of studies have suggested that successful 
regeneration templates for natively aligned tissues such as peripheral nerves [73], the 
myocardium [74], and tendon [60, 61, 75-78] must provide tissue-specific, aligned contact 
guidance cues that recapitulate aspects of the tissue anisotropy. In addition to altering the 
structural organization of ligands available to cells within the biomaterials, the degree of 
anisotropy can also significantly influence scaffold modulus [79]. The use of anisotropy in 
biomaterials has been extended from providing a bioactive platform for culturing differentiated 
cells from natively aligned tissues (e.g., tenocytes) [60] towards a tools for inducing selective 
differentiation of mesenchymal stem cells (MSCs) towards a tenogenic lineage [61]. 
1.4.3 Passive versus instructive biomaterials 
Porous, three-dimensional scaffolds have been used extensively as biomaterials in the field of 
tissue engineering for both in vitro study of cell-scaffold interactions as well as for in vivo 
investigations of tissue regeneration. These scaffolds, as analogs of the ECM, can act as a 
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physical support that permits resident cell activity. However, advances in the field of tissue 
engineering are increasingly reliant on biomaterials that instruct, rather than simply permit, a 
desired cellular response [80]. Tissues can be dynamic, spatially-patterned, or inhomogeneous 
over multiple length and time scales, thereby motivating development of approaches to engineer 
biomaterials at multiple structural and biomolecular levels [60, 81-83]. Such instructive 
biomaterials hold significant promise for clinical applications in tendon repair as well as a wide 
range of regenerative applications in vivo and mechanistic investigations in the laboratory.  
1.5 Bioactive materials to direct cellular response 
While material composition and structural properties are important design criteria for tendon 
tissue engineering, it is increasingly apparent that approaches which replicate elements of the 
complex biomolecular environment of the extracellular matrix are equally critical. Such 
biomolecular modifications can take many forms. Some efforts focus on improving the 
biocompatibility of synthetic polymer analogs; for instance, the incorporation of the arginine-
glycine-aspartic acid (RGD) amino acid sequence to enhance cell attachment [84]. However, this 
section will focus on functionalization strategies for natural polymer ECM analogs.  
Many biomolecular supplementation strategies are inspired by the native environment during 
development and fetal wound healing, tissue homeostasis, as well as the environment often 
found during acute or chronic wound healing processes. There are important shifts in the 
expression of growth factors and matrix proteins between adult and fetal tendons in the case of 
normal physiology as well as damage and disease. Notably, transforming growth factor beta 
(TGF-β) exhibits varying isoforms over the course of development, homeostasis, and wound 
healing. TGF-β3 is prevalent in the early timepoints during development most associated with 
enhanced regenerative capacity [39], but transitions to enhanced expression of TGF-β1 isoform 
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prior to birth (15.5 days post-conception in a mouse model of tendon development) [85]. TGF-β1 
is prevalent in the wound environments of adult tendons and not in fetal tendon wounds [24]. 
Such transitions in growth factors between healthy and diseased tendon, as well as fetal vs. adult 
healing mechanisms [86], are likely to inform the selection of growth factors or TGF-β receptor 
inhibitors for future tendon tissue engineering materials. 
1.5.1 Soluble and covalent presentation of biomolecules 
Growth factors and other biomolecules play a significant role in the overall health, function and 
phenotypic fate of cells in vivo and in vitro. For instance, increases in tenocyte chemotaxis and 
proliferation are induced, dose-dependently, by insulin-like growth factor 1 (IGF-1) and platelet-
derived growth factor BB (PDGF-BB) [87]. Additionally, bFGF, GDF-5, and GDF-7 have been 
shown to drive MSCs towards a tenogenic phenotype in anisotropic CG scaffolds [88]. Chemical 
signaling via soluble factor presentation depends on many variables including the concentration 
of the growth factor, diffusion rate within the scaffold, and metabolic activity of the cells [89]. 
Not surprisingly, many effective strategies require the incorporation of multiple signals to meet 
tissue engineering design goals: e.g., incorporation of multiple factors to induce proliferation and 
maintain cell phenotype [87, 90]. Despite the responses seen using soluble factors, current 
research advances have been moving towards the design of an active, instructive biomaterial; one 
that endogenously contains signals to promote a desired cellular response in vivo or in vitro 
culture, making them attractive as ‘off-the-shelf’ constructs. 
Covalent attachment of growth factors to an ECM analog has been proposed as a way to extend 
the activity and availability of a biomolecule as well as control the factor’s spatial presentation. 
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) is a commonly used 
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chemistry for the immobilization of factors on 2D and within 3D tissue engineering materials 
[87, 91, 92]. This zero length crosslinker couples carboxyl groups to primary amines. Shen et al. 
showed that VEGF could be covalently attached (not simply adsorbed) onto a porous collagen 
scaffold using EDC chemistry without altering the effectiveness of the growth factor; scaffolds 
with immobilized VEGF showed a higher degree of endothelial cells penetration into the 
collagen scaffold [91]. Furthermore, Odedra et al. showed that EDC chemistry could be used to 
create a gradient of VEGF within a porous collagen scaffold [92]. Previous work in the Harley 
lab has shown that immobilization of PDGF-BB within aligned collagen scaffolds can both 
extend and localize its effects and promote significant increases in tenocyte metabolic activity 
over long-term culture versus an equal soluble factor dose [87]. While effective, bulk covalent 
attachment does not allow for local growth factor presentation (e.g., compartments, gradients, 
patterns). 
Photolithography-based methods offer the potential to pattern factors within three dimensional 
ECM scaffolds [93, 94]. Here, biomolecules of interest can be spatially patterned within a 
material. Additionally, multiple factors can be attached in complementary patterns or gradients. 
This technique has been demonstrated on collagen scaffolds using benzophenone-based 
chemistry where growth factor patterns were created at a depth of 300 micrometers and the 
resultant pattern growth factors induced a patterned cellular response [93, 95-98]. Similarly, a 
number of publications highlight the generation of biomolecular patterns within three-
dimensional hydrogel structures using light-based lithography methods [94, 99-101]. 
Growth factor loaded microparticles of various materials have also been employed in a number 
of tissue engineering scaffolds. This technique bypasses adding growth factors to the primary 
ECM analog components and uses a secondary vessel to contain the biomolecules within the 
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scaffold [102, 103]. Growth factor carriers have been fabricated from a range of materials: 
PLGA [104], gelatin [105, 106], chitosan [107], and hybrids [108, 109]. By using microspheres, 
control over the factor release rate can be maintained through crosslinking [110] and dual factor 
release can be achieved by using multiple delivery vehicles [106]. Such signals may be used to 
guide cell in-growth from the construct periphery while providing separate signals to aid 
regeneration or integration with the surrounding tissue. These approaches offer significant 
potential for future tissue engineering applications. 
1.5.2 Sequestration of growth factors via glycosaminoglycans 
While providing opportunities to augment the bioactivity of tissue engineering scaffolds, 
presenting biomolecules via covalent functionalization is limited to growth factors that do not 
need to be internalized by cells to elicit their effects. In the native ECM, growth factor 
sequestration and release is modulated by large polysaccharides called glycosaminoglycans 
(GAGs). In nature, GAGs can exist as either protein-bound proteoglycans, sulfated variants 
(heparan sulfate, heparin, chondroitin sulfate, dermatan sulfate, or keratan sulfate) or as a free 
glycosaminoglycan with no sulfate groups (hyaluronic acid) [111]. The sulfated molecules, in 
particular, are known to sequester growth factors electrostatically; presenting varying levels of 
negative charges depending on their degree of sulfation [54, 112]. These interactions are known 
to transiently regulate the bioavailability of growth factors, both exogenously-delivered and 
endogenously-produced, to cells within a tissue [81]. However, it should be noted that the degree 
of GAG sulfation is not solely responsible for the modulation of cellular activity and growth 
factor sequestration. CD44 binds the non-sulfated hyaluronic acid [111] and differences in the 
GAG backbone, as well as position of sulfate groups, alters the degree of protein interaction [53, 
54, 113].  
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The knowledge of proteoglycan-protein interactions in vivo can be used in the design of 
biomaterials that rely on transient, bioinspired interactions instead of covalently-linking growth 
factors. Murphy et al. has demonstrated, using a two-dimensional model system, that heparin-
binding peptides can enhance human mesenchymal stem cell (hMSC) bioactivity on a self-
assembled monolayer via selective binding of heparin then heparin-binding growth factors to the 
substrate [114]. Other groups have adapted this work to fully three-dimensional materials. 
Incorporation of heparin-binding peptides was shown to maintain the activity and prolong the 
release of the heparin-binding growth factor basic fibroblast growth factor (bFGF) within PEG-
based hydrogels [115]. Artificially sulfated alginate (plant-derived polysaccharide) hydrogels 
showed enhanced binding of heparin-binding growth factors over native alginate gels [116]. 
Efforts that used selectively desulfated chondroitin sulfate in a series of hydrogels resulted in a 
decreased ability to sequester transforming growth factor- beta 1 (TGF-β1), leading to increased 
MSC expression of chondrogenic cues [117]. 
Further, this concept has been extended to collagen-GAG biomaterials being developed 
explicitly for tissue engineering applications. Increasing the degree of sulfation within the GAG 
component of a collagen-GAG substrate induced increased dermal fibroblast adhesion and 
proliferation which is linked in vivo to the speed and quality of wound closure [118]. Similar 
efforts have associated increased adsorption and release of TGF-β1 within the scaffold with the 
degree of GAG sulfation [119]. This system of sequestration and release resulted in higher 
collagen synthesis by human mesenchymal stromal cells, suggesting that bioinspired GAG 
formulations may be used to enhance the correct presentation of growth factors to cells.  
Work described in Chapter 2 of this document shows that the degree of GAG sulfation of a 
collagen-GAG scaffold could be used to modify the scaffold’s capacity to sequester 
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biomolecules in order to enhance the bioactivity of scaffolds being developed explicitly for 
tendon tissue engineering applications [59]. The ability to mimic dose-dependent changes in cell 
activity in response to a single dose of growth factor highlights an intriguing avenue for future 
biomaterial development.  
1.5.3 The use of gene delivery to alter cellular activity 
The use of growth factors in tissue engineering applications is effective but not necessarily 
efficient, especially when growth factor half-life and cost are taken into account. The use of gene 
delivery vehicles takes an upstream approach to altering cellular bioactivity. Instead of providing 
the growth factors necessary for enhanced responses (proliferation, differentiation, etc.), this 
method introduces, directly to the cells, the genes that encode for the proteins of interest. 
The use of viruses for gene delivery is efficient, however, non-viral gene delivery vectors are 
advantageous in terms of safety, design flexibility, and ease of production [120]. A range of 
materials has been used for these types of vectors: chitosan [121, 122], alginate [123], 
hydroxyapatite [124, 125], and polyethylenimine (PEI) [120, 126-129]. PEI is one of the most 
efficient and widely studied non-viral gene delivery vectors in literature. As a positively charged 
polymer, PEI complexes with the negatively charged backbone of DNA, forming a polyplex. 
This charge interaction allows us to capitalize further on the use of biomaterial systems with 
differential charges (like that of the sulfated GAG scaffold described in the previous section). 
Work in this area of gene activated matrices is detailed in Chapter 3 of this thesis. 
1.5.4 Cellular response to biomaterials 
As part of the tissue engineering triad, the cells introduced to the extracellular matrix, as either 
cells seeded on the matrix prior to implantation or infiltrating cells in vivo, play a large role in 
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the study of biomaterials. Three categories of cells that are of particular interest for the work 
described in this thesis are terminally differentiated primary cells, pluripotent adult stem cells, 
and immune cells. 
Primary tenocytes can be isolated from tendon and approaches such as mechanical stimulation, 
aligned biomaterials, and growth factors have been previously applied to facilitate the 
maintenance of a tenocyte phenotype in vitro [60, 61, 87, 130]. Tenocytes are either sourced 
from an animal (xenograft), in which case they must be bio- and immuno-compatible with the 
patient, or they can be sourced from the patient (allograft), in which case there is a risk of donor 
site morbidity. Once obtained, the proper design of biomaterial substrate can enhance tenocyte 
remodeling and long-term improvements in the scaffold mechanical properties [131]. 
MSCs are pluripotent adult stem cells which can be readily isolated from the patient’s own bone 
marrow and have the potential to differentiate into a variety of musculoskeletal tissues [55, 132, 
133]. As many tendon injuries are composite injuries which require multi-tissue regeneration 
strategies (tendon-to-bone, tendon-to-muscle), the use of a multi-potent progenitor cells provides 
additional advantages and complexities. For these types of injuries, a biomaterial with gradation 
in biomechanical and biomolecular cues may eventually be able to locally direct stem cell fate 
down multiple tissue lineages, leading to improved multi-tissue regeneration. Additionally, 
MSCs have a role in modulating the immune response in wound sites. Following the initial 
inflammatory response, MSCs stimulate the transition to the proliferative, healing phase of the 
wound cascade. It has been suggested that MSCs produce biological factors that shield local 
fibroblasts from the negative effects of pro-inflammatory cytokines as well as promote the 
transition of macrophages from their pro-inflammatory to their anti-inflammatory phenotype 
[134-136]. 
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While the body’s immune response is a complicated concert of cells and soluble factors, it has 
been shown that macrophages, white blood cells initially known for their phagocytic activity, 
play an important role in a wound’s transition from inflammation to remodeling. Recent 
literature has reviewed a spectrum of macrophage phenotypes; M1 (pro-inflammatory), M2a 
(wound healing), and M2c (regulatory) [137]. The transition from a primarily M1 population to a 
M2 population is indicative of better healing outcomes in diabetic foot ulcers [138]. Designing a 
biomaterial scaffold that facilitates this transition in vivo would be an asset to the field. 
1.6 Challenges in tissue regeneration associated with the inflammatory response 
Following tissue injury, the body immediately begins to work to clear the injury site of debris, 
close the wound, and lay down new extracellular matrix (ECM). In adult wounds this wound 
healing cascade can be described in three overlapping phases: inflammation, proliferation, and 
remodeling (Fig. 1.1). During the inflammatory phase, the chemotaxis of inflammatory cells 
(neutrophils, macrophages) to the wound site is stimulated by platelet release of platelet-derived 
growth factor (PDGF) and transforming growth factor-beta (TGF-β) [139]. Pro-inflammatory, 
wound macrophages secrete key inflammatory cytokines, tumor necrosis factor alpha (TNFα) 
and interleukin-1 (IL-1) during this phase [139]. The transition to the proliferation phase is 
characterized by the macrophage shift to an anti-inflammatory, tissue repair phenotype [140] and 
the presence of fibroblasts along with the upregulation of genes associated with matrix proteins 
(collagen, proteoglycans, fibronectin) [139]. The final phase of wound healing, remodeling, can 
continue for weeks or months as the tissue matrix is reorganized.  
Inflammation, while a necessary component of wound healing, can hinder tissue regeneration in 
cases such as biomaterial implantation or chronic wounds. Inflammation is not only a result of 
the original injury; the surgical implantation and biomaterial presence can also stimulate 
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inflammation through the foreign body reaction (Fig. 1.1). Therefore, it should follow that the 
design of biomaterials for tissue regeneration, normally focused on biocompatibility and 
recapitulation of the composition, structure, and mechanics of native tissue, should also include 
features that mitigate the inflammatory response. The goal for scaffold design in the future 
should be two-fold: to provide instructive signals necessary for cell attachment, proliferation, and 
function in the context of the native tissue (bioactivity) and also to modulate the immune 
response. 
Physical properties of scaffolds, such as composition [59, 141], mechanical properties [142], and 
microarchitecture [61], can all influence cell bioactivity. But these features may also explicitly 
regulate the immune response. Aligned, electrospun polycaprolactone fibers implanted 
subcutaneously in a rat model, showed increased cell infiltration and a thinner fibrous capsule as 
compared to fibers with random orientation [143]. Variations in pore size of 
polytetrafluoroethylene materials result in differential expression of pro-inflammatory cytokines 
in vitro and decreased fibrous capsule thickness in vivo [144]. 
Traditionally, materials for reducing the inflammatory response of biomaterials have relied on 
the incorporation of anti-inflammatory therapeutics. One technique is to use plasmids of the anti-
inflammatory cytokine IL-10 in the pretreatment of cells or to incorporate them into a collagen 
biomaterial scaffold [145, 146]. This approach reduces inflammation and enhances MSC 
survival in vitro [145] and in an in vivo model for myocardial infarction, there was increased 
wall thickness, increased ratio of collagen III to I, and a shift to a regulatory macrophage 
phenotype leading to functional recovery [146]. The incorporation of anti-inflammatory drugs 
such as ibuprofen [147] and tetrandrine [148] into PLA-based scaffolds has also shown reduced 
inflammation and improved tissue regeneration in in vivo rat models. 
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The ability to leverage biologically-derived materials with intrinsic anti-inflammatory properties 
for tissue regeneration has the potential to generate a new class of biomaterials with the capacity 
to promote regeneration and alter the inflammatory response in the wound site. Coordinated 
efforts in biomaterial design may offer the possibility to improve regenerative potential because 
of the ability to alter native inflammatory responses. Pro-inflammatory signals are not inherently 
detrimental to healing; in fact, they are necessary for repair as long as they subside in a timely 
fashion [149]. It is hypothesized that biomaterials that first promote the M1 macrophage 
phenotype and then M2 would enhance ultimate healing [149]. These observations reinforce the 
idea that biomaterial design should not simply reduce or enhance inflammatory response, but that 
the kinetics of the inflammatory response offer intriguing targets for biomaterial design. To date, 
the study of a wide range of naturally-derived materials for their potential 
immunomodulatory/anti-inflammatory capability and their ability to support tissue regeneration 
has begun. From this wide variety of materials, this section focuses on three particular classes of 
biomaterials – chitin, decellularized extracellular matrix, and amniotic membrane – that show 
particularly intriguing properties in the context of biomaterial design. While many current 
observations described in the following sections and seen in Table 1.1 focus on solely reducing 
the inflammatory response, future generation tissue engineering products are likely to exhibit 
more nuanced control over the inflammatory cascade.  
1.7 Naturally-derived materials for addressing inflammation 
1.7.1 Immunomodulatory activity of chitin-derived materials 
Chitin is one of the most abundant polysaccharides in nature, second only to cellulose [150]. It is 
an inexpensive and readily available material that is found in the exoskeletons of invertebrates, 
such as crabs and shrimp, as well as the cell walls of fungi and yeast [151, 152]. Chitin is a linear 
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polymer composed of N-acetyl-D-glucosamine subunits [151]. Since chitin is not readily 
dissolvable, its deacetylated derivative, chitosan, is frequently studied and used in biological 
applications [152, 153]. Chitosan can be further degraded and deacetylated to form 
chitooligosaccharides (COS) [150, 154-157].  
Chitin, chitosan, and their derivatives have been extensively studied for their anti-inflammatory, 
anti-microbial, antioxidant, and anti-cancer effects [151, 152, 158]. The range of anti-
inflammatory applications for chitin-derived materials encompasses the treatment of chronic 
inflammatory conditions (asthma [150], inflammatory bowel disease [157], sepsis [156], 
arthritis[159]), the use of chitosan composite particles for drug delivery [160], and the 
modulation of immune responses of implanted chitin-based biomaterials [161]. Low molecular 
weight chitosan oligosaccharides significantly inhibit asthma-related cytokines (IL-4, IL-13, 
TNFα) in vitro and in vivo [150]. Additionally, oral administration of COSs has been effective in 
attenuating pro-inflammatory cytokine production and reducing intestinal inflammation in 
models of induced colitis [157]. Bacterial-stimulated inflammation, such as that seen in acne, can 
also be treated with chitin-derived materials [160]. Nanoparticles of chitosan and alginate 
(without anti-acne mediation) were able to inhibit bacterial induction of IL-12 in macrophages in 
a dose-dependent manner. Further, the presence of these nanoparticles was able to also inhibit 
the induction of IL-6 in keratinocytes [160].  
The anti-inflammatory mechanism of orally-administered chitosan, in particular, has been 
attributed to its release of N-acetyl-β-D-glucosamine during degradation [151, 162]. 
Glucosamine is a structural unit of hyaluronan, a glycosaminoglycan shown to have roles in the 
promotion of cell motility and accelerated wound healing. Glucosamine is also a primary 
component of proteoglycans of the native extracellular matrix of cartilage and connected tissue. 
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A decrease in the occurrence of osteoarthritis-related total joint replacements has been linked to 
treatment with glucosamine sulfate [159]. Further disruption of inflammation via chitin-derived 
materials (outside the field of tissue regeneration) has been observed through the inhibition of 
pro-inflammatory MMP-2 [163], the decrease in IL-1β-induced chondrocyte apoptosis [164], and 
the attenuation of nitric oxide and inflammatory cytokine (such as TNF-α, IL-6, IL-1β) 
production in in vitro dose-dependent culture [154, 155] as well as in vivo [156]. 
An early study of chitin as a wound healing accelerant was conducted by Prudden et al [165]. 
Additional study has shown that chitosan fibers stimulate early cell migration and production of 
granulation tissue in canine open wounds [166]. More recent work has focused on the response 
of specific wound healing cells to chitosan-based implants. Immune cells, particularly 
macrophages, have roles in inflammation and tissue regeneration. Through the production of 
cytokines and chemokines, macrophages attract or decrease the inflammatory cells within the 
injury site [161]. By modulating the macrophage response to an implant, the rate and outcome of 
healing can be altered and chitosan has been found to promote anti-inflammatory macrophage 
polarization in vitro without the use of exogenous growth factors/cytokines [161]. 
Chitosan scaffolds for use in skin, bone, cartilage, liver, nerve and blood vessel wounds have 
been well summarized [167, 168]. However, considering the range of anti-inflammatory uses for 
chitin-derivatives, the study of chitosan scaffold-based therapies for immunomodulation in tissue 
regeneration is limited. Chitosan fibers [166] and hydrogels [169] have been evaluated for skin 
regeneration. In both forms, chitosan promotes migration of inflammatory cells to the wound site 
and collagen matrix deposition. In the hydrogels, chitosan also promoted angiogenesis resulting 
in vascularization of the new tissue [169]. These findings suggest that chitin-based materials may 
have potential in future tissue engineering products. However, significant new efforts to link 
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current observations regarding immune response with functional metrics of tissue regeneration 
are required. 
1.7.2 Decellularized matrix as scaffold for tissue regeneration 
Scaffolds derived from decellularized matrix (from both allogeneic and xenogeneic sources) 
have been investigated as materials for regeneration in a range of tissues; heart valve [170-173], 
nasal cartilage [174], skeletal muscle [175], gastrointestinal tract [176, 177], ureters [178], liver 
[179], and flexor tendons [180]. Both segmented and whole tissues can be decellularized [177, 
179]. The prevailing advantage to using decellularized matrix scaffolds is the maintenance of 
important properties of the native ECM. The ability to use site-specific tissue, in particular, is 
advantageous for tissue regeneration applications. This ensures that the distinct matrix 
architecture and composition are appropriate for the functional cells specific to that tissue, 
allowing for the enhancement of tissue-specific differentiation [181] and promoting chemotaxis 
and proliferation of progenitor cells [182]. Additionally, decellularized matrices have been 
shown to have immunomodulatory properties and the ability to influence the host response in 
vivo. Removing the cellular component of the transplanted tissue is key to this result as the 
cellular presence contributes to a predominantly M1 macrophage phenotype [174, 183]. 
Decellularized ECM scaffolds intrinsically have the chemical composition of the natural tissue; 
they contain ECM proteins, particularly collagen and glycosaminoglycans, that are highly 
conserved across species [170, 175, 183]. This conservation of biomolecules lends these 
materials to be biocompatible in vivo, exhibiting a low immune response [175, 183]. Also 
maintained within the scaffolds are the complex three-dimensional microstructure, important for 
directing cellular phenotype via geometric cues [174] and growth factors that have roles in cell 
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attachment, proliferation, migration, and differentiation [174]. Further, the matrix retains its 
mechanical properties following decellularization allowing for mimicry of the native tissue and 
long term function [171]. This property, in particular, negates the need for exogenous chemical 
crosslinking, presenting a material that is accessible to naturally occurring degradation and 
remodeling [176]. In contrast, manufactured collagen-based materials rely on crosslinking to 
increase their mechanical properties which significantly reduces the cellular degradation of the 
material [184]. The ability of cells to remodel their surrounding matrix is critical for regenerative 
success. Through the process of constructive remodeling, the degradable matrix template is 
gradually replaced by native tissue with the appropriate function, matrix organization, and 
cellular phenotype [185]. This remodeling outcome in vivo is dependent on a favorable response 
from the innate inflammation associated with both the original injury and/or the biomaterial 
implantation [149, 185]. 
While chemical crosslinking is commonly used in collagen-based ECM matrix analogs to 
stabilize the scaffold, it has been proposed that the inhibition of decellularized scaffold 
degradation, and therefore, the release of degradation products, through chemical crosslinking 
holds great influence over not only the regenerative capacity (noted earlier) but also the cellular 
immune response. Indeed, the products of enzymatically degraded porcine urinary bladder 
influence cell migration in vitro [186]. However, reports on the effects of chemically 
crosslinking decellularized matrices differ based on the tissue type and crosslinking agent. 
Porcine colonic decellularized ECM (coECM) exhibited extensive cellular infiltration and 
degradation in vivo as compared to coECM that had been chemically crosslinked with N(3-
dimethylaminpropyl)-N’-ethylcarbodiimide hydrochloride [176]. Additionally, the crosslinked 
matrices exhibited evidence of encapsulation and disorganized connective tissue, results that are 
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not desired in tissue regeneration applications [176]. Conversely, carbodiimide crosslinked 
porcine ureteral scaffolds implanted in a subcutaneous rat model showed a macrophage 
phenotypic switch to the anti-inflammatory M2 phenotype [178]. Crosslinking with 
glutaraldehyde or genipin stimulated a pro-inflammatory M1 macrophage switch in vivo [178]. 
These data are consistent with glutaraldehyde crosslinking of decellularized bovine pericardium 
which resulted in limited attachment and survival of macrophage-like cells (U937) and increased 
release of pro-inflammatory cytokines (MMP-1) [173]. Future work should carefully consider 
the balance between scaffold degradation and the inflammatory wound healing response in the 
use of decellularized matrix for tissue regeneration applications. 
Beyond the role chemical crosslinking can play in the cellular response to decellularized 
matrices, researchers have extensively studied how these biomaterials influence the 
inflammatory response in vitro [149, 170, 171, 173, 175, 176, 178] and in vivo [149, 175, 176, 
178, 180]. The overwhelming observation, detailed in the following paragraphs, is that 
decellularized matrix can modulate the immune response by exhibiting anti-inflammatory effects 
and promoting a shift in macrophage phenotype from M1 to M2.  
In studies of monocyte-derived macrophages cultured on decellularized bovine pericardium 
(DBP), researchers have observed decreased cell spreading and decreased formation of multi-
nucleated cells on DBP (compared to PDMS and TCPS), indicating a low inflammatory response 
[170, 171]. An ex vivo culture model was used to monitor the cellular events at the interface 
between a fresh tissue (porcine bladder) and decellularized tissue (porcine acellular bladder 
matrix) [187]. There, macrophages were the first cells to move from the tissue into the 
decellularized matrix, where they matured to CD163+ (M2 phenotype) cells [187].  
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Autologous tissue grafts have the advantage of not requiring immunosuppression but their use is 
limited to static organs (i.e. skin) or those that move passively (i.e. blood vessels, bladder, 
trachea, heart valves) [175] and by supply (like in cases of significant injury to the flexor tendons 
of the hand) [180]. Decellularized tissue provides a potential solution in each of these cases. 
Skeletal muscle was decellularized and either cultured with rat CD3+ splenocytes or implanted 
into the tibialis anterior muscle of an immunocompetent rat [175]. Results showed decreased T 
cell proliferation in both experiments. Decellularized scaffolds had slower degradation times and 
polarized macrophages towards an M2 phenotype in vivo [175]. In vitro, the decellularized 
skeletal muscle led to decreased levels of pro-inflammatory TH1 cytokines (IL-2, IFN-γ) and 
increased levels of anti-inflammatory TH2 cytokines (IL-10) compared to fresh tissue, 
effectively modulating the immune response [175]. Emerging work combining decellularized 
bone matrices with the sequential release of growth factors/cytokines that can stimulate M1 and 
then M2 macrophage phenotypes has shown the ability to enhance healing and vascularization 
[149]. 
The mechanism of immunomodulatory behavior by decellularized matrices is not completely 
understood. It is hypothesized that the removal of MHC classes I and II during the 
decellularization process contributes to the anti-inflammatory effects of the matrix in vivo, the 
decreased T-cell proliferation in vitro, and reductions seen in IL-1 and IFN-γ expression [175]. 
The theory that the decellularization process exposes critical surface molecules for 
immunomodulation could be another explanation [175]. 
Like any biomaterial, there are disadvantages associated with the use of decellularized matrices. 
These are a result of the variations between properties on the basis of tissue source and 
processing (method of decellularization, crosslinking, sterilization methods) [176] along with the 
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potential for pathogen transfer to the host [188]. Cell-derived extracellular matrices present an 
exciting alternative for future study [188].  
1.7.3 Fetal wound-inspired materials for regeneration and scarless healing 
The wound healing process and outcome is fundamentally different in fetal as compared to adult 
wounds. While adult wounds exhibit inflammation and result in disorganized matrix and scar 
formation, healing in fetal wounds proceeds in a regenerative fashion, with neither the typical 
inflammatory response nor the formation of scar tissue [189-191].  
The most prevalent example of fetal wound healing in literature is that of skin which has been 
well reviewed elsewhere [190-193]. Fetal skin has the potential to heal via complete regeneration 
(scarless), with normal tissue architecture and a minimal inflammatory response, but this 
response is dependent on gestational age and the size of the wound [194-197]. This scarless 
healing phenomenon does not only occur in skin tissue. Similar outcomes have been seen in 
tendon injury as well, where the restoration of function in adults can be hindered by the 
development of adhesions [24]. It should be noted that fetal scarless wound healing is not 
universal to all tissues. It has also been seen in heart and lung tissue but fetal wounds in the 
stomach, intestine, and diaphragm heal with a scar [198]. 
Two leading differences between adult and fetal wound healing are the cytokines/growth factors 
expressed following injury and the composition of the native extracellular matrix. The decreased 
inflammatory response in fetal wounds can be attributed to the minimal infiltration of immune 
cells due to lower levels of PDGF, TGF-β1 and TGF-β2 and pro-inflammatory cytokines such as 
IL-6 and IL-8 [190, 199-203]. Additionally, the anti-inflammatory cytokine IL-10 is significantly 
expressed in fetal wounds [204]. Studies have shown that treating adult wounds with IL-10 
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results in decreased inflammation and scarless wound repair [205, 206]. Growth factors TGF-β1 
and TGF-β2 are highly expressed in adult wounds as compared to uninjured tissue but their 
baseline levels are maintained in fetal wounds [207]. Fetal wounds contain the third TGF-β 
isoform, TGF-β3, which decreases scar formation through the regulation of collagen deposition 
as demonstrated in fetal rat skin [208, 209]. Collagen type I is the primary ECM protein in both 
adult and fetal skin (normal and wounded) but fetal skin exhibits a higher ratio of collagen III to 
collagen I [210]. Hyaluronic acid (HA), a non-sulfated glycosaminoglycan, is also prevalent in 
the ECM and promotes cell proliferation and motility. Although HA is present in both adult and 
fetal wound fluid, it has been detected later in the healing process in fetal wound environments 
[211].  
The results of fetal wound healing cannot be solely attributed to the sterile, intrauterine 
environment and the interface with the surrounding amniotic fluid. Marsupial pouch young, who 
develop outside of the uterus, have the ability to heal cutaneous wounds in a scarless fashion 
[212]. Even without the uterine environment, the wounds created on the backs of grey short-
tailed opossums were able to quickly undergo re-epithelialization and dermal repair [212]. The 
rate and degree of regeneration is dependent on the pouch age of the animal. It has also been 
shown that scar formation occurs when adult tissue is placed in the fetal environment [213]. 
Being perfused with fetal blood and bathed in amniotic fluid is not sufficient to induce fetal-like, 
scarless wound healing [213]. Fetal skin can also heal without scar in an adult subcutaneous 
environment [214]. These observations have led researchers to focus on the role the fetal 
extracellular matrix has on inflammation and resultant healing.  
The amniotic membrane (amnion, AM) has been investigated as a valuable biomaterial for 
promoting healing with low immune response and decreased scar formation [215]. The amniotic 
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membrane, found in the fetal environment, is the innermost layer of the placenta, surrounding the 
fetus in utero. It is composed of a single epithelial layer and a collagen-rich (collagen I as well as 
types III, IV, V, and VI) extracellular matrix that also contains laminin, fibronectin, elastin, and 
proteoglycans [215-218]. Following birth, it can be easily removed from the placenta and 
separated from the interfacing maternal membrane (chorion). From there it can be utilized in a 
range of forms: (1) living tissue containing cells; (2) decellularized matrix; or (3) in combination 
with other scaffold materials. Isolated AM matrix contains and elutes a range of biological 
factors (growth factors and cytokines) that are important components of the wound healing 
cascade [219]. The presence of anti-inflammatory cytokines such as IL-4 and IL-10 as well as 
inhibitors of matrix degradation (TIMPs 1, 2, 4) is of particular interest [219]. 
The amniotic membrane has long been recognized for its anti-inflammatory properties and 
wound healing capacity. The use of amnion sheets for treatment of adhesions (scar formation) 
between digital flexor tendons and their sheathes was reported in 1942 [220]. A 1950 report 
details the use of boiled amniotic membrane to treat chronic skin ulcers [221]. In it the authors 
describe six case studies in which patients with longstanding, unhealed leg ulcers were treated 
with a dressing of amnion. Each of the wounds was healed within 10 weeks of treatment and the 
resulting skin was thick, healthy, and elastic [221]. 
More recently, it has been shown that the intact amnion membrane sheet is effective in the 
treatment of corneal surfaces [222-224], skin wounds [219, 225], oral cavity reconstruction 
[226], and many other reconstruction applications summarized elsewhere [215, 227]. Amniotic 
membranes applied to the ocular surface in cases of surface abnormalities [222], limbal stem cell 
deficiency [223], and corneal ulcers [224] has led to rapid epithelialization, reduced 
inflammation, and surfaces that are smooth and wettable. Amniotic membranes were implanted 
30 
 
subcutaneously in mice and shown to enhance progenitor cell recruitment [219]. In a porcine full 
thickness skin defect, crosslinked collagen-amnion dermal substitutes exhibited few 
inflammatory cells, rapid healing, and good neovascularization [225]. Micronized, dehydrated 
human amnion membrane has been shown to reduce cartilage degeneration in an osteoarthritic 
rat model [228].  
While the use of intact and injectable amniotic membrane matrix has been investigated for two-
dimensional tissue regeneration applications, the potential of the AM as a bioactive component 
in 3D biomaterials has not been extensively studied. Three-dimensional matrices made entirely 
of decellularized amniotic membrane have been fabricated via lyophilization [229]. The resulting 
scaffold has been shown to support fetal dermal fibroblast cells in vitro. Recent work in our lab 
(described fully in Chapters 4, 5, and 6) has investigated scaffolds that combine amniotic matrix 
within or in combination with lyophilized collagen materials [230]. Incorporating fetal wound 
inspired matrix components in a collagen scaffold for tissue regeneration supports cellular health 
and tempers pro-inflammatory gene expression in vitro. 
1.8 Conclusion 
Emerging efforts in the field of tissue engineering seek to develop biomaterials that not only 
promote cell bioactivity using conventional, tissue-specific metrics (e.g., proliferation, 
differentiation, matrix synthesis), but that also begin to see the biomaterial as a vehicle that can 
modulate the host immune response after injury. Wound healing cascades are complex and vary 
tissue to tissue, but also in the context of age, disease, and the acute or chronic nature of the 
defect. Typical design parameters for tissue regeneration biomaterials are focused on providing 
the appropriate extracellular matrix analog to mimic the native tissue compositionally, 
structurally, and mechanically. These signals aid local cells in building new tissue as part of the 
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wound healing cascade. However, the process of wound healing can be hindered by the presence 
of an extensive inflammatory response. Recent results in the literature suggest the intriguing 
possibility that biomaterial design might also be considered as a tool for modulating the immune 
response following injury. While not specific or nuanced to date, the idea of instructive signals 
changing the kinetics of the wound healing cascade offers an exciting glimpse into the future of 
tissue engineering. The careful design of tissue regeneration biomaterials to both avoid the 
stimulation of an immune response and promote the resolution of any existing inflammation will 
be critical for efficient healing and functional outcomes, suggesting the development of 
immunomodulatory biomaterials as an emergent subfield of tissue engineering with significant 
potential for clinical success.  
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1.9 Tables 
Table 1.1. Materials studied for the modulation of inflammation during wound healing 
  Material Form Immunomodulatory Function Reference 
C
H
IT
IN
-D
ER
IV
ED
 
Low molecular 
weight chitosan 
oligosaccharides 
Significantly inhibited expression of asthma related cytokines in vitro and in vivo [150] 
Chitosan 
oligosaccharides 
Suppressed NF-κB activation, reduced proinflammatory cytokine production, 
inhibited TNF-α and oxidative stress-induced apoptosis in vitro and relieved 
intestinal inflammation in vivo 
[157] 
Nanoparticles of 
chitosan and 
alginate 
Inhibited bacterial-induced pro-inflammatory cytokine production in 
macrophage and keratinocyte in vitro culture 
[160] 
Chitosan films 
In vitro monocyte culture showed variation in pro- and anti-inflammatory 
cytokine production over time (corresponding to monocyte to macrophage 
differentiation) 
[161] 
Chitosan fibers 
Promoted migration of inflammatory cells to the wound site and collagen matrix 
deposition in open skin wounds 
[166] 
Chitosan 
hydrogels 
In treatment of third-degree burns, this chitosan material favors inflammatory 
cell migration and angiogenesis 
[169] 
D
EC
EL
LU
LA
R
IZ
ED
 M
A
TR
IX
 Bovine 
pericardium 
Monocyte-derived macrophages seeded on the decellularized matrix in vitro 
exhibited decreased spreading and lower levels of pro-inflammatory 
interleukins 
[170, 171] 
Skeletal muscle 
Decreased levels of pro-inflammatory cytokines and increased levels of anti-
inflammatory cytokines (in vitro); polarized macrophages towards M2 
phenotype (in vivo); decreased T cell proliferation 
[175] 
Porcine colon 
Extensive cellular infiltration and degradation in vivo as compared to colonic 
ECM that had been chemically crosslinked 
[176] 
Porcine ureter 
Carbodiimide crosslinking corresponds to M2 macrophage phenotype shift in 
subcutaneous rat model; crosslinking with glutaraldehyde or genipin leads to 
M1 
[178] 
A
M
N
IO
TI
C
 M
EM
B
R
A
N
E 
B
A
SE
D
 
Amniotic 
membrane sheet 
In treatment of adhesions between digital flexor tendons and their sheathes, 
AM sheets exhibited no inflammation and restored function to the fingers 
[220] 
Chronic ulcers treated with AM were healed within 10 weeks [221] 
In ocular surface applications, AM leads to rapid epithelialization and reduced 
inflammation 
[222-224] 
Collagen-amnion 
dermal substitute 
Results in few inflammatory cells, rapid healing, and good neovascularization in 
porcine full thickness skin defect 
[225] 
Micronized, dry 
amnion-chorion 
membrane 
Injected, reduces cartilage degeneration in osteoarthritic rat model [228] 
Collagen-amnion 
porous scaffolds 
Decreased expression of TNF-α and MMP-3 genes, increased expression of COLI 
under pro-inflammatory condition in vitro 
[230] 
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1.10 Figures 
 
 
Figure 1.1. (A) Sequence of events in the body’s normal response to injury (adapted from 
Bentzen et al. [231]). (B) This chain of events can change depending on the tissue type, age of 
the individual, disease state, and the acute/chronic nature of the defect. In some cases, wounds 
undergo excessive inflammation leading to chronic wounds or scar formation. Biomaterials with 
immunomodulatory properties have the potential to enhance healing.  
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CHAPTER 2: USING GLYCOSAMINOGLYCANS TO ALTER GROWTH FACTOR 
DELIVERY AND CELLULAR RESPONSE† 
2.1 Chapter overview 
The design of biomaterials for regenerative medicine can require biomolecular cues such as 
growth factors to induce a desired cell activity. Signal molecules are often incorporated into the 
biomaterial in either freely-diffusible or covalently bound forms. However, biomolecular 
environments in vivo are often complex and dynamic. Notably, glycosaminoglycans (GAGs) are 
linear polysaccharides found in the extracellular matrix involved in transient sequestration of 
growth factors via charge interactions. Biomaterials mimicking this phenomenon may offer the 
potential to amplify local biomolecular signals, both endogenously produced and exogenously 
added. GAGs of increasing sulfation (hyaluronic acid, chondroitin-sulfate, heparin) were 
incorporated into a collagen-GAG (CG) scaffold under development for tendon tissue 
engineering. Manipulating the degree of GAG sulfation significantly impacts sequestration of 
growth factors from the media. Increasing GAG sulfation improved equine tenocyte metabolic 
activity in normal serum (10% FBS), low serum (1% FBS), and IGF-1 supplemented media 
conditions. Notably, previously reported dose-dependent changes in tenocyte bioactivity to 
soluble IGF-1 within the CG scaffold were replicated by using a single dose of soluble IGF-1 in 
scaffolds containing increasingly sulfated GAGs. Collectively, these results suggest that CG 
scaffold GAG content can be systematically manipulated to regulate the sequestration and 
resultant enhanced bioactivity of growth factor signals on cell behavior within the matrix. 
  
                                                 
 
† This chapter has been adapted from the following publication: Rebecca A. Hortensius and Brendan A. C. Harley. 
“The use of bioinspired alterations in the glycosaminoglycan content of collagen-GAG scaffolds to regulate cell 
activity.” Biomaterials, 2013; 34(31): 7645-7652. 
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2.2 Introduction 
A major focus in the field of tissue engineering is the development of biomaterials able to mimic 
critical features of the extracellular matrix (ECM), the three-dimensional microenvironment 
surrounding cells in the tissues and organs of the body. Beyond the use of scaffold mechanical, 
structural, and compositional signals to impact cell fate, the addition of growth factors into the 
biomaterial is often a primary way of providing instructive signals within the matrix [81]. 
Methods for biochemical supplementation include providing factors free in solutions [55, 87, 
232-234], covalently tethering factors in random and specific orientations to the materials [93, 
235-237], and growth factor release vectors [238-240]. However, growth factor activity within 
the native ECM is often dictated by non-covalent interactions with ECM biomolecules such as 
proteins and proteoglycans that mediate transient immobilization and release.  
Glycosaminoglycans (GAGs) are linear polysaccharides found in the native ECM and are known 
to play a critical role in sequestering growth factors within the matrix [53, 54, 112, 114, 115, 
119, 241-243]. Along with structural variations in their carbohydrate backbone, GAGs can 
present varying levels of negative charges depending on their degree of sulfation [53, 54], 
making them attractive for developing growth factor sequestering biomaterials. In addition to the 
nonspecific, electrostatic growth factor-GAG interactions facilitated by the sulfate groups, it has 
also been shown that the sulfation code, the positions of the sulfate groups on the carbohydrate 
backbone, has an impact on growth factor binding [54]. Recently Hudalla et al. immobilized 
heparin-binding peptides on a self-assembled monolayer to demonstrate sequential binding of 
first heparin and then heparin-binding growth factors to the substrate in order to enhance human 
mesenchymal stem cell (hMSC) bioactivity [114]. Similar work has also shown that TGF-β1 can 
be adsorbed onto biomaterials composed of type I collagen and a sulfated hyaluronan [119]. 
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Considering that charged moieties have been shown to sequester biomolecules [54, 114, 115, 
119, 242, 243], systematic incorporation of differentially-charged GAGs within a biomaterial to 
selectively impact growth factor sequestration represents a promising avenue for tuning 
biomolecular signals. The efforts described here are therefore targeted at exploring whether the 
degree of GAG sulfation of a collagen-GAG scaffold could be modified to impact the scaffold’s 
capacity to transiently sequester activity-impacting molecules within the scaffold network. 
Collagen-GAG (CG) scaffolds have been used for a wide variety of applications for skin, 
peripheral nerve, and cartilage tissue engineering as well as 3D environments for in vitro studies 
of cell behavior [55-57, 67, 244-246]. Early development of the CG scaffold platform for skin 
regeneration included comparison of the effects of the type and weight percent of GAG 
contained in the scaffold [247], though these studies did not consider biomolecule sequestration. 
Based on results from in vivo kinetics of wound contraction and quality of regeneration studies, 
CG scaffolds have traditionally included a 11:1 (wt:wt) collagen:GAG ratio employing 
chondroitin-sulfate [248]. Recent efforts in our lab have described modification of the CG 
scaffold platform for tendon repair applications. As tendon is composed primarily of type I 
collagen arranged into aligned fibrils [77, 249, 250], we described a directional solidification 
method to fabricate CG scaffolds with highly anisotropic (aligned) morphology composed of 
longitudinally-aligned ellipsoidal pores [61]. Notably, scaffold anisotropy was found to improve 
equine tenocyte alignment as well as long-term maintenance of a pro-tenogenic phenotype [60, 
61]. Further, incorporation of growth factor signals within the anisotropic scaffold in either 
freely-soluble or covalently immobilized forms have been shown to impact tenocyte bioactivity 
in a dose-dependent manner [87]. In particular, soluble or covalently-bound insulin-like growth 
factor 1 (IGF-1) was found to enhance tenocyte proliferation but at the expense of tenocyte 
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phenotype [61]. Similarly, soluble growth/differentiation factor 5 (GDF-5) was used to increase 
expression of tenogenic-specific genes within the CG scaffolds [87].  
This manuscript described the manipulation of the degree of GAG sulfation within the CG 
scaffold to promote transient, non-covalent sequestration of growth factors for applications in 
tendon tissue engineering. As prior work has shown dose-dependent tenocyte responses to 
growth factor within the CG scaffold [61, 87], this work investigated whether alterations of GAG 
content within the scaffold could replicate dose-dependent effects using a single growth factor 
dose. Notably, it was hypothesized that scaffolds containing a highly sulfated GAG (heparin) 
would show an increase in transient growth factor sequestration and enhanced bioactivity of cells 
seeded within these scaffolds relative to less sulfated GAGs such as chondroitin-sulfate, the 
GAG traditionally used in CG scaffolds, or non-sulfated hyaluronic acid. The response of equine 
tenocytes and human mesenchymal stem cells (hMSCs) to pro-proliferation (IGF-1) and pro-
tenocyte phenotype (GDF-5) factors in the culture media as well as metabolically limited culture 
environments (low serum) was examined to explore the impact of GAG-mediated non-covalent 
sequestration on cellular bioactivity [87].  
2.3 Materials and methods 
2.3.1 Preparation of CG suspension 
A suspension of collagen and a defined glycosaminoglycan was made by homogenizing type I 
collagen from bovine Achilles tendon (Sigma-Aldrich, St. Louis, MO) and one of three 
glycosaminoglycans (GAGs): hyaluronic acid from Streptococcus equi (Sigma-Aldrich #53747, 
St. Louis, MO), chondroitin-sulfate from shark cartilage (Sigma-Aldrich #C4384, St. Louis, MO) 
or heparin from porcine intestinal mucosa (Sigma-Aldrich #H4784, St. Louis, MO) in 0.05 M 
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acetic acid [56]. A constant collagen concentration (1.5% w/v) and collagen:GAG ratio (11.28:1) 
was used for all experiments. The suspension was stored at 4°C and degassed prior to use [251].  
2.3.2 Fabrication of CG scaffolds via freeze drying 
CG scaffolds were fabricated as previously described [61]. Briefly, the scaffolds were produced 
via directional solidification using a polytetrafluoroethylene (PTFE)-copper mold. The mismatch 
in thermal conductivity between the mold materials promotes unidirectional heat transfer through 
the copper bottom when the mold is placed on a precooled freeze-dryer shelf (VirTis, Gardiner, 
NY). The CG suspension was added to the cylindrical wells of the mold and frozen at -10˚C for 
two hours prior to the sublimation of the resulting ice crystals at 0˚C and 200 mTorr. This 
resulted in a dry, porous scaffold 6 mm in diameter and 20 mm in length with constant pore size 
along its length [61]. 
2.3.3 Crosslinking of CG scaffold 
Following lyophilization, scaffolds were sterilized and dehydrothermally crosslinked in a 
vacuum oven (Welch, Niles, IL) at 105˚C under vacuum for 24 hours [56]. 5 mm long sections 
were cut from the scaffold and used for all experiments [61]. Prior to use, these scaffolds were 
hydrated in 100% ethanol overnight and washed in phosphate-buffered saline (PBS) for 24 
hours. Scaffolds were subsequently crosslinked using carbodiimide chemistry to make them 
resistant to tenocyte contraction [248, 252]. Scaffolds were immersed in 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide 
(NHS) at a molar ratio of 5:2:1 EDC:NHS:COOH for 2 h under shaking at room temperature. 
Following crosslinking, scaffolds were washed with PBS and stored in fresh PBS at 4˚C. 
2.3.4 SEM analysis 
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Scanning electron microscopy (SEM) was used to visualize the scaffold microstructure. Dry, 
uncrosslinked sections from the center of the scaffold were used for analysis. Samples were 
sputter-coated with gold-palladium and imaged with a JEOL JSM-6060LV scanning electron 
microscope using secondary electron and backscattered electron detectors under high vacuum.  
2.3.5 Evaluation of CG scaffold microstructure 
Microstructural features (pore size, aspect ratio) of the aligned CG scaffold variants were 
calculated using previously described stereology approaches [61]. Briefly, serial longitudinal and 
transverse sections were generated from glycolmethacrylate (Polysciences, Warrington, PA) 
embedded scaffolds using a microtome (Leica Microsystems, Germany) and mounted on slides. 
Sections were then stained with aniline blue stain to facilitate the visualization of the scaffold 
struts on an optical microscope (Leica Microsystems, Germany). Multiple images were captured 
per section and then analyzed using MATLAB equipped with a linear intercept method which 
outputs parameters used to calculate pore diameter and aspect ratio [69]. For each GAG variant a 
minimum of 6 scaffold sections were analyzed (3 longitudinal, 3 transverse) with a minimum of 
5 fields of view captured per section. 
2.3.6 Pull down sequestration assay 
The degree of growth factor sequestration by CG scaffold variants was determined via a pull 
down assay. Ten hydrated crosslinked scaffolds were incubated overnight at 37°C in a single 
well of an ultra-low attachment 6-well plate (Fisher, Waltham, MA) in 4 mL of a pH 7.4 PBS 
solution with 500 ng/mL IGF-1 (ProSpec, Israel) and 1% bovine serum albumin (BSA). 
Scaffolds fabricated from each GAG were tested separately, with wells containing the IGF-1 
solution but no scaffolds used as controls. Following incubation, the amount of IGF-1 remaining 
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in solution was measured via an ELISA kit (R&D Systems, Minneapolis, MN). Relative pull 
down, the amount of IGF-1 trapped within the CG scaffolds, was calculated from the difference 
in IGF-1 remaining in the media of the experimental versus control wells. Pull down for each CG 
variant was reported as a percentage of the total IGF-1 concentration in the loading solution. 
2.3.7 Tenocyte isolation and culture 
Tenocytes (tendon cells) were isolated from 2-3 year old horses that were euthanized for reasons 
not related to tendinopathy using previously described methods [253]. Tenocytes were expanded 
in standard culture flasks in high glucose Dulbecco’s modified Eagle’s medium supplemented 
with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 1% Antibiotic-Antimycotic 
(Invitrogen, Carlsbad, CA ), 1% L-glutamine (Invitrogen, Carlsbad, CA), and 50 µg/mL ascorbic 
acid (Wako, Richmond, VA). The tenocytes were cultured to confluence at 37˚C and 5% CO2 
and the media was changed every 3 days. Passage 4 cells were used for all culture experiments. 
2.3.8 hMSC culture 
Human mesenchymal stem cells (hMSC) from human bone marrow (Lonza, Switzerland) were 
cultured in standard culture flasks in low glucose Dulbecco’s modified Eagle’s medium 
supplemented with 10% MSC FBS (Invitrogen, Carlsbad, CA), 1% Antibiotic-Antimycotic 
(Invitrogen, Carlsbad, CA ), 1% L-glutamine (Invitrogen, Carlsbad, CA). Media was changed 
every 3 days and the cells were cultured to confluence at 37˚C and 5% CO2. Cells were used at 
passage 6. 
2.3.9 Scaffold seeding and culture conditions 
Hydrated scaffold sections (6 mm diameter, 5 mm thick) were placed in ultra-low attachment 6-
well plates (Fisher, Waltham, MA). Confluent tenocytes or hMSCs were trypsinized and 
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resuspended at concentrations of 5 x 105 tenocytes or 7.5 x 104 hMSCs per 20 µL of media. 
Scaffolds were seeded with either tenocytes or hMSCs using a previously established method 
[61]. Briefly, 10 µL of the cell suspension was added to each scaffold and then the scaffolds 
were incubated for 15 minutes at 37˚C. The scaffolds were flipped over and another 10 µL of 
cell suspension was added for a total of 5 x 105 tenocytes or 7.5 x 104 hMSCs seeded on each 
scaffold. After 2 hours of incubation to facilitate initial cell attachment, additional media was 
added and scaffolds were incubated at 37˚C and 5% CO2 with the media changed every 3 days 
for the duration of the experiment. Scaffolds were cultured in tenocyte or hMSC culture media as 
described above, with or without the addition of serum or soluble growth factors. While standard 
media contained 10% FBS, some cultures were performed at low serum levels (1%). 
Experiments including growth factor supplementation (50 ng/mL IGF-1, 500 ng/mL GDF-5) 
were performed in serum free media. 
2.3.10 Quantification of cell metabolic activity 
The metabolic activity of the cells contained within the CG scaffolds was measured using a non-
destructive alamarBlue® assay (Invitrogen, Carlsbad, CA) [61, 251] that uses the conversion of 
resazurin to the fluorescent byproduct resorufin by metabolically active cells. Briefly, scaffolds 
were removed from culture, rinsed in PBS, then incubated in a 1x alamarBlue® solution at 37˚C 
for 2 hours under shaking [61]. Using a fluorescent spectrophotometer, resorufin fluorescence 
was measured (excitation: 540 nm, emission: 590 nm) and compared to a standard curve created 
from a known number of cells (tenocytes, hMSCs). While not all cells are known to attach to the 
scaffold during seeding [67], metabolic activity at each time point was reported as a percentage 
of the total number of seeded cells to provide a standard comparison metric. 
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2.3.11 RNA isolation and real-time PCR 
RNA was isolated from cells (tenocytes or hMSCs) using an RNeasy Plant Mini kit (Qiagen, 
Valencia, CA). Cell seeded scaffolds were rinsed in PBS, cut longitudinally with a razor, and 
immersed in the kit’s lysis buffer for 5 minutes on ice [87]. After lysing, RNA was isolated per 
the kit’s instructions and total RNA quantified via spectrophotometry. The isolated RNA was 
reverse transcribed in a Bio-Rad S1000 thermal cycler using a QuantiTect Reverse Transcription 
kit (Qiagen, Valencia, CA). Real-time PCR reactions were performed in an Applied Biosystems 
7900HT Fast Real-Time PCR System (Carlsbad, CA) to measure gene expression levels for 
collagen type I alpha 2 (COL1A2), scleraxis (SCXB), and tenascin-C (TNC). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as a housekeeping gene. All primer sequences 
used (Table 2.1) were taken from the literature [130, 254], and were synthesized by Integrated 
DNA Technologies (Coralville, IA). Analysis was completed with Sequence Detection Systems 
software v2.4 (Applied Biosystems, Carlsbad, CA). All results were expressed as fold changes 
normalized to the expression levels of cells in CG scaffolds containing hyaluronic acid for the 
GAG constituent at the first time point unless otherwise noted. 
2.3.12 Statistical analysis 
One-way analysis of variance (ANOVA) was performed on all data sets followed by Tukey-HSD 
post-hoc test. A p-value < 0.05 was used for significance. All analyses were based on a minimum 
of n=3 scaffolds. In figures, error is reported as the standard error of the mean. 
2.4 Results 
2.4.1 Scaffold microstructure and pore size analysis 
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Scaffolds fabricated via freeze drying techniques showed highly porous, sponge-like features 
when imaged with SEM (Fig. 2.1). Analysis of scaffold microstructure suggested minimal 
structural differences between scaffolds. Notably, in the longitudinal direction, mean pore 
diameters varied between 184 and 199 µm for all three variants, with no statistically significance 
differences between GAG types (C:HA, C:CS, C:HP) (Table 2.2). In the transverse plane, mean 
pore sizes for the scaffold groups varied between 195 and 306 µm with a statistically significant 
difference (p < 0.05) observed between C:CS and C:HP scaffolds (Table 2.2). However, 
increasing (or decreasing) level of GAG sulfation was not correlated with a change in scaffold 
pore size since the transverse pore sizes of the C:HA scaffolds fall between those of the higher 
sulfated GAGs.  
2.4.2 Growth factor sequestration within CG scaffolds 
Scaffold GAG content was found to significantly impact sequestration of IGF-1 from the media 
to the scaffold (Fig. 2.2). Notably, sulfated C:CS and C:HP scaffolds showed significantly (p < 
0.05) increased IGF-1 sequestration compared to non-sulfated C:HA scaffolds. Additionally, no 
significant increase in IGF-1 pull down was observed for non-sulfated C:HA scaffolds over 
control (no scaffolds) were observed (data not shown). 
2.4.3 Tenocyte response to altered serum concentrations 
Equine tenocyte metabolic activity was evaluated in each GAG scaffold at days 1, 4, 7 and 14 
(Fig. 2.3). Cells were cultured in media with either normal (10%) or metabolically-limiting (1%) 
levels of fetal bovine serum (FBS). Tenocytes cultured in 10% media showed GAG-dependent 
trends in metabolic activity; notably C:HP scaffolds showed elevated metabolic activity over 
other groups at all experimental timepoints, with a significant (p < 0.05) increase in metabolic 
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activity seen compared to both C:HA and C:CS scaffolds at day 7 (Fig. 2.3A). The effect was 
heightened in low serum conditions, where all groups showed reduced metabolic activity 
compared to normal serum. However, tenocytes within the highest sulfated C:HP scaffolds 
showed significantly enhanced metabolic activity over the other CG scaffold variants after the 
first day in culture. Tenocyte metabolic activity in C:HP scaffold was significantly higher (p < 
0.05) at days 4, 7 and 14 compared to all other scaffold groups (C:HA, C:CS; Fig.2.3B).  
Prior work has linked increases in tenocyte metabolic activity with increased expression levels of 
the tendon-associated structural matrix gene COL1A2 as well as decreases in the tenocyte 
phenotype associated gene TNC [87]. Expression levels of COL1A2 and TNC were therefore 
evaluated for tenocytes cultured in normal (10% FBS) media in the three scaffold variants at 
days 4, 7, and 14 (Fig. 2.4). COL1A2 gene expression was significantly upregulated in the most 
highly-sulfated C:HP scaffolds compared to the C:HA group at day 7 and both lower-sulfated 
C:HA and C:CS groups at day 14 (p < 0.05) (Fig. 2.4A). Separately, a trend of downregulation 
of TNC gene expression was observed with increasing GAG sulfation (Fig. 2.4B). This effect 
was significant (p < 0.05) in C:HP scaffolds compared to C:HA at days 4 and compared to both 
scaffold types at day 7 (p < 0.05) (Fig. 2.4B). 
2.4.4 Tendon cell metabolic activity and gene expression with IGF-1 supplementation 
Prior work has shown dose-dependent effects of IGF-1 supplementation (10, 50, 200 ng/mL) on 
tenocytes cultured in C:CS scaffolds [87]. These effects were reflected in both measures of 
growth (metabolic activity and COL1A2 gene expression) and phenotype (gene expression of 
SCXB and TNC). Here, tenocytes were seeded in the three differentially-sulfated CG scaffold 
variants, then cultured in serum-free media supplemented with insulin-like growth factor 1 (IGF-
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1) at a concentration of 50 ng/mL. Previously observed IGF-1 dose-dependent responses for 
tenocyte metabolic activity as well as gene expression profiles were observed for a single IGF-1 
dose across scaffolds of increasing GAG-sulfation (Fig. 2.5). Tenocytes in the most highly-
sulfated C:HP scaffolds showed significantly higher metabolic activity at days 4, 7, and 14 
compared to cells seeded in the other GAG variants of our CG scaffolds at the same timepoints 
(p < 0.01). A trend of increasing COL1A2 expression was observed starting at day 4 in the 
scaffolds, with significant (p < 0.05) upregulation observed at days 4 and 14 in the most highly-
sulfated C:HP scaffolds compared to lesser-sulfated C:HA and C:CS scaffolds (Fig. 2.5B).  
Increasing levels of IGF-1 supplementation has been previously shown to decrease expression of 
tenocyte phenotypic markers scleraxis (SCXB) and tenascin-C (TNC) [87]. Similarly, expression 
of SCXB (Fig. 2.5C) and TNC (Fig. 2.5D) was significantly downregulated with increasing GAG 
sulfation. Notably, SCXB expression was significantly lower in the most highly-sulfated C:HP 
scaffolds than C:HA scaffolds at day 4 and significantly lower than both lesser-sulfated scaffolds 
variants at day 14 (p < 0.05). Similarly, TNC gene expression was significantly (p < 0.05) 
downregulated in more-highly sulfated C:CS and C:HP scaffolds compared to non-sulfated 
C:HA scaffolds at day 4, and significantly (p < 0.05) downregulated in the most highly-sulfated 
C:HP scaffolds versus non-sulfated C:HA scaffolds at day 14. 
2.4.5 hMSC metabolic activity and gene expression with GDF-5 supplementation 
Previous investigations have shown the use of sequestered heparin on chemically-defined culture 
substrates could impact the bioactivity of human mesenchymal stem cells (hMSCs) through 
transient sequestration of growth factors [114]. Separately, growth/differentiation factor 5 (GDF-
5) has been identified as a pro-tenogenic morphogen [255, 256]. Here, the metabolic activity and 
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gene expression levels of the tenogenic gene SCXB were monitored in hMSCs cultured in serum-
free media containing 500 ng/mL GDF-5 in the range of CG scaffolds. While hMSC metabolic 
activity remained low for all variants, likely a consequence of serum free conditions, hMSCs in 
the most highly-sulfated C:HP scaffolds were significantly (p < 0.05) more metabolically active 
than those in the C:CS scaffolds at day 4 and significantly (p < 0.05) more metabolically active 
than either of the lesser-sulfated (C:HA, C:CS) scaffolds at day 7 (Fig. 2.6A). Further, although 
the expression of SCXB was globally upregulated at day 7 compared to day 4, there was no 
significant difference between any of the groups (Fig. 2.6B). 
2.5 Discussion 
This study sought to determine whether the degree of sulfation of the GAG component of a 
model CG scaffold could impact growth factor sequestration and, further, whether such 
sequestration was sufficient to alter the bioactivity of both differentiated (equine tenocytes) and 
non-differentiated (hMSCs) cells. This effort was inspired by GAG-mediated sequestration of 
factors within the native ECM [81] and prior work showing heparin-binding peptides 
incorporated within a chemically-defined two-dimensional substrate were able to bind heparins 
from the cell culture media which in turn were able to transiently sequester growth factors on the 
culture surface [114, 243]. Incorporating charged moieties into a biomaterial able to replicate 
such sequestration of the ECM offers a route to locally amplify biomolecular signals, to either 
reduce required factor dose or direct autocatalytic processes. Systematic variation of 
sequestration capacity using bioinspired GAG design has not before been implemented in 3D 
collagen-based biomaterial systems. 
GAGs with known differences in their degree of sulfation were integrated into a three-
dimensional CG scaffold. CG scaffolds have been previously used for a range of in vitro and in 
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vivo applications, including prior work in our lab examining the importance of soluble growth 
factor supplementation schemes to enhance tenocyte bioactivity for tendon tissue engineering 
applications [60, 61, 251]. In particular, insulin-like growth factor 1 (IGF-1) and growth and 
differentiation factor 5 (GDF-5) were shown to drive dose-dependent responses in tenocyte 
metabolic activity and gene expression [87]. Notably, IGF-1 enhanced tenocyte proliferation but 
at the expense of phenotype [233, 257] while GDF-5 could be used to maintain tenogenic 
phenotype in vitro but at the expense of proliferation [255, 256]. Importantly for this application, 
dose-dependent increases in COL1A2 gene expression and collagen biosynthesis as well as dose-
dependent decreases in SCXB and TNC gene expression in equine tenocytes with IGF-1 
supplementation have been previously described. Additionally, dose-dependent increases in 
expression of tenogenic markers SCXB and TNC in equine tenocytes with GDF-5 
supplementation were noted [87].  
The three CG scaffold variants all displayed microstructural features characteristic of low-
density, open-cell foams (Fig. 2.1). All three scaffolds contained consistent pore structures in the 
longitudinal plane (Table 2.2), the direction previously identified as having the primary impact 
on tenocyte bioactivity [60, 61]. Sequestration of growth factors from the media into the scaffold 
structure was examined across the three CG scaffold variations using a modified pull down assay 
(Fig. 2.2). There was a significant increase in the amount of IGF-1 bound to the moderately (CS) 
and highly (HP) sulfated GAG scaffolds compared to the non-sulfated GAG (HA) scaffold. This 
supports the claim that the presence of charged glycosaminoglycans within the CG scaffold, even 
at relatively low concentration (11.28:1 collagen:GAG) can impact the sequestration of growth 
factors. We acknowledge that the difference in transverse pore size between C:CS and C:HP 
scaffolds may impact cell activity. Indeed, CG scaffold pore size has previously been observed to 
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impact cell attachment [67], motility [244], and even tenocyte alignment and distribution within 
the scaffold [61]. However, the differences in pore size between the C:CS and C:HP scaffolds in 
this study is outside the range of pore sizes (50 – 150 μm) previously reported to affect cell 
activity. Further, the difference in pore size in this study was only observed between two scaffold 
variants and in only a single plane, so does not explain the entirety of the reported data that 
showed increases and decreases in cell activity across the range of GAG types. 
In order to study the effects of GAG-mediated sequestration on tenocyte bioactivity, the 
metabolic activity of cells cultured in the CG scaffold variants at two concentrations of FBS was 
examined (Fig. 2.3). The objective was to determine whether the highly sulfated GAG scaffolds 
could support enhanced cellular bioactivity even in metabolically limited cultures. Such 
observations had been previously made for hMSCs cultures on 2D, chemically-defined culture 
substrates presenting heparin binding peptides [114], but had not been extended to a fully-3D 
biomaterial composed of native ECM proteins. Since serum contains a large number of growth 
factors, scaffold bioactivity was evaluated at normal (10%) and restricted (1%) serum levels. At 
normal serum levels tenocytes proliferated in all scaffold variants and scaffold GAG sulfation 
impacted tenocyte metabolic activity (Fig. 2.3A) with the greatest effect observed in 
metabolically-limited cultures (1% serum) (Fig. 2.3B). Here, a significant effect of GAG type 
was seen for all culture conditions, with the most highly-sulfated C:HP scaffolds inducing 
significant increases in tenocyte metabolic activity at days 4, 7, and 14 in low serum conditions 
(Fig. 2.3B). This supports the hypothesis that the highly sulfated heparin GAG scaffolds enhance 
tenocyte metabolic activity even at reduced metabolic support, which may be critical for future 
in vivo studies where metabolic support is significantly reduced immediately after implantation.  
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Further, when examining gene expression profiles for tenocyte growth in the scaffolds under 
normal metabolic support, GAG sulfation-dependent increases in COL1A2 expression was 
observed (Fig.2.4A) indicating an increase in the signal to produce collagen type I, a primary 
tendon-associated structural protein. Future investigations will employ longer culture times (4 – 
8 weeks) to quantify differences in collagen production via ELISA or histology. Such studies are 
not included as part of this work because the current goal was to elucidate whether the initial 
GAG content of the scaffolds could impact cell bioactivity; longer-term experiments would 
involve significant scaffold remodeling, making it difficult to assess GAG-mediated influences. 
In addition to the effects of GAG sulfation on COL1A2 expression, GAG-dependent 
downregulation of the TNC gene, which encodes for a glycoprotein found in developing and 
mature tendon, was seen (Fig. 2.4B). These results are consistent with prior work that 
demonstrated a tradeoff between tenocyte proliferation and maintenance of the tendon phenotype 
[87, 90]. 
Following the investigation of tenocyte bioactivity at different serum concentrations, the 
examination of tenocyte response to the proliferative growth factor (IGF-1) was undertaken. 
Prior work using the C:CS scaffold demonstrated dose-dependent increases in tenocyte 
proliferation with IGF-1 supplementation (10, 50, 200 ng/mL) [87]. It was hypothesized that this 
dose-dependent increase in tenocyte metabolic activity could be replicated with a single dose of 
IGF-1 (50 ng/mL) and differential levels of GAG-mediated IGF-1 sequestration within the 
matrix. Indeed, dose-dependent trends and significant (p < 0.01) increases in tenocyte metabolic 
activity at days 4, 7, and 14 in the CG scaffolds with the highest degree of GAG-sulfation were 
seen (Fig. 2.5A). In addition, GAG-dependent upregulation of COL1A2 and downregulation of 
TNC and SCXB was observed (Fig. 2.5B-D). Critically, in enhanced proliferative conditions 
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established in scaffolds of increasing GAG-sulfation, COL1A2 expression increased while 
markers of tenogenic phenotype decreased. 
Finally, the use of GDF-5 to alter hMSC bioactivity within the CG scaffold variants was studied 
(Fig. 2.6). To specifically interrogate the addition of GDF-5, these experiments were completed 
in serum-free conditions, leading to a shortened experimental time (7 days) and overall reduced 
metabolic activity for all conditions. As seen with tenocyte cultures (Fig. 2.3), hMSC metabolic 
activity was enhanced in the most highly-sulfated C:HP scaffolds. These results confirm that 
even without serum or a pro-proliferative factor the highly sulfated GAGs can improve cellular 
bioactivity, likely through local amplification of biomolecule signals [243]. Examining 
expression of a characteristic tenogenic gene SCXB, global increases over time for all groups 
were observed with no significant differences between the GAG variants, perhaps due to the 
reduced metabolic support from the media or the overall GDF-5 dose.  
Taken together, this work illustrates the application of bioinspired proteoglycan design within a 
model collagen-GAG scaffold with focus on creating a 3D biomaterial construct able to leverage 
concepts taken from GAG-mediated local sequestration of biomolecular signals within the native 
ECM. The incorporation of three distinct GAGs into a model CG scaffold was examined to 
determine the ability for each scaffold variant to sequester growth factors from the media. 
Further, scaffolds with increasing degrees of GAG sulfation were used to replicate previously 
observed dose-dependent effects of growth factor supplementation on cell bioactivity using 
single factor dosages. Notably, there was enhanced sequestration of IGF-1 within the CG 
scaffold structure with moderately or highly sulfated GAGs. While an increased degree of 
sulfation led to increased tenocyte metabolic activity in low serum and IGF-1 supplemented 
media conditions, this increase in metabolic activity is accompanied by a decrease in tendon 
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phenotypic markers. Although this effort used a single collagen:GAG ratio previously described 
in the literature as optimal for a range of tissue regeneration studies [56, 258], future work will 
include modifying the overall collagen:GAG ratio or gradually desulfating a particular GAG of 
interest (e.g., CS, HP [117, 259]) to investigate the impact of GAG concentration on cell 
bioactivity. Future endeavors may also consider more specific alteration to the carbohydrate 
backbone or GAG sulfation code to gain improved control over factor sequestration and release. 
2.6 Conclusions 
Recognizing the significance of GAGs in the native ECM for transiently sequestering and 
amplifying biomolecular signals, this manuscript demonstrated the use of bioinspired GAG 
design within a collagen-GAG scaffold to impact cell bioactivity for a tendon tissue engineering 
application. This study showed that increasing scaffold GAG sulfation increases equine tenocyte 
metabolic activity in low serum and IGF-1 supplemented media conditions, but at the expense of 
tendon phenotypic markers. Previously described dose-dependent effects of IGF-1 and GDF-5 
supplementation on equine tenocytes and hMSCs in CG scaffolds were replicated by using a 
single dose of IGF-1 or GDF-5 and the series of CG scaffolds with increasing degree of GAG 
sulfation. These results suggest ways that scaffold chemistry may be optimized to reduce 
required dosages of growth factors in the cell culture media.  
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2.7 Tables 
 
Table 2.1. Primer sequences used in RT-PCR. 
Transcript Sequence Reference 
COL1A2 
(equine) 
Forward: 5’-GCACATGCCGTGACTTGAGA-3’ 
Reverse: 3’-CATCCATAGTGCATCCTTGATTAGG-5’ 
[130] 
TNC 
(equine) 
Forward: 5’-GGGCGGCCTGGAAATG-3’ 
Reverse: 3’-CAGGCTCTAACTCCTGGATGATG-5’ 
[130] 
SCXB 
(equine) 
Forward: 5’-TCTGCCTCAGCAACCAGAGA-3’ 
Reverse: 3’-TCCGAATCGCCGTCTTTC-5’ 
[130] 
GAPDH 
(equine) 
Forward: 5’-GCATCGTGGAGGGACTCA-3’ 
Reverse: 3’-GCCACATCTTCCCAGAGG-5’ 
[130] 
   
SCXB 
(human) 
Qiagen QuantiTect Primer Assay Kit. Commercial product (no 
sequence available) 
[130] 
GAPDH 
(human) 
Forward: 5’- CCATGAGAAGTATGACAACAGCC-3’ 
Reverse: 5’- CCTTCCACGATACCAAAGTTG-3’ 
[254] 
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Table 2.2. Mean pore size (longitudinal, transverse plane) for the three aligned CG scaffold 
variants (GAG: Hyaluronic acid, chondroitin-sulfate, heparin). Data expressed as mean ± 
standard deviation, n = 3. (*) significance (p < 0.05) between groups in the transverse direction. 
 
Longitudinal pore size Transverse pore size 
C:HA 184 ± 46 µm 221 ± 27 µm 
C:CS 196 ± 11 µm 195 ± 27 µm 
C:HP 199 ± 25 µm 306 ± 31 µm 
 
  
* 
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2.8 Figures 
 
 
 
 
Figure 2.1. SEM images of CG scaffold pore structure for each GAG variant (left to right): 
collagen:hyaluronic acid (C:HA), collagen:chondroitin-sulfate (C:CS, standard), 
collagen:heparin (C:HP).Scale bar: 100 µm. 
 
 
Figure 2.2. IGF-1 sequestration by CG scaffolds with varying degree of GAG sulfation. The 
degree of pull down is normalized to the no scaffold control. (*) significance (p < 0.05) between 
scaffold groups. 
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Figure 2.3. Tenocyte metabolic activity as a function of scaffold GAG sulfation as well as media 
serum level. (A) Tenocyte metabolic activity in scaffolds cultured in media containing normal 
(10%) FBS concentrations. (B) Tenocyte metabolic activity under reduced (1%) FBS 
concentrations. (*) significance (p < 0.05) between groups at a given time point. 
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Figure 2.4. Tenocyte gene expression levels for (A) Collagen I (COL1A2) and (B) Tenascin C 
(TNC) as a function of scaffold GAG sulfation at days 4, 7, and 14 of culture. Gene expression 
was normalized to tenocytes cultured in the C:HA scaffold variant at day 4. (*) significance (p < 
0.05) between GAG groups at a given time point. 
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Figure 2.5. Tenocyte response to IGF-1 supplementation (50 ng/mL in serum-free media) as a 
function of scaffold GAG content. Tenocyte response is reported as (A) total metabolic activity 
as well as gene expression levels (normalized to C:HA scaffolds at day 1) for (B) collagen I 
(COL1A2), (C) scleraxis (SCXB), and (D) tenascin-C (TNC). (*) significance (p < 0.05) between 
groups at a given time point. (**) significance (p < 0.01) compared to all groups at a given time 
point. 
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Figure 2.6. (A) Metabolic activity and (B) normalized (to 2D control at day 4) scleraxis gene 
expression of hMSCs cultured in CG scaffolds with varying GAG content in serum-free media 
supplemented with 500 ng/mL GDF-5. (*) significance (p < 0.05) between groups at a given 
time point. 
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CHAPTER 3: GENE DELIVERY INFLUENCED BY ELECTROSTATIC 
INTERACTIONS‡ 
3.1 Chapter overview 
The design of biomaterials for increasingly complex tissue engineering applications often 
requires exogenous presentation of biomolecular signals. Integration of gene delivery vectors 
with a biomaterial scaffold offers the potential to bypass the use of expensive and relatively 
inefficient growth factor supplementation strategies to augment cell behavior. However, 
integration of cationic polymer based gene delivery vectors within three-dimensional 
biomaterials, particularly matrices which can carry significant surface charge, remains poorly 
explored. We examined the potential of polyethylenimine (PEI) as a gene delivery vector for 
three-dimensional collagen-glycosaminoglycan (CG) scaffolds under development for tendon 
repair. While acetylated versions of PEI have demonstrated improved transfection efficiency in 
2D culture assays, we investigated translation of this effect to a 3D biomaterial that contains 
significant electrostatic charge. A reporter gene was used to examine the impact of polymer 
modification, polymer:DNA ratio, and the degree of sulfation of the biomaterial 
microenvironment on gene delivery in vitro. We observed highest transgene expression in 
acetylated and unmodified PEI at distinct polymer:DNA ratios; notably, the enhancement often 
seen in two-dimensional culture for acetylated PEI did not fully translate to three-dimensional 
scaffolds. We also found highly sulfated heparin-based CG scaffolds showed enhanced initial 
luciferase expression but not prolonged activity. While PEI constructs significantly reduced 
tenocyte metabolic health during the period of transfection, heparin-based CG scaffolds showed 
                                                 
 
‡ This chapter has been adapted from the following publication: Rebecca A. Hortensius, Jacob R. Becraft, Daniel W. 
Pack, and Brendan A. C. Harley. “The effect of glycosaminoglycan content on polyethylenimine-based gene 
delivery within three-dimensional collagen-GAG scaffolds.” Biomaterials Science, 2015; 3(4): 645-654. 
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the greatest recovery in tenocyte metabolic health over the full 2 week culture. These results 
suggest that the electrostatic environment of three-dimensional biomaterials may be an important 
design criterion for cationic polymer-based gene delivery. 
3.2 Introduction 
Traditionally, biomaterial design has focused on optimizing a range of biophysical properties 
such as structure, mechanics, and rate of degradation. Often, efforts have focused on artificial 
extracellular matrix (ECM) analogs that support cellular health and function by mimicking the 
native tissue’s structure, mechanics, and composition. More recently, the impact of biomolecular 
supplementation and delivery methods has been incorporated into biomaterial design. While 
growth factors are still primarily introduced freely in solution as soluble media additives [87, 
232-234, 260], efforts have turned to exploring approaches that could extend the time a growth 
factor is present within the biomaterial or that could spatially control factor localization. In these 
cases, designs have included strategies to release a biomolecule of interest from a degradable 
construct (e.g., microspheres) [238-240] or to covalently bind the biomolecule to the surface of 
the biomaterial [93, 235, 237]. Inspired by transient immobilization of growth factors within the 
native ECM, recent approaches have also begun to incorporate charged moieties within the 
biomaterial (e.g., glycosaminoglycans, heparin binding peptides) that are able to transiently 
sequester factors – either exogenously added or endogenously produced – to the surface of the 
biomaterial [114, 115, 242, 243, 261]. However, growth factors still incur a high cost, require 
large dosages, and suffer from relatively short half-lives as well as the potential for significant 
diffusive loss after in vivo implantation. 
Gene delivery approaches offer the potential to address a number of limitations associated with 
conventional biomolecular supplementation. Although viral-based gene vehicles are most 
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efficient in achieving gene expression, concerns remain about their immunogenic safety, and 
hence regulatory approval [262, 263]. Non-viral gene vectors, in the form of proteins, lipids and 
cationic polymers, provide an alternative path for transient gene delivery [121, 129, 264-270]. 
One of the most efficient and well-studied off-the-shelf cationic polymers is polyethylenimine 
(PEI) [126, 128, 271, 272]. Through electrostatic interaction, PEI binds the negatively charged 
phosphates on the DNA backbone, spontaneously condensing into a polymer:DNA complex 
(polyplex) on the order of hundreds of nanometers [120]. The polymer:DNA weight-to-weight 
(w:w) ratio is a critical design parameter to control both transfection efficiency and cytotoxicity. 
If the w:w ratio is too low, there is minimal gene transfection. Alternatively, high polymer:DNA 
ratios often result in significant polymer-induced cytotoxicity [271, 273]. In the context of 
designing a more efficient PEI-based delivery system, recent efforts have focused on selective 
acetylation of the primary and secondary amines of the polymer. Acetylation decreases the 
density of protonated amines, decreasing the cationic charge of the polymer, and allowing for a 
weaker polymer:DNA interaction, leading to easier release of the nucleic acid cargo and 
significant improvements in gene delivery efficiency [126, 127].  
Our laboratory has recently described a series of collagen-GAG (CG) scaffolds under 
development for tendon regenerative medicine applications. Fabricated via lyophilization, we 
have described approaches to create anisotropic pore architectures to improve tenocyte 
bioactivity as well as influence mesenchymal stem cell differentiation down a tenogenic lineage 
[60, 61, 274]. We have also explored the use of growth factor supplementation strategies to 
balance tenocyte bioactivity versus proliferation [61, 87, 275]. Recently, biomaterials such as CG 
scaffolds which contain charged ECM-derived matrix components have increasingly been 
explored in the context of bioinspired biomaterial design. For example, glycosaminoglycans 
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(GAGs) in the native ECM are known to play an important role in sequestering biomolecules 
within the matrix based on their degree of sulfation and structural variations in their carbohydrate 
backbone [53, 114]. Biomaterials incorporating GAGs have increasingly been explored as a 
means to transiently regulate growth factor availability [114, 117, 242, 243]. Recently, we 
demonstrated that modifying the GAG content of collagen-GAG (CG) scaffolds imparts 
differential capacity for non-covalent, electrostatic growth factor binding [59]. Notably, by 
incorporating highly sulfated heparin into the CG scaffold, we saw increased growth factor 
sequestration and positive impacts on cellular bioactivity compared to scaffolds containing lesser 
charged GAGs (hyaluronic acid, chondroitin sulfate). While modifying the degree of GAG-
sulfation within three-dimensional biomaterials has been shown to impact both biomolecule 
sequestration and resultant cell response, its impact on the activity of cationic-polymer gene 
delivery vectors remains poorly understood. 
The objective of this study therefore was to examine the efficiency of PEI-based gene delivery of 
a luciferase reporter gene to tenocytes within a collagen-GAG scaffold variant under 
development for tendon tissue engineering. In particular, we compared the optimal 
polymer:DNA ratios for transfection in two-dimensional culture and three-dimensional CG 
scaffolds. Further, given the known impact of scaffold GAG content on non-covalent growth 
factor sequestration as well as the central importance of electrostatic interactions in the context 
of PEI polyplexes, we explored the combined impact of polymer:DNA w:w ratio, PEI 
acetylation, and scaffold GAG content on polyplex efficiency. We tested the hypotheses that the 
electrostatic environment of the scaffold may enhance the expression or, alternatively, enhance 
the delivery of PEI-based gene vectors by preventing diffusion of the polyplexes out of the 
scaffold.  
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3.3 Materials and methods 
3.3.1 CG suspension preparation 
Type I collagen from bovine Achilles tendon (Sigma-Aldrich) was homogenized together with 
one of three glycosaminoglycans (GAGs): hyaluronic acid from Streptococcus equi (Sigma-
Aldrich), chondroitin sulfate from shark cartilage (Sigma-Aldrich) or heparin from porcine 
intestinal mucosa (Sigma-Aldrich) in 0.05 M acetic acid to create a CG suspension [56]. All 
experiments used suspensions with a collagen concentration of 1.5% (w/v) and a collagen:GAG 
ratio of 11:1. The suspensions were stored at 4°C and degassed prior to use [251].  
3.3.2 CG scaffold fabrication via freeze drying 
CG scaffolds were fabricated using a previously described approach [61]. Briefly, the CG 
suspension was added to cylindrical wells (6 mm dia., 15 mm tall) in a polytetrafluoroethylene 
(PTFE)-copper mold then placed onto a precooled (-10oC) freeze-dryer shelf (VirTis). The 
suspension was frozen at -10˚C for two hours prior to the sublimation of the resulting ice crystals 
at 0˚C and 200 mTorr [61]. Unidirectional heat transfer through the mold’s copper bottom has 
previously been shown to induce formation of anisotropic scaffolds for tendon applications [61]. 
3.3.3 Crosslinking of CG scaffold 
After lyophilization, scaffolds were placed in a vacuum oven (Welch) at 105˚C under vacuum 
for 24 hours for sterilization and dehydrothermal crosslinking [56]. Scaffolds were cut to 5 mm 
length (6 mm dia.) for all experiments. All CG scaffolds were hydrated in 100% ethanol 
overnight and washed in phosphate-buffered saline (PBS) for 24 hours. To increase their 
resistance to tenocyte contraction, scaffolds were crosslinked using carbodiimide chemistry [248, 
252]. Scaffolds were covered with a 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide 
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hydrochloride (EDC) and N-hydroxysulfosuccinimide (NHS) solution (molar ratio of 5:2:1 
EDC:NHS:COOH) and agitated at room temperature for 2 hours. Following crosslinking, 
scaffolds were washed with PBS and stored in fresh PBS at 4˚C. 
3.3.4 Tenocyte isolation and culture 
Tenocytes (tendon cells) were isolated from 2-3 year old horses that were euthanized for reasons 
not related to tendinopathy using previously described methods [253]. Tenocytes were expanded 
in standard culture flasks in high glucose Dulbecco’s modified Eagle’s medium supplemented 
with 10% fetal bovine serum (Invitrogen), 1% Antibiotic-Antimycotic (Invitrogen), 1% L-
glutamine (Invitrogen), and 50 µg/mL ascorbic acid (Wako). The media was changed every 3 
days and the tenocytes were cultured to confluence at 37˚C and 5% CO2. Passage 4 cells were 
used for all experiments. 
3.3.5 Polyplex fabrication 
The luciferase reporter vectors pGL3 (Promega) and pGLuc (New England BioLabs) were 
grown in DH5α E. coli (Gibco BRL) and were purified using a commercial plasmid purification 
kit (BioRad). Acetylation was carried out as previously described [127], with 60% acetylated 
PEI used throughout. Briefly, branched 25-kDa PEI (0.5 g) was transferred to a 20 mL 
scintillation vial in freshly distilled methanol and dissolved. Acetic anhydride was added and the 
reaction was carried out for 4 hours at 60°C with stirring before quenching with double distilled 
water, as previously described [127]. The solvent was removed under reduced pressure. The 
remaining solution was purified by gel filtration chromatography (PD-10 columns, Pharmacia) 
and eluted with double distilled water. The purified polymers were then concentrated and stored 
at -80°C until use.  
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3.3.6 Preparation of polymer-DNA polyplexes 
Stock polymer solutions of unmodified or 60% acetylated PEI were thawed and diluted to 1 
mg/mL. DNA (2 µg per scaffold) and PEI were combined at a range of polymer:DNA weight-to-
weight ratios (1:1 to 5:1) with 20 mM PIPES and distilled water to achieve a desired final 
volume (30 µL) to be added per scaffold. Polyplexes were allowed to equilibrate at room 
temperature for 20 minutes before use. 
3.3.7 Scaffold seeding and culture conditions 
Hydrated and crosslinked scaffolds (6 mm in diameter, 5 mm in height) were incubated in 
complete media at 37˚C for at least one hour prior to seeding. Excess media was removed and 
the scaffolds were placed in ultra-low attachment well plates. Polyplexes were added by direct 
loading to the scaffolds, in a manner inspired by previous efforts by Tierney et al [128, 276]. 
Briefly, 15 µL of polyplex suspension was added to one side of the scaffold followed by 15 
minute incubation at room temperature. The scaffold was then flipped over and another 15 µL of 
polyplex suspension was added. Following a second 15 minute incubation, tenocytes were 
trypsinized and resuspended at a concentration of 5 x 105 cells per 20 µL of media. The cells 
were seeded into the polyplex containing scaffolds by directly loading 10 µL of the cell 
suspension to each side of the scaffold using a previous described static seeding method [61]. 
Briefly, the scaffolds were incubated at 37˚C for 15 minutes in between each seeding and then 
incubated without additional media for 2 hours to allow for initial cell attachment. After two 
hours, serum-free growth media was gently added. Four hours post-seeding, the serum-free 
media was replaced with full tenocyte culture media. Media was changed every 3 days for the 
duration of each experiment. 
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3.3.8 Assay for pGL3 expression 
Luciferase expression was first quantified 48 hours after cell seeding as a function of 
polymer:DNA w:w ratio and acetylation via a destructive assay using the Promega luciferase 
assay system. Scaffolds were lysed with Complete Cell Lysis Reagent and 20 µL of lysate was 
used for analysis. Activity was measured in relative light units (RLU) using a Lumat LB 9507 
luminometer (Berthold). The results were normalized to relative light units measured from 
tenocyte seeded scaffolds that were treated with the pGL3 plasmid only with no PEI carrier. 
3.3.9 Assay for pGLuc expression 
Luciferase expression was subsequently quantified over time (through 14 days) after cell seeding 
using the BioLux Gaussia Luciferase Assay Kit (New England BioLabs). Aliquots of media (50 
µL) were taken at regular intervals (2, 5, 7, 14 days post transfection) and stored for analysis at 
either 4˚C (less than 1 week storage) or -20˚C (longer than 1 week storage). Activity was again 
reported in relative light units (RLU) versus a DNA only, no PEI carrier control using a Lumat 
LB 9507 luminometer (Berthold). 
3.3.10 Quantification of metabolic health 
The metabolic activity of the tenocytes within the CG scaffolds was measured using the non-
destructive alamarBlue® assay (Invitrogen) as previously described [61, 251]. Briefly, scaffolds 
were removed from culture at each timepoint, rinsed in PBS, then incubated in alamarBlue® 
solution at 37˚C under shaking for 2 hours [61]. Using a fluorescent spectrophotometer, resorufin 
fluorescence was measured (excitation: 540 nm, emission: 590 nm) and compared to a standard 
curve created from a known number of tenocytes. Tenocyte metabolic activity has been 
previously shown to be tightly correlated with overall tenocyte number within the scaffold [61, 
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87]. Here, metabolic activity of the tenocyte-scaffold construct was determined at each time 
point, then normalized to the metabolic activity of the total number of tenocytes initially seeded 
into the scaffold, to provide a standard comparison metric. 
3.3.11 Statistical analysis 
Two-way analysis of variance (ANOVA) was performed on all data sets followed by Tukey-
HSD post-hoc test. Pair-wise comparisons were also completed as necessary. A p-value < 0.05 
was used for significance. All analyses were based on a minimum of n = 3 scaffolds. In figures, 
error is reported as the standard error of the mean. 
3.4 Results 
3.4.1 The impact of polyplex polymer:DNA ratio and acetylation on gene delivery in a three 
dimensional CG scaffold 
To screen the impact of a range of polyplex formulations on transfection efficiency within the 
three-dimensional CG scaffold, we quantified delivery of the pGL3 plasmid, which encodes the 
luciferase reporter protein, to equine tenocytes within CG scaffolds containing the conventional 
GAG, chondroitin sulfate (C:CS scaffold). Unmodified and acetylated PEI-containing polyplexes 
were tested at a range of polymer:DNA weight-to-weight ratios (1:1 to 5:1) previously validated 
as exhibiting high transfection activity in 2-D cultures. Luciferase expression was quantified 48 
hours after seeding equine tenocytes into polyplex modified C:CS scaffolds.  
Results suggested the presence of a separate optimal polymer:DNA ratio for unmodified versus 
acetylated PEI (Fig. 3.1). The acetylated PEI-mediated transfection efficiency of tenocytes in 2D 
culture, similar to previous studies [126, 127], was significantly greater at higher polymer:DNA 
ratios (data not shown). For three-dimensional CG scaffolds, unmodified PEI constructs showed 
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higher efficiency at lower polymer:DNA ratios, with a 2:1 ratio showing significantly (p < 0.014) 
increased luciferase as compared to all other polymer:DNA ratios and control in the C:CS 
scaffold. Also like previous 2D studies [126, 127], acetylated PEI required higher polymer:DNA 
ratios, with 4:1 and 5:1 polymer:DNA polyplexes showing significantly (p < 0.05) increased 
luciferase activity. However, unlike previous studies in two-dimensional culture, acetylated PEI 
did not significantly outperform unmodified PEI in CG scaffolds. Unmodified PEI showed 
significantly increased luciferase activity compared to acetylated PEI at 1:1 (p = 0.032), 2:1 (p < 
0.001), and 3:1 (p = 0.016) polymer:DNA ratios. While luciferase activity was greater in 
acetylated PEI for 4:1 and 5:1 polymer:DNA ratios compared to unmodified PEI, the increases 
were not statistically significant.  
3.4.2 The impact of acetylation on the kinetics of gene expression 
We next examined the time course for luciferase expression using PEI polyplexes incorporating 
the pGLuc plasmid encoding the Gaussia princeps luciferase reporter protein. This modification 
allowed gene expression of tenocyte seeded C:CS scaffolds to be assessed non-destructively 
from aliquots taken from the culture media over 14 days (Fig. 3.2). Here, luciferase expression 
was normalized against a three dimensional control that contained the plasmid DNA without a 
delivery vector. While the naked pGLuc gene gave very low chemiluminescent background, 
suggesting minimal transfection efficiency (Fig. 3.1), it was not possible to track cell response 
over time. While the pGL3 gene allowed for tracing cell response, it had not been previously 
optimized for gene delivery and led to significant chemiluminescent background during analysis 
(Fig. 3.2). 
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As observed with the pGL3 plasmid, at 2 days post-transfection the 2:1, 3:1, 4:1 and 5:1 w:w 
ratios of the polyplexes containing unmodified PEI showed significantly (p ≤ 0.001) higher 
luciferase expression compared to the control and the 1:1 w:w ratio (Fig. 3.2A). At day 5, 
significantly increased luciferase expression over control was still observed for 2:1, 3:1 and 5:1 
polymer:DNA ratios (p < 0.011) for unmodified PEI constructs (Fig. 3.2A). Examining the 
results over time, luciferase expression in tenocytes was significantly (p < 0.001) greater at day 2 
than at later timepoints (days 5, 7 and 14) for 2:1, 3:1, 4:1 and 5:1 unmodified PEI polyplexes. 
By days 7 and 14, there was no significant increase in luciferase expression over control (Fig. 
3.2A).  
When considering the polyplexes based on the acetylated PEI, 4:1 and 5:1 w:w ratios again led 
to significantly (p < 0.001) greater luciferase expression than the control at both days 2 and 5 
(Fig. 3.2B). Luciferase expression in the 4:1 and 5:1 constructs were significantly (p ≤ 0.001) 
greater than all lower polymer:DNA ratios at day 2. Examining the results with time, the 3:1, 4:1 
and 5:1 PEI:DNA w:w ratio polyplexes demonstrated significantly (p < 0.05) increased 
luciferase expression at day 2 compared to all later days (Fig. 3.2B). There was no statistical 
significance between the polyplex groups at days 5, 7 and 14 (Fig. 3.2B).  
Comparing the top performing unmodified PEI (2:1 w:w) and acetylated PEI (4:1 w:w) groups, 
no significant differences were observed in the performance over time between unmodified and 
acetylated PEI (Fig. 3.2C). Both unmodified and acetylated PEI groups significantly 
outperformed control (bare DNA) cultures at both day 2 (p < 0.001) and day 5 (p ≤ 0.02), 
following similar trends seen in earlier transfection studies using these identical systems in 2D 
cultures [127]. Contrary to those results, acetylated PEI polyplexes again did not exhibit 
increased gene expression versus unmodified PEI polyplexes at any time. 
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3.4.3 The impact of variable GAG incorporation on polyplex efficiency  
Given the observed differences in response in three-dimensional CG scaffolds versus previously 
reported two-dimensional cultures, we subsequently examined the impact of sulfated scaffold 
GAG content on gene expression. Here, a sub-set of polyplex polymer:DNA ratios were chosen 
for a narrow range surrounding the identified optimal unmodified (2:1) and acetylated (4:1) PEI 
ratios (Fig. 3.2). Unmodified PEI polyplexes were tested at polymer:DNA at ratios of 1:1, 2:1 
and 3:1 while acetylated PEI polyplexes were tested at w:w ratios of 3:1, 4:1 and 5:1. 
The initial impact of GAG charge on tenocyte luciferase expression was examined 2 days after 
tenocytes were exposed to the gene activated matrices (Fig. 3.3). For unmodified PEI polyplexes, 
scaffold GAG content significantly (p < 0.05) impacted luciferase expression. Luciferase activity 
was significantly (p < 0.03) enhanced in the CG scaffolds containing heparin (C:HP) compared 
to C:CS or hyaluronic acid (C:HA) CG scaffolds for a 2:1 polymer:DNA ratio (Fig. 3.3A). 
Luciferase activity was also significantly (p < 0.01) enhanced in the C:HP scaffolds compared to 
the C:HA scaffold for the 3:1 polymer:DNA ratio, while no difference was observed between 
groups at 1:1 polymer:DNA ratio (Fig. 3.3A). A similar effect was observed with acetylated PEI 
polyplexes (Fig. 3.3B). Here, tenocytes cultured in C:HP scaffolds show significantly (p ≤ 0.001) 
enhanced luciferase expression over C:HA and C:CS scaffolds at both the 4:1 and 5:1 w:w ratios. 
The expression profiles of the most effective polymer:DNA ratios (2:1 for unmodified PEI; 5:1 
for acetylated PEI) were subsequently traced over 7 days in culture to determine whether 
scaffold GAG content was able to mediate extended DNA delivery as well (Fig. 3.4). For 
unmodified PEI polyplexes (2:1 w:w), a significant (p ≤ 0.001) decrease in expression was 
observed across the 7 day experiment between each time point and also within each GAG 
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variant. The expression in the C:HP scaffolds is significantly (p < 0.001) higher at day 2 
compared to C:HA and C:CS scaffolds (Fig. 3.4A). Results were similar for acetylated PEI 
polyplexes (Fig. 3.4B). Significantly (p < 0.001) increased luciferase expression was observed at 
day 2 as compared to days 5 and 7. Like with unmodified PEI, the impact of the highly charged 
C:HP scaffold on increased expression was limited to the first time point (day 2). 
3.4.4 The impact of PEI gene delivery on tenocyte metabolic activity 
PEI-based delivery vectors have been shown to have the potential for significant cytotoxicity 
[277]. However, we have previously shown that increasing the degree of glycosaminoglycan 
sulfation in the CG scaffold can enhance tenocyte metabolic health [59]. We therefore examined 
the long-term (14 days) consequences of PEI-based luciferase delivery on tenocyte metabolic 
activity as a function of scaffold GAG content for both unmodified (2:1 polymer:DNA ratio) and 
acetylated (5:1 polymer:DNA ratio) PEI polyplexes (Fig. 3.5). Here metabolic activity is 
reported as normalized against the number of initially seeded tenocytes, with data from day 2 
suggesting initial cell attachment efficiencies on order of 30 – 50% as previously described for 
CG scaffolds by O’Brien et al [67]. Overall, the metabolic activity of tenocytes exposed to DNA 
alone was significantly (p < 0.05) higher than tenocytes exposed to unmodified or acetylated PEI 
polyplexes across all time points. However, consistent with previous observations [59], scaffold 
GAG content impacted cell metabolic activity. For the control group that did not receive PEI, the 
C:HP scaffold showed significantly (p < 0.05) increased metabolic activity at day 7 and 14 of 
culture compared to day 2. Examining the overall effect of PEI type and scaffold GAG content in 
more detail, while the metabolic activity of tenocytes exposed to PEI (unmodified, acetylated) is 
reduced compared to control for each scaffold type, the reduction is not significant at day 2 (Fig. 
3.5). However, by day 4 the metabolic activity of tenocytes in scaffolds not exposed to PEI starts 
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to increase, with C:HA and C:HP scaffolds showing significantly (p < 0.05) higher metabolic 
activity compared to their corresponding polyplex receiving groups (Fig. 5). Identical results are 
also observed at day 7. By day 14 there were no significant differences in metabolic activity 
observed between control or either PEI groups in both the C:HA or C:CS scaffolds. Interestingly, 
tenocytes in the C:HP scaffolds that were exposed to PEI show significantly (p < 0.05) higher 
metabolic activity compared to all earlier time points (Fig. 3.5). 
3.5 Discussion 
The development of therapeutic scaffolds for tissue regeneration has largely focused on 
mimicking the mechanical, structural and compositional features of the extracellular matrix. 
Additionally, efforts are being made to increase the bioactivity of these scaffolds although much 
of the literature to date has focused on the presentation of recombinant proteins and growth 
factors [106, 278, 279]. Alternatively, gene therapy has the potential to facilitate localized, 
sustained delivery of beneficial growth factors by delivering therapeutic plasmids to the affected 
areas. Such approaches may eventually offer value in the context of wound healing [280] and for 
promoting lineage specification from patient-derived MSC populations [260, 281-283]. Early 
work in the development of gene-activated matrices demonstrated the ability to improve bone 
healing in a canine defect model through administration of plasmid DNA in a collagen sponge 
[281]. More recent studies have shown the influence PEI and nano-hydroxyapatite, individually 
and in combination, have on gene (reporter and therapeutic) delivery to MSCs within collagen-
based scaffolds for bone regeneration [124, 128, 269, 276]. Further, studies focused on 
optimizing PEI chemistry for gene delivery have shown that increased efficiency of the PEI 
vector can be achieved through acetylation of the polymer. This was attributed to the lower 
electrostatic binding affinity of the polymer and DNA, as the cationic charge is reduced from 
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acetylation of the polymer’s amine groups [127]. While this previous work suggested the 
electrostatic environment within the cell can impact the efficiency of gene delivery, our work 
here suggests that the electrostatic environment surrounding the cell can also significantly impact 
polyplex delivery. 
The work described here examines the impact of the electrostatic environment of a three-
dimensional collagen-GAG scaffold on the efficiency of PEI-based polyplexes under 
development for a range of gene delivery applications. Glycosaminoglycans are native to the 
extracellular matrix and are known for their role in sequestering growth factors in vivo [81]. 
Recent work by our group has shown that the degree of sulfation (negative charge) of the GAG 
component of 3D CG scaffolds could be used to impact the degree in which the scaffold was 
able to sequester growth factors and, furthermore, the cellular activity of equine tenocytes [59]. 
We sought to determine whether the presence of a three-dimensional CG scaffold impacted the 
efficiency of PEI-based polyplex gene delivery, and subsequently whether altering the degree of 
GAG sulfation in the CG scaffolds could impact polyplex activity or maintain their delivery over 
an extended period of time.  
Initial experiments examined the response of the PEI polyplexes within CG scaffolds containing 
the moderately sulfated chondroitin sulfate (CS), our CG scaffold standard. It was found that the 
unmodified PEI polyplexes led to significantly higher luciferase expression at lower PEI:DNA 
w:w ratios when compared to acetylated PEI polyplexes 2 days after transfection (Fig. 3.1). 
While the acetylated polyplexes seemed to have higher expression at higher w:w ratios, it was 
not statistically significant. This is in contrast to transfection results seen in 2D [126, 127]. In 
order to examine the time course of transfection and expression, luciferase expression was 
subsequently monitored over an extended 14 day period (Fig. 3.2A). The active time of 
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luciferase expression in the polyplex seeded C:CS scaffolds (compared to bare DNA alone) was 
found to be limited to 2-5 days (Fig. 3.2). Unmodified PEI polyplexes showed significantly 
improved luciferase expression at 2:1, 3:1, 4:1 and 5:1 w:w ratios at day 2 and 2:1, 3:1 and 5:1 at 
day 5. Consistent with initial results and those in the literature, acetylated PEI polyplexes at 
higher w:w ratios (4:1, 5:1) were the only variants to show significantly higher luciferase 
expression, again at both day 2 and 5 post-transfection (Fig. 3.2B). Interestingly, acetylation did 
not significantly improve luciferase expression, with the top performing unmodified (2:1) and 
acetylated (4:1) PEI showing nearly identical performance over time (Fig. 3.2C).  
In order to determine the effect of the electrostatic environment on gene delivery efficiency, 
polyplex delivery efficiency was subsequently tested across three CG scaffold variants, each 
with a differentially sulfated glycosaminoglycan: hyaluronic acid (HA), chondroitin sulfate (CS), 
or heparin (HP). A non-sulfated GAG, hyaluronic acid was not expected to have a positive 
impact on gene delivery efficiency or duration. Chondroitin sulfate (CS), a moderately sulfated 
GAG, was tested as the conventional CG scaffold formulation reported in the literature [56]. As 
a highly-sulfated, negatively charged glycosaminoglycan, we hypothesized the C:HP scaffolds 
would more strongly interact with the positively charged PEI polyplexes, retaining more of the 
polyplex within the scaffold and enhancing either the efficiency or duration of gene expression. 
Indeed, increasing the degree of sulfation of the CG scaffolds, through incorporating highly 
sulfated heparin, led to significantly improved gene delivery efficiencies in both unmodified and 
acetylated PEI polyplexes two days after tenocytes were exposed to the gene activated matrices 
(Fig. 3.3). The effects were observed at higher w:w ratios of the range tested for unmodified and 
acetylated PEI, suggesting at low cationic polymer densities the effect of scaffold GAG content 
was lost. Notably, significant increases in luciferase expression were noted for tenocytes in the 
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C:HP scaffolds versus both C:HA and C:CS scaffolds for a 2:1 w:w polymer:DNA ratio using 
unmodified PEI (Fig. 3.3A). Similar results were observed at 4:1 or 5:1 w:w ratios using 
acetylated PEI (Fig. 3.3B). These results suggest that the electrostatic scaffold environment can 
significantly impact the short term efficiency of gene delivery. Considering recent approaches 
describing fabrication of CG scaffolds with regional control over composition [284], these 
results also suggest a path for developing biomaterials able to spatially-enhance the efficiency of 
a ubiquitously added gene delivery vector. However, when examining the impact of scaffold 
GAG content over the course of 7 days (Fig. 3.4), it was apparent that scaffold GAG content may 
not be sufficient to enhance the duration of functional gene delivery. Here, the significant 
increase in luciferase expression between scaffolds only appears at day 2 (2:1 unmodified, 5:1 
acetylated polyplexes), with no significant differences seen between groups at days 5 or 7 (Fig. 
3.4).  
The mechanism by which scaffold GAG content impacts PEI delivery remains undetermined. 
The presence of increasingly anionic GAGs within the CG scaffolds may promote the 
maintenance of the cationic polyplex in the scaffold, decreasing the rate of diffusive loss. 
Alternatively, scaffold GAG content may enhance partial dissociation of the DNA from the 
polymer, potentially allowing for effective transcription within the cells. As unmodified PEI 
constructs exhibit higher charge [127], they may be sequestered in the charged C:CS and C:HP 
scaffolds more readily than the acetylated PEI. Further, interactions with the charged GAG, 
especially in the case of the more weakly associated acetylated PEI polyplexes, may also 
facilitate the release of the DNA from the polyplex, with acetylated PEI showing highest 
transfection efficiency in the C:HP scaffolds (Fig. 3.4). While future efforts will need to examine 
mechanisms by which the scaffold GAG content impacts polyplex stability or retention, it is 
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clear that the biophysical properties of a tissue engineering scaffold can significantly impact 
polyplex-based gene delivery. Further, these results highlight that polyplexes optimized in 
conventional two-dimensional cultures may show significantly different behavior when 
translated to biomaterial systems. 
Moving forward, it would be important to extend these studies to examine the transfection 
efficiency on a per-cell basis. Experiments such as those were not performed as part of this study 
because established methods (e.g., normalizing to protein or DNA content) could not be 
performed in the presence of the collagen scaffold or the charged PEI polymer, respectively. In 
the future, the use of a GFP reporter and flow cytometry would be a viable way to obtain the 
percent of transfected cells present as a function of culture time. Further, while here we 
examined delivery of a reporter gene, delivery of a therapeutic gene to direct mesenchymal stem 
cell differentiation towards a tenogenic lineage would be an important step in the development of 
a functional gene delivery matrix for tendon repair. Recent efforts understanding conserved 
processes of tendon development and repair offer a number of therapeutic targets for 
incorporation into a gene activated matrix in the future [15, 285-287]. 
Finally, a well-documented drawback of PEI-based gene delivery systems is the significant 
potential for PEI-induced cytotoxicity [277]. At first glance, results from this study suggest that 
appropriate design of the correct biomaterial platform may offer an orthogonal design parameter 
for enhancing the activity of a given gene delivery vector. However, here we also explored the 
potential for the scaffold GAG content to enhance tenocyte long-term metabolic activity as a 
potential strategy to help cells recover more rapidly after the cytotoxic insult associated the PEI 
polyplex exposure. Tenocyte metabolic activity was monitored over 2 weeks in the GAG 
scaffolds variants as they were exposed to different gene delivery vehicles: DNA only control, 
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2:1 unmodified PEI polyplexes, and 5:1 acetylated PEI polyplexes (Fig. 3.5). There are 
significant, but temporary, decreases in the metabolic activity at early time points (4, 7 days) for 
cells exposed to the DNA polyplexes, corresponding to the active period of time for polyplex 
transfection. Notably, we observed significantly enhanced recovery of the metabolic health of 
tenocytes cultures in the heparin-based CG scaffolds by day 14. These results are encouraging as 
they suggest no long term damage may have been done to the cells as a result of the transfection. 
Further, these results mimic previous findings showing that C:HP scaffolds can enhance cell 
activity in metabolically taxing environments. 
3.6 Conclusions 
It has been previously shown that the GAG content of CG scaffolds can impact the transient 
sequestration of growth factors and subsequent cellular responses. Here we described the effect 
that sulfated GAG content of CG scaffolds has on gene delivery via cationic polymeric 
polyplexes. Using the cationic polymer polyethylenimine (PEI) to condense DNA into 
polyplexes, we were able to also examine the impact of polymer acetylation and polymer:DNA 
weight-to-weight ratio on delivery of a luciferase reporter gene within a three-dimensional 
biomaterial. We found that increasing the weight-to-weight ratio and employing the highly 
sulfated heparin glycosaminoglycan in the scaffold design increased the initial luciferase 
expression in tenocytes treated for acetylated PEI polyplexes. Notably, heparin-based CG 
scaffolds also enhanced metabolic activity over 14 days. These results suggest that the 
electrostatic environment of a gene activated scaffold may prove to be an important design 
parameter to consider in order to enhance the efficiency and perhaps to moderate cytotoxic side-
effects of cationic polymer based gene therapy for tissue engineering applications. 
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3.7 Figures 
 
 
Figure 3.1. Luciferase expression (pGL3 vector) 48 hours post-transfection from tenocytes 
cultured in 3D C:CS scaffolds. (*) significant (p < 0.05) up-regulation compared to all other 
unmodified PEI groups. (^) significant (p < 0.05) up-regulation compared to control, 1:1, and 2:1 
acetylated PEI groups. (#) significant (p < 0.05) up-regulation between unmodified and 
acetylated PEI groups at given polymer:DNA ratio. 
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Figure 3.2. Luciferase expression (pGLuc vector) in tenocytes over two weeks of culture in 
C:CS scaffolds. Expression of polyplex variant with unmodified PEI (A) or acetylated PEI (B) 
over the full range of weight-to-weight ratios. Relative light units (RLUs) are normalized to a 3D 
control of DNA without a polymer vector. (C) Top performing ratios (w:w) for unmodified and 
acetylated PEI over 14 days. (*) significance (p < 0.05) when compared to control. (^) 
significance (p < 0.05) between 1:1 ratio at same day. (†) significance (p < 0.05) between 
groups. 
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Figure 3.3. Day 2 luciferase expression (pGLuc) of a focused range of weight-to-weight ratios 
for each type of PEI within scaffolds of varying charge. (*) significance (p < 0.05) between 
groups. 
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Figure 3.4. Luciferase expression (pGLuc) from the most effective weight-to-weight ratios in 
scaffolds with variant glycosaminoglycan content over 7 days. (*) significant (p < 0.05) increase 
relative to other timepoints within the same scaffold group.  
 
 
Figure 3.5. Tenocyte metabolic activity as a function of scaffold GAG content as well as 
polyplex group. (*) significance (p < 0.05) over corresponding experimental groups at same 
timepoint. (^) significance (p < 0.05) between earlier timepoints. (†) significance (p < 0.05) to 
day 2 groups. 
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CHAPTER 4: THE INCORPORATION OF AMNIOTIC MEMBRANE MATRIX 
ALTERS TENOCYTE ACTIVITY IN VITRO§ 
4.1 Chapter overview 
Adult tendon wound repair is characterized by the formation of disorganized collagen matrix 
which leads to decreases in mechanical properties and scar formation. Studies have linked this 
scar formation to the inflammatory phase of wound healing. Instructive biomaterials designed for 
tendon regeneration are often designed to provide both structural and cellular support. In order to 
facilitate regeneration, success may be found by tempering the body’s inflammatory response. 
This work combines collagen-glycosaminoglycan scaffolds, previously developed for tissue 
regeneration, with matrix materials (hyaluronic acid and amniotic membrane) that have been 
shown to promote healing and decreased scar formation in skin studies. The results presented 
show that scaffolds containing amniotic membrane matrix have significantly increased 
mechanical properties and that tendon cells within these scaffolds have increased metabolic 
activity even when the media is supplemented with the pro-inflammatory cytokine interleukin-1 
beta. Collagen scaffolds containing hyaluronic acid or amniotic membrane also temper the 
expression of genes associated with the inflammatory response in normal tendon healing (TNF-
α, COLI, MMP-3). These results suggest that alterations to scaffold composition, to include 
matrix known to decrease scar formation in vivo, can modify the inflammatory response in 
tenocytes.  
                                                 
 
§ This chapter has been adapted from the following publication: Rebecca A. Hortensius, Jill H. Ebens, Brendan A. 
C. Harley. “Immunomodulatory effects of amniotic membrane matrix incorporated into collagen scaffolds.” Journal 
of Biomedical Materials Research: Part A, 2016; 104(6): 1332-1342. 
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4.2 Introduction 
Tendon healing following injury, even when surgically repaired, results in fibrocartilagenous 
scar formation which in turn leads to decreased ultimate tendon strength and disorganized 
collagen fibers. Adult wound repair occurs in the three overlapping phases: inflammation, 
proliferation, and remodeling [249, 288]. The inflammatory phase in adult wound healing is 
characterized by the recruitment of cells to the site of injury [139, 249]. Platelets release platelet-
derived growth factor (PDGF) and transforming growth factor-beta (TGF-β) in order to initiate 
the chemotaxis of fibroblasts and inflammatory cells (neutrophils, macrophages) to the wound 
[139]. Additionally, TGF-β stimulates macrophages to secrete the key inflammatory cytokines, 
tumor necrosis factor alpha (TNFα) and interleukin-1 (IL-1) during this phase [139]. Scar 
formation is the ultimate end point of adult wound repair and studies have shown that the 
inflammatory response is an essential prerequisite for scarring [189]. The limited healing of 
tendons calls for new techniques and materials that will promote tendon regeneration in vivo. 
In contrast to adult wounds, healing in fetal cutaneous wounds proceeds in a regenerative 
fashion, with neither the typical inflammatory response nor the formation of scar tissue [189-
191]. Extensive studies have shown that differences between adult and fetal wound healing are 
found at many levels of the wound healing cascade; cells, cytokines, growth factors, and the 
ECM [190]. Fetal wounds exhibit lower levels of PDGF, TGF-β1 and TGF-β2 [201]; leading to 
reduced numbers of immune cells in fetal skin and lower inflammatory reaction [190, 199, 200]. 
Pro-inflammatory cytokines (e.g. TGF-β1) are also less prevalent in fetal wounds [202, 203]. 
Beredjiklian et al examined differences between adult and fetal tendon wound healing via partial 
mid-substance tenotomies of the lateral extensor tendon in pregnant ewes and their fetal lambs 
[24]. Maternal and fetal tendons were harvested for histological and mechanical testing 7 days 
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post-surgery. Testing showed that fetal tendons exhibited highly aligned and organized collagen 
fibers, no macroscopic abnormalities or adhesions, and no increases in TGF-β1 expression; all in 
direct contrast to the corresponding adult tendons.  
We hypothesize the composition of biomaterials that mimic the extracellular matrix found in low 
inflammatory environments (such as the fetal wound environment) may be particularly relevant 
for modifying adult immune responses. The non-sulfated glycosaminoglycan hyaluronic acid 
(HA) is found in both adult and fetal wounds [211] and assists in rapid cell proliferation and 
motility. HA is a significant component of the fetal, scarless wound healing cascade [289] and 
has been extensively studied in the context of burns and chronic wounds [290] as well as 
reducing adhesion [291]. Separately, the amniotic membrane (AM), known for its anti-
inflammatory and anti-microbial properties as well as scarless wound healing capacity, is the 
innermost layer of the placenta. Clinicians and scientists have shown that the intact AM sheet is 
valuable in the treatment of corneal surfaces [222-224], skin wounds [219, 225], oral cavity 
reconstruction [226] and many other reconstruction applications [215, 227]. In addition, the use 
of dry, micronized human amnion membrane has been shown to reduce cartilage degeneration in 
an osteoarthritic rat model [228]. While the AM has been implemented successfully in these 
wound healing applications and studied as an anti-inflammatory therapeutic for degenerative 
disease, its potential as a bioactive component in 3D biomaterials has not been extensively 
investigated. 
Collagen-glycosaminoglycan (CG) scaffolds have been used in a wide variety of applications for 
skin, peripheral nerve, and cartilage tissue engineering as well as 3D environments for in vitro 
studies of cell behavior [55-58, 67, 244, 292]. It has been shown that in severe skin wounds the 
application of these scaffolds decreases the population of myofibroblasts at the wound site [293]. 
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By delaying these contraction processes, collagen-based scaffolds have induced regeneration and 
decreased scar formation in skin and nerve defects [36]. Our lab has recently developed scaffold 
variants to mimic the anisotropic microstructure of native tendons [61]. While typically 
fabricated with chondroitin sulfate, modifications to the scaffolds’ glycosaminoglycan (GAG) 
content were subsequently used to modulate growth factor sequestration, much like the native 
tendon ECM [59]. The capacity to alter the biomolecular environment and cellular response via 
scaffold composition may be a way to address needs for immunomodulatory biomaterials for 
tissue regeneration. The work described here combines CG scaffolds with fetal wound healing-
inspired matrix (HA, AM) in order to study their ability to temper pro-inflammatory conditions 
in vitro. 
4.3 Materials and methods 
4.3.1 Amnion membrane isolation 
In collaboration with Carle Foundation Hospital Tissue Repository (Urbana, IL), human 
placentas were obtained following uncomplicated vaginal births. The amniotic membrane (AM) 
matrix components have been isolated from these placentas as described [294]. Briefly, excess 
blood was washed from the fetal membrane and the AM was mechanically separated from the 
placenta [294]. The AM was cut into sections, washed, and then decellularized via incubation in 
thermolysin (125 μg/mL) [295]. Decellularized AM were then rinsed with shaking in PBS to 
remove cellular debris and stored in PBS at 4°C. Following 24-48h of storage, in which the 
spongy layer of the AM was allowed to swell, decellularized AM pieces were scraped (spatula) 
in order to fully separate the AM matrix of the compact layer from the underlying spongy layer. 
The remaining matrix (basement membrane, compact layer) was lyophilized and stored in a 
dessicator until further use. 
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4.3.2 Amnion membrane characterization 
Biopsies of placental tissue were fixed in 10% formalin and embedded in paraffin in a cross-
sectional orientation. Serial slices of 5 μm thickness were cut and mounted on slides. Slides were 
deparaffinized and stained with either hematoxylin and eosin (H&E) or Masson’s Trichrome 
stain. All slides were mounted with Permount and a coverslip prior to imaging on an optical 
microscope (Leica Microsystems, Germany). The isolated decellularized and dried amniotic 
membrane was analyzed for its collagen and GAG content via a hydroxyproline [296] and a 1,9-
dimethylmethylene blue (DMMB) [297] assay, respectively.  
4.3.3 Preparation of collagen suspension 
A suspension of collagen and one of three components was made by homogenizing type I 
collagen from microfibrillar collagen (Collagen Matrix, Oakland, NJ) in 0.5 M acetic acid with 
either (1) chondroitin sulfate from shark cartilage (Sigma Aldrich, St Louis, MO), (2) hyaluronic 
acid from Streptococcus equi (Sigma-Aldrich, St. Louis, MO), or (3) ground (mortar and pestle) 
and, further, homogenized amniotic membrane as collected above [56]. Scaffolds containing CS 
and HA components were made with a 11:1 collagen:component ratio while C:AM were made at 
a 5:1 w:w ratio due to the high AM collagen content. All scaffolds were made with a target total 
density of 0.5% w/v [251]. The suspensions were stored at 4°C and degassed prior to use [251].  
4.3.4 Fabrication of collagen-based scaffolds via freeze drying 
Isotropic CG scaffolds were fabricated as previously described [61, 69]. The collagen suspension 
was transferred to an aluminum tray mold and placed into the freeze-dryer with a shelf 
temperature of 4°C. The suspension was frozen to a final freezing temperature of -40°C. To form 
a porous, sponge-like scaffold, ice crystals were sublimated under vacuum (200 mTorr) at 0°C. 
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4.3.5 Crosslinking of CG scaffold 
In order to sterilize and dehydrothermally crosslink the scaffolds, the lyophilized sheets were 
placed in a vacuum oven (Welch, Niles, IL) at 105˚C under vacuum for 24 hours [56]. A biopsy 
punch was used to cut 6mm diameter cylinders from the 4mm thick scaffold sheet for use in all 
experiments. Scaffolds were hydrated by soaking in 100% ethanol overnight and washing in PBS 
for 24 hours. Scaffolds were then crosslinked via carbodiimide chemistry by immersing in 1-
ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) and N-
hydroxysulfosuccinimide (NHS) at a molar ratio of 5:2:1 EDC:NHS:COOH for 1.5 h under 
shaking at room temperature [248, 298]. Prior to use, scaffolds were washed with and stored in 
PBS at 4˚C. 
4.3.6 SEM analysis 
Scanning electron microscopy (SEM) was used to visualize the cross-sectional interior 
microstructure of dry, uncrosslinked scaffolds. Samples were imaged with a JEOL JSM-6060LV 
scanning electron microscope using secondary electron and backscattered electron detectors 
under low vacuum.  
4.3.7 Mechanical testing 
Compression testing was carried out on crosslinked, hydrated samples. Scaffolds from each 
group (CS, HA, AM) were cut from the scaffold sheet (approx. 4 mm thick) with 12mm biopsy 
punches before being hydrated and crosslinked as described above. Using a TA.XTplus Texture 
Analyzer (StableMicro Systems Ltd., Surrey, UK) equipped with a 1 kg load cell, the stress-
strain behavior of each scaffold variant was measured. Samples were loaded in unconfined 
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compression to approximately 75% strain at a rate of 0.01 mm/min. The elastic moduli were 
determined from the linear elastic region (approx.. 1-10% strain) of each stress-strain plot [248]. 
4.3.8 Pull down sequestration assay 
The degree of cytokine sequestration in each CG scaffold variant was determined via a pull 
down assay [59]. Three hydrated, crosslinked scaffolds were placed in a single well of an ultra-
low attachment 24-well plate (Fisher, Waltham, MA) with 1 mL of a pH 7.4 PBS solution 
supplemented with 1 ng/mL interleukin-1 beta (IL-1β) (ProSpec, Israel) and 1% bovine serum 
albumin (BSA). Control wells containing the IL-1β solution and no scaffolds were used. The 
scaffolds and controls were incubated under gentle shaking at 37˚C for 1 hour. Immediately 
following incubation, an ELISA kit (R&D Systems, Minneapolis, MN) was used to measure the 
amount of IL-1β remaining in solution. The difference between the concentration of IL-1β 
remaining in the solutions containing scaffolds and the solutions that did not have scaffolds 
(controls) was regarded to be the amount of cytokine in the scaffolds. IL-1β pull down for each 
CG variant was reported as a percentage of the total IL-1β concentration in the loading solution. 
4.3.9 Tenocyte isolation and culture 
Tenocytes (tendon cells) were isolated from 2-3 year old horses and expanded in growth media: 
high glucose Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum 
(Invitrogen, Carlsbad, CA), 1% Antibiotic-Antimycotic (Invitrogen, Carlsbad, CA ), 1% L-
glutamine (Invitrogen, Carlsbad, CA), and 50 µg/mL ascorbic acid (Wako, Richmond, VA) in 
standard culture flasks [253]. The cells were cultured at 37˚C and 5% CO2 and the media was 
changed every 3 days until the tenocytes reached confluence. Passage 5 cells were used for all 
experiments. 
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4.3.10 Scaffold seeding and culture conditions 
Hydrated, crosslinked scaffolds were soaked in growth media for one hour at 37°C before being 
placed in ultra-low attachment 6-well plates (Fisher, Waltham, MA). Confluent tenocytes were 
trypsinized and resuspended in growth media at a concentration of 2.5 x 105 tenocytes per 20 µL. 
Scaffold variants were seeded with tenocytes using a previously established static seeding 
method [61]. The scaffolds were incubated for 15 minutes at 37˚C following the addition of 10 
µL of the cell suspension to one side of the scaffold. The scaffolds were then flipped over and 
another 10 µL of cell suspension was added for a total of 2.5 x 105 tenocytes seeded on each 
scaffold. To allow for initial cell attachment, scaffolds were placed in the incubator for 2 hours. 
After this period, additional media was added and scaffolds were incubated at 37˚C and 5% CO2 
for 24h before the media was changed for one of three inflammatory media variants. These 
variants included: (1) growth media (control), (2) media supplemented with 0.1 ng/mL of the 
pro-inflammatory factor interleukin-1 beta (IL-1β) (inflammatory), and (3) media supplemented 
with 1 ng/mL of IL-1β (high inflammatory). Scaffolds were cultured in culture media as 
described above, with or without the addition of serum, for the duration of the experiment. Media 
changes occurred every 3 days. 
4.3.11 Histological analysis of cell-seeded scaffolds 
Following 7 days of culture, tenocyte-seeded scaffolds were fixed in 10% formalin overnight and 
then washed and stored in PBS. Fixed scaffolds were blocked with PBS containing 2% bovine 
serum albumin and 0.1% Tween 20 for one hour under shaking at room temperature. Then 
scaffolds were incubated overnight in vimentin antibody (Cell Signaling Technology, 1:800 
dilution), washed and stored in 0.1% Tween 20 PBS. Prior to embedding at -80°C, scaffolds 
were soaked in 20% sucrose for 1 hour followed by Optimal cutting temperature compound 
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(OCT) for 1 hour. Sections of 25 micro thickness were obtained using a Leica CM3050 S 
cryostat and imaged via fluorescence microscopy (Leica DMI4000B fluorescence microscope, 
Qimaging camera). Fluorescent and brightfield channels were merged using ImageJ. 
4.3.12 Quantification of TGF-β1 protein release 
Tenocyte-seeded scaffolds were cultured in serum-free media variants for 24h. Following this 
culture period, the amount of TGF-β1released into the media was measured via an ELISA kit 
(R&D Systems, Minneapolis, MN). Concentrations were determined using a standard curve and 
a four parameter logistic (4-PL) curve-fit. Results were normalized to acellular scaffold variants 
cultured in control media. 
4.3.13 Quantification of cell metabolic activity 
Metabolic activity of the tenocytes within the collagen scaffolds was measured using a non-
destructive alamarBlue® assay (Invitrogen, Carlsbad, CA) [61, 251]. Briefly, scaffolds were 
removed from culture, rinsed in PBS, and incubated under gentle shaking at 37˚C for 2 hours in a 
1x alamarBlue® solution containing the media variant of the primary culture. Using a fluorescent 
spectrophotometer, resorufin fluorescence was measured (excitation: 540 nm, emission: 590 nm) 
and compared to a standard curve created from a known number of cells from the start of the 
experiment. The standard curve was run on well-plated cells, with known numbers of cells in 
each well, ranging from 25% to 300% of the number of cells seeded per scaffold. Metabolic 
activity was tracked over a 7 day period and, at each time point, was interpolated to the standard 
curve and reported as a percentage of the total number of seeded cells. 
4.3.14 Gene expression analysis through RNA isolation and real-time PCR 
91 
 
An RNeasy Plant Mini kit (Qiagen, Valencia, CA) was used to isolate RNA from cell-seeded 
scaffolds. The scaffolds were rinsed in PBS, cut in half with a razor, and immersed in the kit’s 
lysis buffer for 5 minutes on ice [87]. Following the kit’s instructions, RNA was isolated and 
total RNA was quantified via spectrophotometry. The QuantiTect Reverse Transcription kit 
(Qiagen, Valencia, CA) was used to reverse transcribe the isolated RNA in a Bio-Rad S1000 
thermal cycler. Real-time PCR reactions were performed in an Applied Biosystems 7900HT Fast 
Real-Time PCR System (Carlsbad, CA) to measure gene expression levels for collagen I 
(COL1A2), matrix metalloproteinase-3 (MMP-3), scleraxis (SCXB), and tumor necrosis factor-
alpha (TNF-α). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a 
housekeeping gene (differences in GAPDH expression between groups were compared and 
found to be statistically insignificant: p > 0.05). Sequence Detection Systems software v2.4 
(Applied Biosystems, Carlsbad, CA) was used to complete analysis. All results were expressed 
as fold changes relative to expression levels of cells in scaffolds of the same type and at the same 
time point but cultured in the control media. 
4.3.15 Statistical analysis 
One-way analysis of variance (ANOVA) followed by Tukey-HSD post-hoc test was performed 
on all data sets except for metabolic activity. The metabolic activity was analyzed using a two-
way, repeated measures ANOVA followed by Tukey-HSD post-hoc test. A p-value < 0.05 was 
used for significance. All analyses were based on a minimum of n=4 scaffolds. Error is reported 
as the standard error of the mean in the figures. 
4.4 Results 
4.4.1 Placental structure and amnion composition 
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Histological staining of placental biopsies shows the structure of the amniotic membrane in 
relation to the rest of the placenta (Fig.4.1A,B). H&E staining (Fig. 4.1A) shows a single layer of 
epithelial cells on the surface of the amniotic membrane. Masson’s Trichrome staining (Fig. 
4.1B) indicates that the amniotic membrane is rich in collagen. Quantitative analysis determined 
AM collagen content (40.83±0.04 wt%) and sulfated GAG content (0.22±0.11 wt%). 
4.4.2 Scaffold microstructure, mechanics, and histological analysis 
The elastic modulus of each of the CG scaffold variants varied between 0.1 and 1 kPa showing a 
significant effect of the included matrix (Fig. 4.1C). Scaffolds containing chondroitin sulfate 
(CS) had an average elastic modulus of 0.169±0.010 kPa. Substituting hyaluronic acid (HA) for 
CS resulted in a significant increase in modulus to 0.511±0.052 kPa while adding amniotic 
membrane (AM) showed a further significant increase (1.065±0.083 kPa). The scaffold variants 
all showed an open porous network via SEM with pores on the order of 100 μm (Fig. 4.1D) and 
by day 7 of culture the tenocytes were well distributed throughout the scaffolds with no obvious 
differences in cell aggregation or distribution (Fig. 4.1E). 
4.4.3 Tendon cell metabolic activity under pro-inflammatory media conditions 
The metabolic activity of equine tenocytes cultured within the CG scaffold variants was 
evaluated prior to the pro-inflammatory challenge (day 0) and subsequently at days 1, 4, and 7 
(Fig. 4.2). Each scaffold variant supported metabolic health over time. However, scaffolds 
containing HA or AM showed a greater increase in metabolic activity. Cells within C:AM 
scaffolds cultured in control media showed increased metabolic activity compared to C:CS 
(standard, control) scaffolds at all time points (Fig. 4.2A). The same was seen in cells cultured in 
C:AM scaffolds with media supplemented with the pro-inflammatory cytokine IL-β at 
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inflammatory (Fig. 4.2B) and high inflammatory levels (Fig. 4.2C). Additionally, scaffolds 
containing hyaluronic acid also promoted significantly increased tenocyte metabolic activity over 
the C:CS scaffolds, especially in high inflammatory media, as seen at all time points (Fig. 4.2C). 
Reorganizing the data to display cell metabolic activity across all media conditions for each 
scaffold type (Fig. 4.2D-F), we find that, following the introduction of variant medias, there was 
no significant difference in cell metabolic activity between C:CS scaffolds across all media 
conditions (Fig. 4.2D). Interestingly, while cell metabolic activity trended to increase throughout 
the 7 days experiment, cells in amniotic membrane matrix scaffolds showed significantly 
enhanced (p < 0.05, day 4) cell metabolic activity in response to inflammatory or high 
inflammatory media formulations (Fig. 4.2F). 
4.4.4 Gene expression of tenocytes cultured in CG scaffolds under IL-1β challenge 
PCR was used to examine the relative expression of inflammatory and tenocyte phenotypic 
genes over the course of 7 days of culture in pro-inflammatory media conditions. The reported 
fold changes are compared to cells cultured in the same scaffold type but in control media. 
Tenocyte expression of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine, is 
significantly downregulated (p < 0.05) in AM containing scaffolds compared to C:HA scaffolds 
cultured in inflammatory media at day 7 (Fig. 4.3A). Further, although not statistically 
significant, AM scaffolds also showed TNF-α downregulation compared to CS scaffolds (p = 
0.0814). When the cell-seeded scaffolds were cultured in high inflammatory media, both HA and 
AM scaffolds induced lower TNF-α expression compared to the standard C:CS scaffolds (Fig. 
4.3B). 
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Further gene expression analysis focused on markers of tendon phenotype (Fig. 4.4). Collagen I 
(COLI) is the primary ECM protein in tendon and is secreted by tenocytes. COLI gene 
expression was significantly downregulated in CS scaffolds following 1 day of inflammatory 
challenge by IL-1β when compared to C:HA scaffolds (Fig. 4.4A). Following 4 days of culture 
in inflammatory media, tenocytes in C:CS scaffolds were expressing COLI at significantly lower 
levels than those in parallel HA or AM scaffolds and in the C:CS scaffolds in control media. 
Across all timepoints cells in both AM and HA scaffolds were maintaining COLI expression 
comparable to their respective controls. Scaffolds cultured in high inflammatory media showed 
no significant differences in COLI gene expression at day 1 (Fig. 4.4B). Analysis of subsequent 
days shows significant downregulation of tenocyte COLI expression in all scaffolds (except HA 
at day 4) as compared to corresponding scaffolds in control media.  
Matrix metalloproteinase-3 (MMP-3) is involved in matrix breakdown in normal tendon 
remodeling and in early wound healing. Under the in vitro inflammatory conditions presented 
here, there was no significant difference in the MMP-3 gene expression between scaffolds or 
when compared to control media (Fig. 4.4C). When considering the cells cultured in scaffolds 
exposed to high inflammatory media, MMP-3 expression is expectantly high in all groups at day 
1 (Fig. 4.4D). By day 4, tenocytes in AM scaffolds had significantly lower MMP-3 expression, 
no different from their respective control, as compared to cells cultured in CS or HA scaffolds. 
The expression level of the pro-tenogenic transcription factor scleraxis (SCXB) was subsequently 
analyzed. While the scaffold variants used here did not contain aligned microstructural elements 
known to promote tenogenic expression profiles, results show little difference between groups 
due to scaffold type or media condition (Fig. 4.4E, F). Cells in HA scaffolds show 
downregulation of SCXB expression compared to CS scaffolds (day1) and control media (day 7) 
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in inflammatory media conditions (Fig. 4.4E). SCXB expression is also downregulated in high 
inflammatory media compared to control media in HA scaffolds (day 1) and all scaffolds at day 
7 (Fig. 4.4F). 
4.4.5 Short term protein release from pro-inflammatory tenocyte culture 
In the absence of a pro-inflammatory signal (control media), cells seeded in CS scaffolds release 
significantly more TGF-β1 than those seeded in HA or AM scaffolds (Fig. 4.5A). When the cell-
seeded scaffolds are exposed to IL-1β in the inflammatory media, there was a significantly 
higher concentration of TGF-β1 in the media surrounding the collagen scaffolds containing CS 
as compared to the HA scaffolds (Fig. 4.5B). In the high inflammatory media, there was no 
statistically significant difference between the amount of TGF-β1 released from each of the 
scaffold groups (Fig. 4.5C). 
4.4.6 Cytokine sequestration within scaffold variants 
A pull down assay was employed to determine whether the three scaffold types were 
differentially sequestering or trapping the pro-inflammatory cytokine (IL-1β) and, thus, 
influencing the cellular response. While the results suggest increased pull down when moving 
from CS to HA to AM scaffolds, there is no statistically significant difference between the 
entrapment of IL-1β in the three scaffold variants (Fig. 4.6). 
4.5 Discussion 
The inflammatory phase of adult wound healing is important for inducing the rapid closure of 
wounds but, as a result, leads to disorganized matrix and scar formation [189]. Studies in the 
healing process following acute tendon injury, in particular, show upregulation in TGF-β1 
mRNA and protein expression, disruption in collagen fiber continuity and organization, and 
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decreases in ultimate stress and modulus when compared to uninjured tendons [23, 24]. Increases 
in the gene expression of pro-inflammation (IL-1β, TNFα) and matrix degradation factors (MMP-
3, MMP-13) as well as decreases in the expression of tendon ECM (COLI) and tendon-specific 
markers (SCX) have also been shown in a canine flexor tendon model [22]. In designing a 
biomaterial to drive tendon regeneration in vivo, the presence of an inflammatory environment 
should be considered.  
It has been previously shown that fetal wounds have the capacity to facilitate scarless wound 
healing with a limited inflammatory response. Interestingly, this phenomenon is not solely 
defined by the sterile, intrauterine environment. Fetal marsupials such as the gray short-tailed 
opossum, which develop outside of the uterus, heal cutaneous wounds in a scarless fashion 
[212]. Research has also shown that scar formation occurs in adult sheep skin transplanted onto 
fetal lambs, but not in adjacent fetal skin wounds [213]. Due to the unique nature of these results, 
efforts have begun to focus on the ECM and the role it plays in wound healing [191]. Hyaluronic 
acid (HA), shown to have a dominant presence in fetal wounds both in the wound ECM [299] 
and surrounding fluid [211], has been used in three-dimensional skin grafts to reduce scar 
formation [300]. Amniotic membrane has also been used in the treatment of skin wounds [219, 
225]. As a result, our effort here investigated whether CG scaffolds containing hyaluronic acid or 
amniotic membrane matrix could reduce the immune response associated with interleukin-1beta 
(IL-1β) in tenocytes. 
Collagen-based scaffold content was altered by incorporating HA or AM in the collagen-
glycosaminoglycan suspension instead of the standard chondroitin sulfate (CS). Prior to 
incorporation into the scaffold, the AM matrix was partially characterized for collagen and 
sulfated GAG content. The complete makeup of the amniotic membrane is not known; however, 
97 
 
other studies have reported that in addition to these two matrix components, the AM also 
contains HA [215], elastin and denatured collagen [217]. Following scaffold lyophilization, SEM 
analysis revealed that all scaffold variants had an open porous microstructure (Fig. 4.1D). 
Mechanical testing on hydrated, crosslinked samples revealed significant increases in modulus 
when moving from CS to HA to AM scaffolds. Each scaffold contained the same overall 
material density and exhibited similar pore structure indicating that the matrix content affects 
scaffold modulus. While statistically significant, the relative differences in the moduli are still 
small compared to native tendon. However, these differences may alter local cellular behavior 
and warrant further investigation in the future. While the scaffolds tested here have insufficient 
mechanical strength for direct tendon application, separate efforts in our group have shown 
reinforcement strategies sufficient to boost the tensile modulus of the scaffold to greater than 1 
MPa [251, 301]. When examining the distribution of cells following the 7 days of culture, the 
representative images in Figure 1E do not show any evidence of cellular clumping in any of the 
collagen-based scaffolds, including C:AM. 
Interleukin-1β is a pro-inflammatory cytokine secreted by macrophages during the inflammatory 
phase of wound healing and was used in this study as the pro-inflammatory challenge. We first 
examined metabolic activity of tenocytes seeded within these scaffolds over a 7 day period (Fig. 
4.2). Not only do the amnion scaffolds support tenocyte metabolic health in control media, cells 
are significantly more active in AM scaffolds than CS scaffolds (Fig. 4.2A). Further, tenocytes in 
AM scaffolds show increased metabolic activity in response to the pro-inflammatory challenge 
of IL-1β (Fig. 4.2B,C). Since metabolic health is dependent on the number of cells present as 
well as the metabolic activity on a per cell basis, the increase of these in the AM scaffolds is a 
critical finding. 
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Genes associated with the early inflammatory response in tendon healing (TNF-α, COL1A2, 
MMP-3) were differentially regulated in tenocytes in each of the three different scaffold 
environments. Each of these has been studied within the context of the normal tendon healing 
cascade [22]. The pro-inflammatory factor TNF-α, which works alongside IL-1β, is normally 
upregulated in adult tendon healing [22]. The results seen here show an upregulation of TNF-α 
expression in CS scaffolds while there is downregulation of this pro-inflammatory marker in HA 
and AM scaffolds after 7 days of culture (Fig. 4.3A). Especially in the high inflammatory media 
conditions (Fig. 4.3B), cells in HA and AM scaffolds show significant downregulation of TNF-α 
suggesting that these fetal ECM components may maintain their native anti-inflammatory 
properties within the CG scaffold platform. 
When considering genes associated with matrix deposition and remodeling, altering the CG 
scaffold composition also resulted in differences in expression (Fig. 4.4). Collagen I (COL1A2) 
is the primary ECM protein in tendon and is secreted by tenocytes but is downregulated in the 
first days following tendon injury compared to healthy tendons [22]. In this experiment, COL1A2 
gene expression of scaffolds cultured in the inflammatory media is only significantly 
downregulated in the CS scaffolds when compared to the control media (day 4) (Fig. 4.4A). HA 
and AM scaffolds show no significant differences in expression when compared to their 
respective controls. Our results show higher COL1A2 expression in the cells cultured in the 
inflammatory media in HA scaffolds compared to CS (day 1) and both scaffold types (day 4) 
(Fig. 4.4A). Cell-constructs cultured in the high inflammatory media exhibited COL1A2 
downregulation compared to the control in all groups (at days 4 and 7) except for HA at day 4 
(Fig. 4.4B). Typically upregulated in adult tendon injury [22], MMP-3 expression was no 
different from the control media in the groups exposed to inflammatory media (Fig. 4.4C). 
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However, in high inflammatory media conditions, cells in AM scaffolds (day 4) showed 
significantly lower expression of MMP-3 that was no different from the control media (Fig. 
4.4D). These results together suggest that fetal wound inspired matrices alter the pro-
inflammatory effects usually seen in tendon wound sites. Implementing scaffolds such as these in 
tendon regeneration applications may reduce inflammation-induced scar formation. 
Tendon is a highly anisotropic tissue with tenocytes longitudinally aligned within its 
microstructure. Geometric cues such as this have been shown to play a role in the maintenance of 
the tenocyte phenotype in vitro [60, 61]. However, due to ease of bulk fabrication, the current 
study used isotropic CG scaffolds, eliminating any geometric cues that would maintain the 
tenocyte phenotype. Gene expression of the tendon-specific gene scleraxis (SCXB) was 
monitored over the 7 day culture period (Fig. 4.4 E,F). Results give no indication that the 
addition of HA or AM into the scaffold either promotes or hinders expression of SCXB. Future 
work will employ anisotropic scaffolds that allow for tenocyte alignment and phenotypic 
preservation [60]. 
Important questions remain: why do scaffolds containing HA or AM alter the cell response to 
inflammatory signals? And what is the means of mechanism? Transforming growth factor-beta 1 
(TGF-β1) is a protein that is highly expressed in adult wound healing but found at very low 
levels in fetal wounds. We hypothesized that AM-matrix decorated scaffolds may promote lower 
TGF-β1expression. An alternative hypothesis was that AM scaffolds may sequester the IL-1β 
from the media, preventing it from interacting with the cells within the scaffold. 
With regards to the presence of TGF-β1, we report significantly less TGF-β1 released from the 
HA and AM containing scaffolds compared to the CS scaffolds (Fig. 4.5A). Once IL-1β was 
100 
 
introduced to the media, AM scaffolds were not significantly different from the other scaffold 
variants (Fig. 4.5B,C). However, scaffolds containing HA showed significantly lower (versus CS 
scaffolds) TGF-β1 release in the inflammatory media groups (Fig. 4.5B). These results were 
normalized versus acellular scaffolds to reveal cell-specific secretions; given the potential for 
AM-matrix to be processed in a manner to facilitate release of large doses of growth factors 
[219], ongoing efforts are examining how these endogenous factors may also affect cell activity. 
To examine the interaction between IL-1β and the different scaffold variants, a pull down assay 
was employed. While no significant difference in sequestration of IL-1β was observed between 
scaffold groups, the overall trend suggests that AM scaffolds have the potential to be optimized 
to sequester more IL-1β than CS scaffolds (Fig. 4.6). Together these observations suggest that 
while material composition may be important in modifying the inflammatory response in vitro, 
the complete mechanism is not yet understood. Additional studies will seek to differentiate 
further, and over longer time periods, the impact of scaffold composition on growth factor 
production, sequestration, and release. Future studies will explore the mechanism behind the 
results seen here, including how cell-matrix interactions are directly influencing cellular response 
to a pro-inflammatory environment.  
A limitation of this current work is that supplementing media with a single pro-inflammatory 
factor is not adequate to replicate the complex inflammatory environment seen in vivo. Ongoing 
work is evaluating cell response to more complex inflammatory signals (e.g. TNF-α in 
combination with IL-1β) and in vitro macrophage phenotype in response to scaffold composition 
as well as inflammatory response and healing in an in vivo porcine defect model. 
4.6 Conclusions 
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In an attempt to replicate the scarless, fetal wound healing properties in scaffolds for tendon 
regeneration, this study incorporated hyaluronic acid and amniotic membrane matrix into 
collagen-based scaffolds. In vitro experiments used interleukin-1 beta to create a pro-
inflammatory environment. Bioactivity of the tenocytes cultured within these scaffold variants 
was assessed over a 7 day period. Following the pro-inflammatory challenge, equine tenocytes in 
amniotic membrane scaffold variants showed increased metabolic activity. These fetal wound 
inspired components also contributed to decreased tumor necrosis factor-alpha and matrix 
metalloproteinase-3 gene expression as well as increased expression of collagen I. Together, 
these results propose a biomaterial for modifying the inflammatory response associated with scar 
formation.  
102 
 
4.7 Figures 
 
 
Figure 4.1. Amniotic membrane histological analysis, scaffold mechanical and microstructural 
analysis. (A) Placental section stained with H&E. Arrows indicate amniotic membrane. Scale 
bar: 200 µm. (B) Masson’s Trichrome staining of placental section. Arrows indicate amniotic 
membrane. Scale bar: 200 µm. (C) Elastic modulus of scaffold variants under compression. (*) 
significance (p < 0.05) between scaffold groups. (D) SEM images of scaffold variants; 
collagen:chondroitin sulfate (C:CS), collagen:hyaluronic acid (C:HA), collagen: amniotic 
membrane (C:AM) (left to right). Scale bar: 100 µm. (E) Histological staining of vimentin in 
cell-seeded scaffolds with varying composition at day 7. Left to right: collagen:chondroitin 
sulfate (C:CS), collagen:hyaluronic acid (C:HA), collagen: amniotic membrane (C:AM). Scale 
bar: 200 µm. 
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Figure 4.2. Tenocyte metabolic activity in scaffolds cultured in (A) control media, (B) 
inflammatory media containing 0.1 ng/mL IL-1β, and (C) high inflammatory media 
supplemented with 1 ng/mL IL-1β. (*) significance between groups indicated (p < 0.05). The 
same data has been grouped by scaffold type and plotted in (D) collagen:chondroitin sulfate, (E) 
collagen:hyaluronic acid, and (F) collagen:amniotic membrane. (**) significance compared to all 
groups at given time point (p < 0.05). (N.S.) no significant differences between groups at a given 
timepoint (p > 0.05). 
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Figure 4.3. Gene expression of tumor necrosis factor-alpha (TNF-α) in tenocytes cultured in 
three scaffold variants in (A) inflammatory (0.1 ng/mL IL-1β) and (B) high inflammatory (1 
ng/mL IL-1β ) media conditions. Gene expression was normalized to tenocytes cultured in 
respective scaffold in control (no inflammatory factors) media. (*) significance between groups 
indicated (p < 0.05). (**) significance compared to all groups at given time point (p < 0.05). 
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Figure 4.4. Tenocyte gene expression levels of collagen I (COL1A2; A, B), matrix 
metalloproteinase-3 (MMP-3; C, D), and scleraxis (SCXB; E, F) as a function of scaffold content 
at days 1, 4, and 7 of culture in inflammatory (0.1 ng/mL IL-1β) (A, C, E) and high 
inflammatory (1 ng/mL IL-1β ) (B, D, F) media. Gene expression was normalized to tenocytes 
cultured in respective scaffold in control (no inflammatory factors) media. (*) significance 
between groups indicated (p < 0.05). (˄,˅) significant increase, decrease (respectively) compared 
to corresponding control (same scaffold type, same time point) (p < 0.05).  
106 
 
 
Figure 4.5. Transforming growth factor-beta 1 (TGF-β1) release from tenocyte-seeded scaffolds 
of varying compositions. Measurements were made after 24 hours of culture in serum-free 
medias: (A) inflammatory (0.1 ng/mL IL-1β ) and (B) high inflammatory (1 ng/mL IL-1β). (*) 
significance between groups indicated (p < 0.05). 
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Figure 4.6. Pull down of IL-1β by scaffolds with varying compositions. The degree of pull down 
was normalized to the concentration of IL-1β in a solution without scaffolds. 
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CHAPTER 5: INCORPORATION OF AMNIOTIC MEMBRANE INTO COLLAGEN 
SCAFFOLDS TO ADDRESS IMMUNOMODULATORY REQUIREMENTS FOR 
TENDON REPAIR** 
5.1 Chapter overview 
Tendon tears often require surgical intervention and even then result in poor outcomes due to 
scar formation and re-failure. Biomaterial implants offer the potential to address multiple 
underlying concerns preventing improved tendon repair. Wrapping repaired tendons with 
commercially available collagen membranes is a technique used in rotator cuff and Achilles 
tendon surgeries to improve the mechanical strength of the repair. Modifications to the 
composition of a biomaterial implant have shown potential to alter the inflammatory response 
and establish conditions for improved regenerative repair. Here, we describe integrating these 
concepts into a three dimensional extracellular matrix analog that combines anti-inflammatory 
amniotic membrane (AM) matrix with an anisotropic collagen-glycosaminoglycan (CG) 
scaffold. AM-derived matrix was incorporated directly within the scaffold microstructure during 
fabrication to form a C:AM composite. Alternatively, native amniotic matrix was wrapped 
around the CG scaffold in a manner similar to current collagen membrane wraps. Human 
mesenchymal stem cells (MSCs) cultured within these materials were evaluated for metabolic 
health and immunomodulatory gene expression in response to inflammatory media challenge of 
interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α). The scaffolds were able to 
maintain MSC metabolic activity in all media conditions over the course of a 7 day culture. 
                                                 
 
** This chapter has been adapted from the following publication: Rebecca A. Hortensius, Jill H. Ebens, and Brendan 
A.C. Harley, “Incorporation of amniotic membrane into collagen scaffolds to address immunomodulatory 
requirements for tendon repair.” In preparation. 
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Expression of genes encoding for pro-inflammatory cytokines was downregulated in AM 
containing scaffolds. Further work needs to be done to elucidate the origins of these effects. 
5.2 Introduction 
While the human body is capable of repairing minor tendon injuries, native repair processes 
often result in a loss of structural integrity and mechanical strength due to the formation of 
poorly organized granulation tissue (scar) [302]. In the cases of massive tissue tears or 
degeneration due to chronic conditions, surgical strategies are frequently required. A range of 
suturing techniques have been developed to facilitate tendon-to-tendon reattachment or tendon 
graft insertion [303]; however, despite surgical improvements these large injuries too result in 
diminished tendon functionality and have a high incidence of re-tear. The implantation of 
biomaterial scaffolds offers a promising avenue for the promotion of tendon repair and 
regeneration in vivo. At the most basic level, biomaterial implants can be used to mechanically 
stabilize the surgical reconnection. Products such as the GraftJacket Regenerative Tissue Matrix 
(Wright Medical Technology), Restore Orthobiologic Implant (DePuy Orthopaedics), 
TissueMend Soft Tissue Repair Matrix (Stryker Orthopaedics), and CuffPatch Bioengineered 
Tissue Reinforcement (Arthrotek) are currently being studied [304] and used in the clinic for 
rotator cuff [305-307] and Achilles tendon tears [308, 309]. Through their use as wraps around 
tendon repairs, they provide mechanical support to the injured area, promote retention of 
surgically placed sutures, and provide a matrix for cellular and vascular ingrowth [310]. 
However, they only provide a two dimensional shell around the existing tendon and do not 
contain internal support of the tendon body. An inherently three-dimensional scaffold may be 
better suited for this application. 
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The inflammatory response following injury plays a significant role in the ultimate healing of a 
tissue [189]. Pro-inflammatory cytokines (such as IL-1β) have been shown to induce the 
expression of inflammatory enzymes and matrix degradation factors in tendon cells which leads 
to tendon destruction and loss of biomechanical integrity [311]. Additionally, by blocking the 
activity of pro-inflammatory cytokine tumor necrosis factor alpha (TNFα), increased 
biomechanical strength in a rat rotator cuff model has been observed [11]. It is hypothesized that 
modulating this early phase of wound healing through tissue engineering strategies (materials, 
cells, and/or soluble factors) could lead to decreased scar formation and, ultimately, better 
healing outcomes. The anti-inflammatory properties of the amniotic membrane (AM), the 
innermost layer of a placenta, have contributed to its success as a wound matrix in the treatment 
of a range of tissues (cornea [222-224], skin [219, 225], oral mucosa [226], and others [215, 
227]). In ocular applications, the use of amniotic membranes tempered inflammation and 
increased the rate of re-epithelialization when used for surface abnormalities [222], limbal stem 
cell deficiency [223], and corneal ulcers [224]. Additionally, amniotic membranes have shown 
the ability to enhance progenitor cell recruitment in a mouse model [219]. Similar to the current 
clinical products listed above, a 1942 report detailed the use of amniotic membrane sheets in the 
treatment of scar formation in digital flexor tendons following injury and subsequent repair 
[220].  
Collagen-glycosaminoglycan (CG) scaffolds are three-dimensional extracellular matrix mimics 
that have been applied to a range of tissue engineering applications [55-58, 67, 244, 292]. Their 
mechanism of regeneration is based on their ability to inhibit myofibroblast recruitment to the 
wound site [293] and therefore the contraction/scar formation that follows [312]. To mimic the 
tendon’s native structural alignment, recently a new class of anisotropic CG scaffolds have been 
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developed [61]. Separately, to introduce anti-inflammatory properties into these CG scaffolds, 
AM derived matrix components have been incorporated into the chemical composition of the 
scaffold during fabrications [230]. Their addition to the CG scaffold promoted fibroblast 
metabolic activity and tempered pro-inflammatory gene expression in vitro [230]. However, the 
mode of the AM’s anti-inflammatory activity is still unknown, suggesting new studies to 
examine the effects of its unique matrix composition [215, 218], soluble factors that it contains 
[219, 313], or a combination of the two. 
Considering the need for tendon regeneration platforms and the role inflammation plays in 
wound healing, the work described in this manuscript combines a three-dimensional, 
microstructurally aligned CG scaffold with a two-dimensional anti-inflammatory allograft shell 
for in vitro evaluation of this core-shell composite. In this work, we examine what dictates the 
cellular response to amnion materials; direct contact with the matrix or altering the kinetics of 
growth factor availability. We examine whether the amniotic membrane matrix needs to be 
directly incorporated into the bulk of the CG scaffold analog to induce an anti-inflammatory 
effect on cells under inflammatory culture conditions or if the incorporation of the AM 
membrane as a membrane shell surrounding a conventional CG scaffold core can provide anti-
inflammatory capabilities as well.  
5.3 Materials and methods 
5.3.1 Amnion membrane isolation 
Human placentas were obtained following uncomplicated vaginal births. The amniotic 
membrane (AM) matrix components were isolated from these placentas as previously described 
[230, 294]. Briefly, the AM was mechanically separated from the placenta, washed, and 
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decellularized via incubation in thermolysin (125 μg/mL) [295]. Following decellularization, 
AM were rinsed in PBS with shaking to remove cellular debris and then stored in PBS at 4°C. 
The spongy layer of the AM was allowed to swell for 24-48 hours before it was separated from 
the AM and discarded. The matrix was lyophilized in a sheet and stored in a dessicator until 
further use. 
5.3.2 Preparation of collagen suspension 
Type I collagen from microfibrillar collagen (Collagen Matrix, Oakland, NJ) was homogenized 
in 0.5 M acetic acid with either chondroitin sulfate from shark cartilage (Sigma Aldrich, St 
Louis, MO) or homogenized amniotic membrane as collected above. A collagen:chondroitin 
sulfate (C:CS) ratio of 11:1 was used while C:AM suspensions were made at a 5:1 w:w ratio due 
to the high AM collagen content. Each suspension was made with a total density of 0.5% w/v, 
stored at 4°C, and degassed prior to use [251].  
5.3.3 Fabrication of anisotropic scaffolds via freeze drying 
Collagen scaffolds were fabricated as previously described [61]. Briefly, collagen suspensions 
were added to cylindrical molds made of polytetrafluoroethylene (PTFE) sides and a copper 
bottom. When placed on a precooled (-10˚C) freeze-dryer shelf (VirTis, Gardiner, NY), 
unidirectional heat transfer through the copper bottom promotes the growth of elongated ice 
crystals. The suspensions were frozen at -10˚C for two hours prior to the sublimation of the 
resulting ice crystals at 0˚C and 200 mTorr. Molds of 8 mm diameter and 20 mm in height were 
used for cell culture experiments. 
5.3.4 Fabrication of wrapped, anisotropic collagen-based scaffolds via freeze drying 
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Similar to previous work [251], scaffold-amniotic membrane core-shell constructs were created 
by cutting a dry sheet of AM to size and placing it along the circumferential surface of the 
cylindrical, PTFE-copper mold (8 mm diameter, 20 mm height). The C:CS suspension was then 
pipetted into the center of the mold. The freeze drying cycle used for these core-shell scaffolds 
was identical to the C:CS and C:AM anisotropic scaffolds. 
5.3.5 Crosslinking of CG and CG-AM core-shell scaffolds 
Scaffolds were sterilized and dehydrothermally crosslinked under vacuum in a vacuum oven 
(Welch, Niles, IL) at 105˚C for 24 hours [56]. 5 mm long sections were cut from the scaffold and 
used for all in vitro culture experiments [61]. Scaffolds were hydrated in 100% ethanol overnight 
and washed in two changes of phosphate-buffered saline (PBS) over 36 hours. Chemical 
crosslinking was applied to strengthen the scaffolds against contraction by seeded cells [248, 
252]. Scaffolds were immersed in a solution of 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride (EDC) and N-hydroxysulfosuccinimide (NHS) at a molar ratio of 5:2:1 
EDC:NHS:COOH. Scaffolds were crosslinked for 1.5h under shaking at room temperature. 
Scaffolds were washed with PBS before being stored in fresh PBS at 4˚C. 
5.3.6 SEM analysis 
The cross-sectional microstructure of dry, uncrosslinked scaffolds was visualized using scanning 
electron microscopy (SEM). Samples were imaged with a Philips XL30 ESEM-FEG scanning 
electron microscope under high vacuum. 
5.3.7 Human mesenchymal stem cell culture 
Bone marrow-derived human mesenchymal stem cells (Lonza, Switzerland) were cultured in 
standard culture flasks in low glucose Dulbecco’s modified Eagle’s medium supplemented with 
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10% MSC FBS (Invitrogen, Carlsbad, CA), 1% L-glutamine (Invitrogen, Carlsbad, CA), and 1% 
Antibiotic-Antimycotic (Invitrogen, Carlsbad, CA). Media was changed every 3 days and the 
cells were cultured to confluence at 37˚C and 5% CO2. Cells were used at passage 6. 
5.3.8 Scaffold seeding and culture conditions 
Hydrated, crosslinked CG scaffolds were soaked in growth media for overnight at 37°C before 
being tapped dry on a Kimwipe and placed in ultra-low attachment 6-well plates (Fisher, 
Waltham, MA). Confluent hMSCs were trypsinized and resuspended in growth media at a 
concentration of approximately 78,000 cells per 20 µL in preparation for static seeding [61]. Ten 
microliters of the cell suspension were added to one side of the scaffolds. Then the scaffolds 
were incubated for 15 minutes at 37˚C, flipped over and another 10 µL of cell suspension was 
added. To allow for initial cell attachment, scaffolds were placed in the incubator for 2 hours 
before additional growth media was added. Scaffolds were incubated at 37˚C and 5% CO2 for 
24h before the media was exchanged for one of three inflammatory challenge media with media 
being replaced every 3 days: 
(1) Control: growth media 
(2) Inflammatory: media supplemented with 0.1 ng/mL of the pro-inflammatory factor 
interleukin-1 beta (IL-1β) and 1 ng/mL tumor necrosis factor alpha (TNFα) 
(3) High inflammatory: media supplemented with 1 ng/mL of IL-1β and 10 ng/mL tumor 
necrosis factor alpha (TNFα). 
5.3.9 Metabolic activity quantification 
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A non-destructive alamarBlue® assay (Invitrogen, Carlsbad, CA) was used to measure the 
metabolic activity of the MSCs within the collagen scaffolds [61, 251]. At the start of the 
experiment, a metabolic activity standard curve was created by culturing a known number of 
cells (ranging from 25-300% of the total cells seeded) for 2 hours in a 1x alamarBlue® solution 
supplemented with cytokines from each of the three media variants. At each experimental 
timepoint (days 1, 4, 7), scaffolds were removed from culture, rinsed in PBS, and incubated 
under gentle shaking at 37˚C for 2 hours in a 1x alamarBlue® solution containing the media 
variant of the primary culture. Using a fluorescent spectrophotometer, resorufin fluorescence was 
measured (excitation: 540 nm, emission: 590 nm). Metabolic activity was interpolated to the 
standard curve and reported as a percentage of the total number of seeded cells. 
5.3.10 Gene expression analysis through RNA isolation and real-time PCR 
RNA was isolated from scaffolds at each timepoint with an RNeasy Plant Mini kit (Qiagen, 
Valencia, CA). The scaffolds were rinsed in PBS to remove any dead/unattached cells, cut in half 
with a razor, and immersed in the kit’s lysis buffer for 5 minutes on ice [87]. RNA was isolated 
following the kit’s instructions and total RNA was quantified using a Nanodrop. The RNA was 
reverse transcribed using a QuantiTect Reverse Transcription kit (Qiagen, Valencia, CA) and a 
Bio-Rad S1000 thermal cycler. Real-time PCR was performed with an Applied Biosystems 
7900HT Fast Real-Time PCR System (Carlsbad, CA) to measure gene expression levels for 
hepatocyte growth factor (HGF), interleukin 6 (IL-6, IL6), interleukin 8 (IL-8, CXCL8), 
indoleamine 2,3, dioxygenase (IDO1) and transforming growth factor beta 1 (TGFB1). 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene. All 
results were expressed as fold changes relative to expression levels of cells cultured in scaffolds 
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of the same type and at the same time point but in control media. Primer sequences are located in 
Table 5.1. 
5.3.11 Statistical analysis 
One-way analysis of variance (ANOVA) followed by Tukey-HSD post-hoc test was performed 
on gene expression data at each timepoint. The metabolic activity was analyzed using a two-way, 
repeated measures ANOVA followed by Tukey-HSD post-hoc test. A p-value < 0.05 was used 
for significance. All analyses were based on a minimum of n=4 scaffolds. Error is reported as the 
standard error of the mean in the figures. 
5.4 Results 
5.4.1 Scaffold microstructure 
SEM images taken of transverse planes through each scaffold variant showed an open pore 
structure with rounded pores on the order of 200 micrometers in size, with longitudinal cross-
sections showing more elongated pores (Fig. 5.1). The core-shell C:CS-AM scaffolds show 
consistent union between the scaffold core and the AM shell without evidence of delamination, 
confirming that the membrane is well integrated with the bulk of the material (Fig. 5.1C). 
5.4.2 Cell metabolic activity under pro-inflammatory media conditions 
The human mesenchymal stem cells (MSCs) that were cultured within each CG scaffold variant 
were evaluated for metabolic health prior to the pro-inflammatory challenge (day 0) and at 
subsequent timepoints (days 1, 4, and 7) (Fig. 5.2). There were no statistically significant 
differences between the metabolic activity of cells within these scaffold groups over the course 
of the entire 7 day experiment, regardless of whether the scaffolds were in control media (Fig. 
5.2A), inflammatory media (Fig. 5.2B), or high inflammatory media (Fig. 5.2C). 
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5.4.3 Expression of immunomodulatory genes in MSCs cultured in 3D scaffolds under pro-
inflammatory conditions 
The expression of MSC immunomodulatory genes such as hepatocyte growth factor (HGF), 
indoleamine 2,3, dioxygenase (IDO) and transforming growth factor beta 1 (TGF-β1) were 
evaluated via PCR. Fold changes were normalized to GAPDH (housekeeping gene) and the 
expression from cells cultured in the same scaffold variant in control media. 
Cellular HGF expression in inflammatory (Fig. 5.3A) and high inflammatory (Fig. 5.3B) media 
resulted in no significant differences between groups or compared to the control, except for the 
C:AM group in high inflammatory media at day 4. This sample group showed significantly 
lower expression compared to the corresponding scaffolds in control media. Similarly, there was 
no significant difference in IDO expression (Fig. 5.3C, Fig. 5.3D) with respect to either of the 
variables (scaffold type, media condition). The final immunomodulatory gene evaluated was 
TGF-β1. In both the inflammatory (Fig. 5.3E) and high inflammatory (Fig. 5.3F) media, the 
TGF-β1 expression in the C:CS scaffolds starts low, trends up at day 4 before dropping again by 
day 7. In the inflammatory media, the peak in C:CS expression at day 4 is significantly different 
from the C:AM group at that timepoint (Fig. 5.3E). In the high inflammatory media, expression 
of TGF- β1 in the C:AM and wrap scaffolds shows a downward trend overtime, resulting in 
expression in the wrapped scaffold significantly different from the control at day 7 (Fig. 5.3F). 
5.4.4 Expression of pro-inflammatory genes MSCs cultured in 3D scaffolds under pro-
inflammatory conditions 
Additionally, the relative expression of genes encoding for pro-inflammatory cytokines 
interleukin 6 (IL-6) and interleukin 8 (IL-8) were analyzed via PCR (Fig. 5.4). In both 
inflammatory media (Fig. 5.4A) and high inflammatory media (Fig. 5.4B), the expression of IL-6 
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is significantly lower (p < 0.05) in C:AM scaffolds compared to C:CS scaffolds following 1 day 
of pro-inflammatory media challenge (Fig. 5.4A). In the following days in inflammatory media 
culture, IL-6 expression is higher in C:CS scaffolds compared to C:AM and the AM wrapped 
scaffolds, although this trend is not significant (Fig. 5.4A). However, at day 4 of culture in high 
inflammatory media, MSCs in C:CS scaffolds show a statistically significant (p < 0.05) increase 
in the expression of pro-inflammatory IL-6 compared to the control and the scaffolds that contain 
AM (C:AM and AM wrapped scaffolds) (Fig. 5.4B).  
When evaluating the expression of IL-8 in 3D MSC culture in inflammatory media, an increase 
in expression in C:CS scaffolds is observed at days 1 and 4 along with lower levels of expression 
in the AM-containing scaffolds (Fig. 5.4C). Although these trends are not significant in the 
inflammatory condition, statistically significant observations can be made regarding IL-8 
expression in the high inflammatory condition. At all timepoints (days 1, 4, 7), the AM wrap 
scaffolds are expressing IL-8 at levels no different from the control (p > 0.05) (Fig. 5.4D). 
Further, at days 4 and 7 the AM wrap scaffolds are exhibiting significant downregulation (p < 
0.05) of this pro-inflammatory gene when compared to C:CS scaffolds (Fig. 5.4D).  
5.5 Discussion 
In the treatment of massive tendon tears, biomaterials provide an alternative to the reliance on 
native healing cascades or use of surgical techniques, both with outcomes compromised by scar 
formation, decreased mechanical properties, and high re-failure rates. In designing bioactive 
materials for this application, the in vivo ECM architecture and local growth factor/cytokine 
environment must be kept in mind. Especially important is the understanding that the material 
implant is likely to experience the body’s native inflammatory response; in response to the 
injury, the implant, or both. Extended inflammation can have detrimental effects on healing 
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outcomes. Facilitating the transition from the inflammatory phase of healing to one of 
proliferation and remodeling is a strategy to prevent the occurrence of scar formation. 
Collagen-glycosaminoglycan (CG) scaffolds are degradable, bioactive, three-dimensional 
materials that mimic the composition and microstructure of the extracellular matrix. Studied for 
an array of applications [55-58, 67, 244, 292], they promote regeneration by preventing 
fibroblast initiated contraction [293, 312]. The amniotic membrane also promotes regeneration, 
typically in two-dimensional applications, by tempering the inflammatory response at the injury 
site. 
This work demonstrates the incorporation of amniotic membrane matrix into both the bulk of a 
collagen-based, open pore scaffold and in wrap form in a scaffold core-membrane shell 
configuration. Each of these scaffold variants, along with a collagen-chondroitin sulfate control, 
exhibit rounded pores in the transverse cross-section and elongated pores in the longitudinal 
direction (Fig. 5.1). This anisotropy is produced using freeze drying and a mold of mismatched 
thermal conductivity. It has been previously shown that this aligned microstructure, mimicking 
the anisotropic characteristics of native tendon, maintains tenocyte phenotype within the material 
[60] and enhances MSC differentiation towards a tenogenic phenotype [88]. Further, the core-
shell wrap design is inspired by current surgical techniques that implement the use of 
commercially available tendon wraps [304] and in vitro work that has attribute increased 
mechanical competence in the CG scaffolds to a core-shell configuration [251]. An added feature 
of the AM wrap is that ability to incorporate more membrane matrix per scaffold (3.4 times in 
mass) than in the traditional C:AM scaffold. 
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Mesenchymal stem/stromal cells (MSCs) are multipotent progenitor cells [314] found in many 
tissues throughout the body [315], but primarily harvested from bone marrow and adipose tissue 
for tissue engineering applications [316]. MSCs are capable of self-renewal [314] and 
differentiation into specialized cells found in tendon, bone, cartilage, ligament, and fat [317]. 
MSCs are also present in sites of injury. Due to these properties, MSC culture within 
biomaterials is often studied. As multipotent cells, MSCs are a likely cell source to be co-
implanted with bioactive substrates intent on providing guided differentiation towards a tissue of 
choice. Additionally, one global objective is to evaluate in vitro the cytocompatibility, 
bioactivity, and differentiation capacity of the designed materials on an element of the native 
cellular environment. For this reason, the bioactivity of the MSCs seeded within the scaffold 
variants presented here was evaluated, using an alamarBlue metabolic activity assay (Fig. 5.2). 
The cells respond consistently to each scaffold variant (C:CS, C:AM, and C:CS-AM wrap) under 
each media condition (growth media control (Fig. 5.2A), inflammatory media (Fig. 5.2B), and 
high inflammatory media (Fig. 5.2C)). Metabolic activity is initially low, as not all cells attach to 
the scaffold, but increased overtime showing that the scaffolds support the cellular activity of the 
MSCs. Even though high levels of IL-1β have led to decreased MSC proliferation [318], there 
are no significant differences here associated with inflammatory media challenge in any of the 
scaffold types. 
In the body, MSCs home to sites of injury and inflammation as part of the tissue 
repair/regeneration process. Their complex immunomodulatory role in wound healing has been 
studied extensively and, while it is not completely clear how MSCs regulate the body’s immune 
response, several MSC secreted factors have been identified as key immunomodulators [319]. 
Hepatocyte growth factor (HGF) and indoleamine 2,3, dioxygenase (IDO) [315, 317] as well as 
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transforming growth factor beta 1 (TGF-β1) [314, 315, 317] are used by MSCs to elicit 
immunosuppressive effects. The increased secretion of each of these factors following 
interferon-gamma (IFN-γ) led to reduced proliferation in allogenic mixed lymphocyte reactions 
[317]. In addition to IFN-γ, IL-1β and TNFα are major pro-inflammatory cytokines that 
contribute to the inflammatory environment in the early stages of wound healing [318, 320, 321]. 
In the current study, the changes in the gene expression of these three factors was minimal (Fig. 
5.3). Cells in each scaffold exposed to IL-1β and TNFα media challenges exhibited expression 
no different from the control media (with the exception of the downregulation of TGF-β1 in AM 
wrap scaffolds in high inflammatory media at day 7 (Fig. 5.3F)). However, when the expression 
of pro-inflammatory genes (IL-6, IL-8) is evaluated, expression is downregulated in AM-
containing scaffolds, especially in high inflammatory conditions (Fig. 5.4 B,D).  
It is suggested, although still unclear, from these data that the MSCs seeded within each of these 
scaffold variants are not displaying their typical immunosuppressive function (increased levels of 
HGF, IDO, TGF-β1) following a pro-inflammatory challenge. Counter to this observation, the 
AM-containing scaffolds show significant downregulation of pro-inflammatory genes (IL-6, IL-
8) in MSCs. It would be interesting to investigate whether the scaffolds are preventing the 
inflammatory cytokines (IL-1β and TNFα) from acting on the MSCs. Ongoing work is focused 
on quantifying cytokine secretion in this experiment. Future work should evaluate bone marrow-
derived MSC immunomodulatory response to IL-1β and TNFα in two dimensions. Priming the 
MSCs with pro-inflammatory factors prior to seeding in each CG scaffold, as in Aktas et al 
[321], will allow for more incremental analysis of MSC response to inflammatory cytokines and 
collagen-based scaffold materials. Also, MSC culture in conjunction with an immune cell type 
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(e.g. macrophages, T cells) will allow for investigation of downstream effects of scaffold-led 
immunomodulation.  
5.6 Conclusions 
The amniotic membrane serves as a powerful source of anti-inflammatory material. While it has 
been used in two-dimensional tissue regeneration applications, the potential benefits in 
translating it to three-dimensional biomaterials is yet unknown. In this manuscript, AM matrix 
was incorporated into 3D collagen-based materials via two means; bulk incorporation or as a 
membrane wrap surrounding a collagen-glycosaminoglycan core. The fabrication of these 
scaffolds allowed for microstructural anisotropy to mimic the aligned ECM of the tendon. 
Human mesenchymal stromal cells, known for their immunomodulatory properties, were 
cultured in these scaffolds under pro-inflammatory media conditions. The results surrounding the 
maintenance of these immunomodulatory properties within these AM-containing scaffolds are 
inconclusive. Further work needs to be done to elucidate the origin of these effects. 
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5.7 Tables 
Table 1.1. Primer sequences used in RT-PCR. 
Transcript Sequence Reference 
HGF 
Forward: ATGCATCCAAGGTCAAGGAG 
[317] 
Reverse: TTCCATGTTCTTGTCCCACA 
IL6 
Forward: CAATATTAGAGTCTCAACCCCCA NCBI Primer BLAST 
search Reverse: TTCTCTTTCGTTCCCGGTGG 
CXCL8 
Forward: ACTGAGAGTGATTGAGAGTGGAC 
[322] 
Reverse: AACCTCTGCACCCAGTTTTC 
IDO1 
Forward: CGCTGTTGGAAATAGCTTC 
[317] 
Reverse: CAGGACGTCAAAGCACTGAA 
TGFB1 
Forward: CAGATCCTGTCCAAGCTG 
[317] 
Reverse: TCGGAGCTCTGATGTGTT 
GAPDH 
Forward: AAGGTGAAGGTCGGAGTCAAC 
[322] 
Reverse: GGGGTCATTGATGGCAACAATA 
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5.8 Figures 
 
 
Figure 5.1. Scanning electron microscopy of (A) collagen-chondroitin sulfate scaffolds, (B) 
collagen-amniotic membrane scaffolds, and (C) core shell scaffolds with collagen-chondroitin 
sulfate core and amniotic membrane shell. Each scaffold was fabricated via unidirectional freeze 
drying to produce the anisotropic pores seen in the longitudinal sections. Scale bars are indicated 
in each image. 
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Figure 5.2. Human mesenchymal stem cell metabolic activity in each scaffold variant was 
completed using alamarBlue. CS = collagen-chondroitin sulfate scaffolds, AM = collagen-
amniotic membrane scaffolds, and Wrap = core shell scaffolds with collagen-chondroitin sulfate 
core and amniotic membrane shell (A) Culture in growth media (control). (B) Culture in media 
supplemented with 0.1 ng/mL of the pro-inflammatory factor interleukin-1 beta (IL-1β) and 1 
ng/mL tumor necrosis factor alpha (TNFα) (inflammatory). (C) Culture in media supplemented 
with 1 ng/mL of IL-1β and 10 ng/mL tumor necrosis factor alpha (TNFα) (high inflammatory). 
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Figure 5.3. Expression of MSC immunomodulatory genes, HGF (A, B), IDO (C, D), and TGF-
β1 (E, F) in scaffolds cultured in media supplemented with 0.1 ng/mL of the pro-inflammatory 
factor interleukin-1 beta (IL-1β) and 1 ng/mL tumor necrosis factor alpha (TNFα) 
(inflammatory) (A, C, E) or media supplemented with 1 ng/mL of IL-1β and 10 ng/mL tumor 
necrosis factor alpha (TNFα) (high inflammatory) (B, D, F). Expressed as fold change internally 
normalized to GAPDH and externally normalized to the expression of cells in the same scaffold, 
at the same timepoint, in control media. 
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Figure 5.4. Expression of pro-inflammatory genes, IL-6 (A, B) and IL-8 (C, D) in scaffolds 
cultured in media supplemented with 0.1 ng/mL of the pro-inflammatory factor interleukin-1 
beta (IL-1β) and 1 ng/mL tumor necrosis factor alpha (TNFα) (inflammatory) (A, C) or media 
supplemented with 1 ng/mL of IL-1β and 10 ng/mL tumor necrosis factor alpha (TNFα) (high 
inflammatory) (B, D). Expressed as fold change internally normalized to GAPDH and externally 
normalized to the expression of cells in the same scaffold, at the same timepoint, in control 
media. 
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CHAPTER 6: MACROPHAGE RESPONSE IN VITRO AND IN VIVO TO AMNION-
CONTAINING COLLAGEN-BASED SCAFFOLDS†† 
6.1 Chapter overview 
Prolonged inflammation following injury is detrimental to healing. Macrophages have a large 
influence on the transition between the phases of the wound healing cascade (inflammation, 
proliferation, remodeling) through their plasticity and ability to display a spectrum of 
phenotypes. A biomaterial design that facilitates this transition would be advantageous in tissue 
regeneration applications. Collagen-glycosaminoglycan porous scaffolds, in combination with 
the matrix of the anti-inflammatory amniotic membrane, were studied for their ability to 
facilitate the macrophage phenotypic shift necessary for improved wound healing in vitro and in 
an in vivo porcine mandibular defect. The results indicate that while the scaffolds do not support 
a M1 (pro-inflammatory) phenotype in vitro, there is some upregulation of M1 associated genes 
at early time points in vivo. The presence of a M2 (pro-healing, anti-inflammatory) associated 
macrophage phenotype is much more dominant in vitro culture. Future work will focus on 
studying macrophage response in an inflammatory environment in vitro and expanding the use of 
histological staining and larger sample numbers in vivo. 
6.2 Introduction 
General wound healing occurs in what can be described as three consecutive, overlapping 
phases: inflammation, proliferation, and remodeling. During inflammation, inflammatory cells 
(such as neutrophils, macrophages) are recruited to the wound site [139]. In the proliferation 
                                                 
 
†† This chapter has been adapted from the following publication: Rebecca A. Hortensius, Amber Boyce, Matthew 
Wheeler, and Brendan A.C. Harley, “Macrophage response in vitro and in vivo to amnion-containing collagen-based 
scaffolds.” In preparation. 
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phase, fibroblasts express genes associated with matrix proteins (collagen, proteoglycans, 
fibronectin) and begin to lay down new matrix [139]. This transition from the inflammatory to 
the proliferative phase of healing is critical [323]. Extended inflammation hinders injury 
resolution and has been associated with scar formation [189]. For weeks and months following 
new matrix deposition, remodeling and reorganization of the matrix occurs as part of the final 
phase of the healing cascade.  
While the interactions between the extensive population of cells (local and immune) and 
signaling molecules in the wound healing cascade is complex, macrophages have been identified 
not only as the initial immune cells at a site of injury but key for ultimate tissue regeneration 
[324, 325]. Macrophages are classically known for their roles in endocytotic removal of cellular 
and matrix debris following injury. However, macrophages have a larger influence on the entire 
time course of the wound healing cascade through their plasticity and ability to display a 
spectrum of phenotypes [137]. Although macrophage phenotype exists on a continuum, literature 
has established a number of phenotypes based on the mode of macrophage activation and 
resultant factor secretion [137]. Macrophages can display a set of attributes that align them with 
a classically activated (M1) phenotype, wound healing (M2a) phenotype, and regulatory/anti-
inflammatory (M2c) phenotype. Recent work by Spiller et al has started to examine how the 
balance of these macrophages can influence healing in vivo, finding that in patients with diabetic 
foot ulcers, the phenotypic shift of the macrophage population from M1 to M2 is indicative of 
better healing outcomes [138]. 
In the field of tissue regeneration, where implanted materials must both overcome the body’s 
potential inflammatory response to the material as well as the inflammation associated with an 
established injury site, it would be advantageous to consider the stimulation of a M1-M2 
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phenotype shift in material design. Scaffolds of decellularized matrix have shown the inherent 
ability to promote an anti-inflammatory environment and a M1-M2 macrophage phenotype shift 
in vitro [149, 170, 171, 173, 175, 176, 178] and in vivo [149, 175, 176, 178, 180]. Additionally, 
by combining decellularized bone matrices with the sequential release of biomolecules that 
stimulate a M1 and then M2 macrophage phenotype, researchers have shown the ability to 
enhance bone healing and vascularization [149]. Further, studies have shown that macrophage 
behavior is different amongst commercially available dermal wound matrices (Integra, 
PriMatrix, AlloMend, Oasis) [326]. Together, this work shows that biomaterials that alter 
macrophage phenotype may be beneficial in stimulating tissue regeneration in vivo. 
Extracellular matrix mimics, like the Integra Dermal Regeneration Template, composed of 
collagen and glycosaminoglycans (GAGs) have been studied for a range of tissue engineering 
applications such as skin, peripheral nerve, cartilage, and tendon regeneration [52, 55-62]. By 
altering the composition of these collagen-based scaffolds, their ability to sequester growth 
factors [59] and temper inflammatory effects in fibroblast populations has been enhanced [230]. 
The incorporation of the amniotic membrane matrix, an anti-inflammatory, anti-scarring allograft 
material used in two dimensional wound healing applications [215, 219, 222-227], has led to 
decreased expression of pro-inflammatory genes in scaffold-seeded tenocytes under 
inflammatory culture conditions in vitro [230]. However, the use of the amniotic membrane to 
alter macrophage phenotype in collagen scaffolds for tissue regeneration has not been previously 
studied. Here, we study the effects of collagen scaffolds with and without the incorporation of 
the amniotic membrane on macrophages in vitro. Additionally, due to the clinical importance of 
translating lab-tested materials to animal models, we also implanted these same scaffold variants 
in a porcine model to study the early inflammatory response in vivo.  
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6.3 Materials and methods 
6.3.1 Amnion membrane isolation 
Human placentas from uncomplicated vaginal births were collected as medical waste by Carle 
Foundation Hospital (Urbana, IL). The amniotic membrane (AM) was isolated as previously 
described [230, 294]. With forceps, the AM was separated from the placenta, washed, and 
decellularized via incubation in thermolysin (125 μg/mL) [295]. Then the AM was rinsed by 
shaking in phosphate buffered saline (PBS) to remove cellular debris and stored in PBS at 4°C. 
Following 24-48 hours in storage, the spongy layer of the AM was removed and discarded. The 
matrix was lyophilized as a sheet and stored in a dessicator until further use. 
6.3.2 Preparation of collagen suspension 
A suspension of microfibrillar collagen (C) type I (Collagen Matrix, Oakland, NJ) in 0.5 M 
acetic acid was homogenized with either chondroitin sulfate (CS) from shark cartilage (Sigma 
Aldrich, St Louis, MO) or dry, ground amniotic membrane (AM) as collected above [56]. 
Scaffolds containing CS were made with a 11:1 C:CS ratio and the C:AM suspension was made 
at a 5:1 w:w ratio due to the high collagen content of AM. All scaffolds were made with a total 
density of 0.5% w/v [251]. The suspensions were degassed prior to use and stored at 4°C [251].  
6.3.3 Fabrication of collagen-based scaffolds via freeze drying 
Isotropic CG scaffolds were fabricated as previously described [61, 69]. For in vitro culture, 
scaffold sheets were made by transferring each collagen suspension to a separate aluminum, 
rectangular tray mold. A Genesis freeze-dryer (VisTis, Gardener, NY) was used to freeze the 
suspension to a final freezing temperature of -40°C. Scaffolds for in vivo culture were made in 6 
well (10 mm diameter, 10 mm height) custom polysulfone array molds. Here, suspensions were 
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frozen to a final freezing temperature of -10°C. In each condition, ice crystals were sublimated 
under vacuum (200 mTorr) at 0°C. 
6.3.4 Preparation of CG scaffolds for use 
In order to sterilize and dehydrothermally (DHT) crosslink the scaffolds, the lyophilized sheets 
for in vitro culture and the cylindrical scaffolds for in vivo used were placed in a vacuum oven 
(Welch, Niles, IL) at 105˚C under vacuum for 24 hours [56]. Following DHT treatment, a biopsy 
punch was used to cut 6mm diameter cylinders from the 4mm thick scaffold sheet for use in all 
in vitro experiments. All scaffolds were hydrated by soaking in 100% ethanol overnight and 
washing in sterile PBS for 24 hours. To increase mechanics, all scaffolds were crosslinked via 
carbodiimide chemistry by immersing in 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride (EDC) and N-hydroxysulfosuccinimide (NHS) at a molar ratio of 5:2:1 
EDC:NHS:COOH (relative to moles of carboxylic acid (COOH) groups present in collagen) for 
1.5 hours under shaking at room temperature [248, 298]. Prior to use, scaffolds were washed 
with and stored at 4˚C in sterile PBS. 
6.3.5 Monocyte culture and differentiation 
A human monocytic cell line (THP1 cells; ATCC, Manassas, VA), derived from an infant with 
leukemia, was cultured per the supplier’s instructions. Briefly, THP1s were cultured in 
suspension in standard tissue culture flasks in RPMI-1640 media, 10% heat-inactivated fetal 
bovine serum (FBS), and 1% penicillin–streptomycin (P/S). Cultures were started at a 
concentration of approximately 3x105 cells and subcultured when the concentration reached 
approximately 8x105 cells. THP1 cells were differentiated into M0 macrophages in ultra-low 
attachment flasks by exposure to media supplemented with 320 nM phorbol 12-myristate-13-
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acetate (PMA) for 3 days. Following washes with fresh media and lifting via cell scraping, these 
cells could then be used for scaffold seeding or polarization in 2D, as described below. 
6.3.6 Macrophage seeding and culture conditions 
Hydrated, crosslinked CG scaffolds were soaked in culture media overnight at 37°C before being 
tapped dry on a Kimwipe and placed in ultra-low attachment 24-well plates (Fisher, Waltham, 
MA). M0 macrophages were suspended in culture media at a concentration of approximately 
5.5x105 cells per 20 µL in preparation for static seeding [61]. Ten microliters of the cell 
suspension were added to one side of the scaffolds. Then the scaffolds were incubated for 15 
minutes at 37˚C, flipped over and another 10 µL of cell suspension was added. To allow for 
initial cell attachment, scaffolds were placed in the incubator for 2 hours before additional 
growth media was added. Scaffolds were incubated at 37˚C and 5% CO2. Scaffolds from each 
composition (n=6) and M0 in 2D culture (n=3) were collected at days 1, 4, 7 for RNA isolation. 
Media was changed on days 3 and 6. 
6.3.7 Macrophage polarization in two dimensions 
Two dimensional controls of polarized macrophages were implemented as follows. Equal to the 
number of cells seeded per scaffold, 5.5x105 cells were plated in each well of an ultra-low 
attachment 6 well plate. Polarization to a M1 phenotype (n=3) was completed using 100 ng/mL 
interferon-gamma (IFN-γ, ProSpec) and 100 ng/mL LPS (Sigma-Aldrich). For a M2a phenotype 
(n=3), 40 ng/mL of interleukin 4 (IL-4, ProSpec) and 20 ng/mL interleukin 13 (IL-13) were 
added to each well. Interleukin 10 (IL-10, ProSpec) was added at 40 ng/mL to induce a M2c 
phenotype (n=3). A M0 control was used as well (n=3). Each group was allowed to polarize for 2 
days before the cells were collected for RNA isolation. 
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6.3.8 Surgical implantation in porcine mandibular defect 
C:CS and C:AM scaffolds were implanted in male Yorkshire pigs (n=6) approximately 6 months 
of age and weighing between 197 and 247 lbs. Each animal was subjected to three 8mm diameter 
bilateral surgical ramus defects on each side of the mandible (Fig. 6.1). The treatment group was 
randomized for each pig but, cautious of global effects on the inflammatory response, each pig 
only received one type of scaffold for all six of its mandibular defects. 
The described surgical procedures and associated protocols and facilities were approved by the 
University of Illinois at Urbana-Champaign Institutional Animal Care and Use committee. All 
pigs received a sedative cocktail (TARK) consisting of Telazol (tiletamine and zolazepam; 
Pfizer, New York, NY), Atropine (Neogen Corporation, Lexington, KY), Rompun (xylaazine; 
Lloyd Laboratories, Shenandoah, IA) and Ketamine (Ketaset®, Fort Dodge Animal Health, Fort 
Dodge, IA) intramuscularly prior to surgery and intravenously via the ear vein canula, as 
necessary. During surgery, an endotracheal administration of 3-5% isoflurane was administered 
in oxygen as anesthesia.  
Surgery proceeded using a previously described protocol [327], Briefly, a single submandibular 
and retromandibular incision tracing the exterior contour of the mandible was made. The 
underlying fat and muscle were incised and elevated. The periosteum was incised and prised to 
expose the posterior region of the underlying hemimandible. A right-angle surgical drill with an 
8 mm (outer diameter) trephine (Stryker, Portage, MI) was used to create three bicortical (full 
thickness), 8 mm diameter cylindrical defects on the exposed region of the hemimandible 
(ramus) (Fig. 6.2 A, B). The excised bone was cut into three pieces and immersed in RNAlater 
solution for future RNA isolation. Irrigation with 0.9% physiological saline was used during 
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drilling to prevent heat damage to the surrounding tissue. Each scaffold was fit into the 8 mm 
defect, rehydrated using 0.9% physiological saline, and anchored at one point to the surrounding 
mandible using Vetbond (3-M, Minneapolis, MN) (Fig. 6.2 C, D).  
The wound site was closed by suturing, with 3-0 Vicryl (Ethicon, Inc, San Angelo, TX), the 
previously described incisions in the periosteum, masseter muscle, superficial fat, and skin. A 
three layer continuous stitch was used; Vetbond was applied to the skin layer incision. Both 
during and after surgery, vital signs were taken every 15 min until the pig became sternally 
recumbent. Physical and social behavior was evaluated twice daily for up to 2 weeks post-
surgery.  
6.3.9 Explant collection and processing 
One pig from each treatment group was sedated and euthanized at days 3, 7 and 14 post-surgery. 
The mandible was explanted and, from each pig, three random samples were taken for RNA 
isolation and the three remaining samples were collected for histological analysis. For RNA 
isolation, scaffolds were isolated from the bone and stored in RNAlater solution at 4°C until 
RNA isolation and PCR could be performed. For histological analysis, scaffolds and the 
surrounding bone were isolated using a bone saw. The samples were immediately fixed in 
formalin overnight, washed with PBS, decalcified using Calci-clear Rapid (National Diagnostics) 
overnight, embedded in OCT, and stored at -80°C until use. 
6.3.10 Analysis of gene expression profiles for scaffolds cultured in vitro 
RNA from cells in polarized 2D culture conditions was isolated at day 2 while scaffolds from 
each composition (n=6) were collected at days 1, 4, 7 (Fig. 6.3). The plates/scaffolds were rinsed 
in PBS and then scaffolds were cut in half with a razor blade while cells were scraped off the 
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plates. The resultant scaffolds/cells were immersed in the lysis buffer of the RNeasy Plant Mini 
kit (Qiagen, Valencia, CA) for 5 minutes on ice [87]. Following the kit’s instructions, RNA was 
isolated and total RNA was quantified using a NanoDrop Lite. RNA reverse transcription was 
carried out using the QuantiTect Reverse Transcription kit (Qiagen, Valencia, CA) in a Bio-Rad 
S1000 thermal cycler. Real-time PCR reactions were performed in an Applied Biosystems 
7900HT Fast Real-Time PCR System (Carlsbad, CA). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as a housekeeping gene for the genes listed in Table 6.1. 
Sequence Detection Systems software v2.4 (Applied Biosystems, Carlsbad, CA) was used to 
complete analysis. The expression levels from the 2D polarization experiment (normalized to M0 
cells at day 0) were used to show the strength of each phenotypic marker (Fig. 6.4). 
6.3.11 Analysis of gene expression profiles for scaffolds implanted in vivo 
RNA was isolated from scaffold explants by first removing the RNAlater solution following 
centrifugation and then proceeding in the same manner described above. RNA was isolated from 
day 0 bone explants using a bead beater (Mini-BeadBeater-16, BioSpec Products) during the 
lysis step prior to continuing with the RNeasy Plant Mini kit’s instructions. Reverse transcription 
and PCR analysis was carried out as described above. Results are presented as fold change 
relative to expression in all bone explants isolated on the day of surgery. The genes analyzed are 
listed in Table 6.2. 
6.3.12 Clustering analysis in R 
R software was used to conduct further analysis on the in vitro macrophage gene expression. 
Principle component analysis was completed in addition to heat map generation, which displays 
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the expression of genes across all samples as a gradient based on the standard deviation from the 
mean expression across all samples. 
6.3.13 Statistical analysis 
Two-way analysis of variance (ANOVA) followed by Tukey-HSD post-hoc test was performed 
on all data sets. A p-value < 0.05 was used for significance. All analyses were based on a 
minimum of n=3 scaffolds, higher n values were used as noted. In the figures, error is reported as 
the standard error of the mean. 
6.4 Results 
6.4.1 Expression of pro-inflammatory genes in macrophage in vitro culture 
Following 1, 4, and 7 days of culture, the expression of pro-inflammatory genes: interleukin 1 
beta (IL-1β), tumor necrosis factor alpha (TNFα), and vascular endothelial growth factor 
(VEGF) was evaluated via PCR from macrophages (initially seeded as M0 phenotype) cultured 
in C:CS and C:AM scaffolds and 2D M0 controls (Fig. 6.5). Expression was normalized to gene 
levels of 2D M0 macrophages at day 0. All three genes showed expression levels less than one 
(1), indicating low expression of pro-inflammatory genes as compared to this day 0 control. 
Expression of genes encoding for the pro-inflammatory cytokine IL-1β (Fig. 6.5A) were highest 
at day 1 in all groups (p < 0.05) and, at the day 1 time point, all groups were statistically different 
from each other with AM scaffolds having the highest IL-1β expression. Expression of TNFα 
was also higher at day 1 in all groups over the timepoints at days 4, 7 (p < 0.05) (Fig. 6.5B). 
Both scaffold groups showed higher expression of VEGF compared to the 2D control at day 1 
while expression only in AM was higher at day 4, CS at day 7 (p < 0.05) (Fig. 6.5C). 
6.4.2 Expression of M2a and M2c macrophage markers in 3D in vitro culture 
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Expression of genes associated with wound-healing (M2a; Fig. 6.6) and regulatory (M2c; Fig. 
6.7) macrophages were evaluated over the 7 day experiment in M0-seeded 2D and 3D culture. 
Of particular interest are the statistically significant (p < 0.05) increases in expression level of 
CCL22 and PDGF in the macrophage-seeded scaffold groups overtime (Fig. 6.6A, D). By day 7, 
CS scaffolds are supporting higher CCL22 expression compared to all groups at day 7 and to the 
CS groups at days 1 and 4. The AM group is showing significantly higher CCL22 expression at 
day 7 compared to day 1 (Fig. 6.6A). Additionally, the PDGF data (Fig. 6.6D) show significant 
increases in gene expression in cells in AM scaffolds at day 7 compared to all other time points 
as well as in CS scaffolds between day 1 and 7. This scaffold data is, surprisingly, significantly 
lower than the PDGF expression in the 2D control at day 7 (Fig. 6.6D). When considering 
expression of genes associated with the macrophage M2c phenotype (Fig. 6.7), the scaffolds 
support the expression of MMP-7 in AM (day 1, 4) and CS (day 4) scaffolds as compared to the 
M0 control (p < 0.05) (Fig. 6.7B). These trends dissipate by day 7. MMP-8 expression is also 
significantly increased in both scaffolds groups at day 1 but not so at the later time points (Fig. 
6.7C).  
6.4.3 Results of gene clustering analysis 
The M1/M2 macrophage ratio for each scaffold group was calculated but summing the GAPDH 
normalized genes associated with M1 phenotypes and dividing by the sum of the same values for 
M2 associated genes. There was no statistically significant difference between the macrophage 
ratio in CS vs AM scaffolds. However, both groups supported a M2 phenotype with all ratios 
being below one (1) (Fig. 6.8A). Principle components analysis (PCA) (Fig. 6.8B) shows that the 
scaffold groups cluster together at days 1 and 4 but do not strongly associate with the 2D 
polarized controls (M1, M2a, M2c). By day 7, the clusters for CS and AM scaffolds are further 
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apart. Observations from the heat map generated (Fig. 6.8C) include the clustering of M1 
macrophage-associated genes (IL-1β, TNFα, VEGF) towards the top of the map, where higher 
expression is seen in the scaffolds at the earlier time points, and clustering of M2-associated 
genes (MRC1, CD163, PDGF, CCL22) at the bottom of the map, where higher expression is 
dominated by the later time points. 
6.4.4 Gene expression of pro- and anti-inflammatory genes following implantation in vivo 
Scaffolds implanted into a porcine mandibular defect were removed 3, 7, or 14 days following 
surgery and PCR was used to characterize gene expression levels relative to the expression in the 
bone explanted to create the wound at day 0 (Fig. 6.9). The expression of the gene for IL-1β 
(pro-inflammatory cytokine) was significantly (p < 0.05) increased in AM scaffolds at day 3, 
compared to the CS scaffolds and control (Fig. 6.9A). IL-1β expression in AM scaffolds 
significantly drops over time (p < 0.05). Conversely, the expression of pro-inflammatory TNFα 
is increased in CS scaffolds at day 3, although this trend is not significant (Fig. 6.9B) and the 
expression level is well below 1 (bone control at day 0). When considering the expression of M2 
markers, the expression of arginase-1 (Arg-1) is significantly higher (p < 0.05) in bone scaffold 
groups at day 3, compared to the bone control (Fig. 6.9C). In the AM scaffolds, this expression 
significantly drops overtime. While the expression of IL-10 is higher in AM scaffolds compared 
to CS scaffolds at day 3 (Fig. 6.9D), this observation is not significant and there are no 
statistically significant differences in this gene’s expression across groups or time. Finally, when 
considering the M1/M2 ratio (Fig. 6.10A) of all genes analyzed (Table 6.2), all the ratios are 
under one (indicating a dominant M2 phenotype) but there is no significant difference between 
the scaffold groups. 
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6.5 Discussion 
In the study of biomaterials for tissue regeneration, it is important to consider the role the 
implanted material will play as part of native wound healing. Will it withstand the cascade of 
cellular activity? Will it contribute to the already present inflammatory response? Will it assist in 
the transition from inflammation to proliferation? It is in this last question that the role of 
macrophages, myeloid derivatives that span a spectrum of phenotypes, becomes increasingly 
important. While inflammation is essential for cellular recruitment, defense against pathogens, 
and removal of debris, prolonged inflammation is detrimental to long term healing outcomes 
[323]. Macrophages are a key player in the transition across each phase of wound healing 
through population shifts from classically activated (M1, pro-inflammatory) to wound-healing 
(M2a) to regulatory (M2c, anti-inflammatory) phenotypes. 
Macrophages exist locally in tissues and have the ability to self-maintain throughout adulthood. 
However, during inflammation, macrophages are derived and replenished from blood circulating 
monocytes [328]. In vitro this differentiation can be stimulated by 12-myristate-13-acetate 
(PMA) which results in inactive macrophages (M0). From this inactive state, macrophages can 
take on the three phenotypes outlined above. M1 macrophages are activated by IFNγ and TNFα 
(produced in the body by natural killer cells and T helper 1 cells), act in defense of intracellular 
pathogens, and produce pro-inflammatory cytokines such as IL-1, IL-6, and IL-23 [137]. The 
secretion of IL-4 by basophils and mast cells is responsible for the macrophage polarization into 
a wound healing phenotype (M2a) and this phenotype is maintained by the secretion of IL-4 and 
IL-13 by T helper 2 cells [137]. M2a macrophages secrete components of the extracellular 
matrix [329] and are less efficient in presenting antigens to T cells, producing pro-inflammatory 
cytokines, and destroying intracellular pathogens [330]. Regulatory (M2c) macrophages usually 
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arise during the later stages of wound healing where their anti-inflammatory role is largely based 
on their secretion of IL-10, a cytokine that can inhibit the production and activity of pro-
inflammatory cytokines [331]. 
In the studies described here, we explore how biomaterial composition can alter macrophage 
response in vitro and in vivo. By using collagen-based scaffolds already studied for tissue 
regeneration applications, we explored the incorporation of the anti-inflammatory matrix of the 
amniotic membrane (AM) and its effects on macrophage phenotype. We hypothesized that the 
use of the AM would result in a diminished M1 (pro-inflammatory) macrophage population and 
an enhanced M2a/M2c population both in vitro and in vivo.  
M0 macrophages were cultured in 3D collagen:chondroitin sulfate (CS) and collagen:amniotic 
membrane (AM) scaffolds as well as in 2D, as a control. All genes were normalized to 
expression in the 2D M0 control at day 0 of the experiment. In the genes associated with a M1 
macrophage phenotype (IL-1β, TNFα, VEGF), expression was lower than the day 0 control (< 1) 
(Fig. 6.5). Expression in all groups was at its highest at day 1 and was significantly lower at days 
4 and 7 in IL-1β and TNFα (Fig. 6.5A, B). The overall gene expression is low and the scaffolds 
are tracking with the M0 control over time; through this, the scaffolds show no support for the 
pro-inflammatory M1 phenotype. When considering the genes associated with the wound 
healing, M2a macrophages (Fig. 6.6), an increase in expression of CCL22 (Fig. 6.6A) and PDGF 
(Fig. 6.6D) in CS and AM scaffolds occurs overtime (by day 7) although this trend is not 
supported in other M2a genes (MRC1 and TIMP3). Finally, higher CD163 expression (M2c 
macrophage marker) is seen in AM scaffolds by day 7 and while both CS and AM scaffolds 
support MMP-7 and MMP-8 expression at earlier time points, this trend is diminished by day 7 
(Fig. 6.7). Higher level analysis confirms these findings (Fig. 6.8). Low M1/M2 ratios (Fig. 
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6.8A) show a predominant M2 macrophage phenotype over time and heat map visualization 
(Fig. 6.8C) appears to show a switch from high expression of M1 genes at early time points to 
higher expression of M2 associated genes at day 7. Together these data suggest that both CS and 
AM scaffolds do more to support an M2a/M2c phenotype than an M1 phenotype. However, 
more work is needed to determine how and whether there are benefits to including AM in tissue 
regeneration scaffolds. 
There are several options to expand this work in vitro. While the amniotic membrane has been 
well characterized by others [219], it would be interesting to evaluate the growth factor and 
cytokine release from the matrix post-processing and following incorporation into the CG 
scaffold. It is likely that the biomolecules in the material are responsible for the effects we have 
seen in Chapters 4 and 5 of this thesis. If the cytokines necessary for macrophage polarization 
(IFNγ, TNFα, IL-4, IL-13, and IL-10) are present in the amnion at high levels, future 
experiments should be run in serum free media to try to elucidate this effect. Further, this in vitro 
study was completed by seeding M0 (inactive) macrophages into each scaffold variant. It would 
be interesting to stimulate an M1 phenotype prior to scaffold seeding or culture cell-seeded 
scaffolds in a pro-inflammatory environment and then monitor the kinetics of macrophage 
phenotype. 
The results of the in vivo subcritical porcine mandibular model remain inconclusive. AM 
scaffolds show early upregulation of both M1 and M2 markers in some cases (IL-1β and Arg-1, 
respectively) (Fig. 6.9A, C) but no or little change in similar markers over all time points (TNFα, 
IL-10) (Fig. 6.7B, D). Preliminary H&E staining shows the scaffold integrates into the defect at 
the day 7 time point (Fig. 6.10B); ongoing work is evaluating, histologically, the presence of M1 
and M2 macrophage populations over time. In vivo experiments should be repeated with a higher 
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sample number to increase the probability of finding significant differences between groups. 
Additionally, optimizing the procedure for collecting RNA from the bone explants will improve 
the RNA normalization procedure. If RNA could be isolated from each sample, the scaffold 
explants could be matched to their corresponding bone core for analysis instead of being 
normalized to an average expression across all animals (eliminating any baseline differences 
between pigs).  
6.6 Conclusions 
The amniotic membrane has been used as an anti-inflammatory matrix in 2D and shown, in 3D 
collagen-based scaffolds, to have inflammation-tempering effects on fibroblast (Chapter 4) and 
mesenchymal cell populations (Chapter 5). Due to the importance of the macrophage in the 
wound healing cascade, this work sought to evaluate macrophage response to these 3D materials 
for tissue regeneration. Both scaffolds (with and without amniotic membrane) promoted an M2 
(pro-healing, anti-inflammatory) macrophage phenotype in vitro. In order to fully realize the 
potential of three dimensional materials that incorporate an anti-inflammatory allograft (like the 
amniotic membrane) in the field of tissue regeneration, more work needs to be done to study this 
effect in vitro and in vivo.  
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6.7 Tables 
Table 6.1. Gene primers used for in vitro human macrophage experiments. 
Description Gene 
Forward Sequence 
Citation 
Reverse Sequence 
M1 Markers 
TNFα 
CCTCTCTCTAATCAGCCCTCTG 
 [322] 
GAGGACCTGGGAGTAGATGAG 
IL-1β 
ATGATGGCTTATTACAGTGGCAA 
 [138] 
GTCGGAGATTCGTAGCTGGA 
VEGF 
AGGGCAGAATCATCACGAAGT 
 [138] 
AGGGTCTCGATTGGATGGCA 
M2a Markers 
CCL22 
GCGTGGTGTTGCTAACCTTCA 
 [326] 
AAGGCCACGGTCATCAGAGT 
MRC1 
AAGGCGGTGACCTCACAAG 
 [138] 
AAAGTCCAATTCCTCGATGGTG 
TIMP3 
ACCGAGGCTTCACCAAGATG 
 [138] 
CATCATAGACGCGACCTGTCA 
PDGF 
CTCGATCCGCTCCTTTGATGA 
 [138] 
CGTTGGTGCGGTCTATGAG 
M2c Markers 
CD163 
TTTGTCAACTTGAGTCCCTTCAC 
 [326] 
TCCCGCTACACTTGTTTTCAC 
MMP7 
CCCCCTGCATTTCAGGAA 
 [332] 
TCCTGGCCCATCAAATGG 
MMP8 
CCAAGTGGGAACGCACTAACTTGA 
 [333] 
TGGAGAATTGTCACCGTGATCTCTT 
Reference GAPDH 
AAGGTGAAGGTCGGAGTCAAC 
[138]  
GGGGTCATTGATGGCAACAATA 
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Table 6.2. Gene primers used for in vivo porcine mandibular defect RT-PCR. 
Description Gene 
Forward Sequence 
Citation 
Reverse Sequence 
Pro-inflammatory 
IL-1β 
CCAATTCAGGGACCCTACC 
[334] 
CATGGCTGCTTCAGAAACCT 
IL-8 
TTCTTCTTTATCCCCAAACTGG 
[334] 
CCACATGTCCTCAAGGTAGGA 
TNFα 
TTGTCGCTACATCGCTGAAC 
[334] 
CCAGTAGGGCGGTTACAGAC 
TGF-β1 
CGGCCCTTCCTGCTCCTCAT 
[335] 
TTCCAGCCCAGGTCCTTCC 
Macrophage 
marker 
CD163 
CTTGGGGCAGCGTTGGCAGGAATAG 
[336] 
ATGCAGGGCTGATGTCCCCTCTGTC 
Arg-1 
CCAGTCCATGGAGGTCTGTCTTAT 
[335] 
TGCTACTGCCGTGTTCACCG 
CCR-2 
GCGGGGTCACCTGGGTGGTA 
[335] 
AGTGGCAGGACCAGCCCCAA 
Anti-inflammatory IL-10 
TGAAGAGTGCCTTTAGCAAGCTC 
[336] 
CTCATCTTCATCGTCATGTAGGC 
Reference GAPDH 
CGTCCCTGAGACACGATGGT 
[337] 
CCCGATGCGGCCAAAT 
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6.8 Figures 
 
Figure 6.1. Schematic of subcritical porcine mandibular ramus defect. Three 8 mm holes were 
drilled in each side of the pig jaw. 
 
 
Figure 6.2. Photographs from pig surgeries showing holes pre-implant (A, B) and post-implant 
with collagen:chondroitin sulfate (C) and collagen:amniotic membrane (D) scaffolds. 
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Figure 6.3. Schematic of in vitro macrophage experiment. 
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Figure 6.4. Results of 2D macrophage polarization experiments. 
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Figure 6.5. Expression of pro-inflammatory, M1-related genes in M0 macrophages seeded in 
collagen:chondroitin sulfate (CS) and collagen:amniotic membrane (AM) scaffolds and 2D 
controls (M0) over 7 days of culture. (A) interleukin 1 beta (IL-1β); (B) tumor necrosis factor 
alpha (TNFα); (C) vascular endothelial growth factor (VEGF). Expression is normalized to M0 
macrophages from day 0 of the experiment. * significant difference between expression of 
groups indicated, ^ significant difference between group indicated and corresponding group at 
other time points (p < 0.05). 
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Figure 6.6. Expression of M2a macrophage markers: (A) C-C motif chemokine 22 (CCL22), (B) 
mannose receptor, C type 1 (MRC1), (C) tissue inhibitor of metalloproteinase 3 (TIMP3), (D) 
platelet-derived growth factor (PDGF) in M0 macrophages seeded in collagen:chondroitin 
sulfate (CS) and collagen:amniotic membrane (AM) scaffolds and 2D controls (M0) over 7 days 
of culture. Expression is normalized to M0 macrophages from day 0 of the experiment. * 
significant difference between expression of groups indicated, ^ significant difference between 
group indicated and corresponding group at other time points (p < 0.05). 
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Figure 6.7. Genes associated with M2c macrophage phenotype were monitored for expression 
over 7 days of culture in 2D controls (M0) and in M0 macrophage-seeded scaffolds - 
collagen:chondroitin sulfate (CS) and collagen:amniotic membrane (AM). (A) Cluster of 
differentiation 163 (CD163), (B) Matrix metalloproteinase 7 (MMP-7), (C) Matrix 
metalloproteinase 8 (MMP-8). Expression is normalized to M0 macrophages from day 0 of the 
experiment. * significant difference between expression of groups indicated, ^ significant 
difference between group indicated and corresponding group at other time points (p < 0.05). 
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Figure 6.8. Alternative displays of macrophage gene expression data. (A) Collection of M1-M2 
ratio across all genes probed in the macrophage seeded scaffolds (collagen:chondroitin sulfate 
(CS) and collagen:amniotic membrane (AM)). (B) Principle components plot of scaffolds 
overtime with the inclusion of macrophage polarization controls carried out in 2D (day 2). (C) 
Heat map displaying array of expression levels for each gene (rows) across macrophages 
polarized in 2D and each of the scaffold groups over time (columns). 
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Figure 6.9. Expression of markers for M1 (A, B) and M2 (C, D) macrophages in scaffolds 
(collagen:chondroitin sulfate (CS) and collagen:amniotic membrane (AM)) implanted in 
subcritical porcine mandibular defects. Expression is normalized to levels from day 0 bone 
explants. * significant difference (p < 0.05) between expression of groups indicated. ^ significant 
difference between group indicated and bone control (p < 0.05). 
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Figure 6.10. (A) M1/M2 macrophage healing score of all porcine genes analyzed. (B) 
Preliminary H&E staining of explant from AM experimental group, day 7 time point.  
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CHAPTER 7: SUMMARY AND FUTURE DIRECTIONS 
7.1 Summary 
Wound healing across many tissue types results in subpar outcomes and could benefit from 
material-based interventions devised to promote restoration of native tissue through the process 
of regeneration. Through this work, we have sought to develop strategies for altering the 
composition of collagen-based biomaterials in order to enhance their inherent tissue regeneration 
capacity. Mimicry of the extracellular matrix is a common strategy for biomaterials for tissue 
engineering applications so, in addition to using porous, collagen materials, each of our 
approaches was based on naturally occurring phenomena. This work demonstrates the effective 
modification of scaffold composition in order to address issues of transient (not covalent) growth 
factor sequestration, gene delivery capacity, or immunomodulation. As a result, this thesis 
demonstrates that changing the material composition alone can have marked control over soluble 
factor and cellular responses. 
Chapter 2 of this thesis demonstrated the ability to mimic the in vivo sequestration of growth 
factors by the selective inclusion of glycosaminoglycans (GAGs) within the collagen-GAG 
scaffold. The degree of GAG sulfation is one of the main factors that dictates electrostatic 
binding of positively-charged growth factors in the body. In this study, GAGs with a range of 
sulfation degrees were incorporated into the collagen suspension used to form open foam 
collagen-glycosaminoglyacn (CG) scaffolds. Increasing scaffold GAG sulfation led to increased 
tenocyte metabolic activity in low serum and IGF-1 supplemented media conditions. This 
followed the significantly increased pulldown of IGF-1 in scaffolds with sulfated GAGs 
compared to scaffolds with non-sulfated GAGs. These data demonstrate that scaffold chemistry 
is important for growth factor presentation, providing inspiration for a number of ongoing 
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research efforts looking to more precisely tailor the local biomolecular environment for cells 
within the scaffold.  
Continuing with the use of GAG-based electrostatic interactions, the work in Chapter 3 
investigated how the differences in GAG charge can also be leveraged to influence the delivery 
of non-viral gene vectors called polyplexes to cells within the scaffold. Polyplexes are formed by 
combining cationic polymer with the gene of interest; these spontaneously condense into a 
nanoparticle as the polymer interacts with the negative DNA backbone. Interested to see how the 
electrostatic scaffold environment would alter the 3D delivery of a reporter gene, polyplexes 
(with varying polymer acetylation and polymer:DNA weight-to-weight ratios) were introduced 
into the scaffolds and cultured with tenocytes. Increasing the weight-to-weight ratio and using a 
highly sulfated glycosaminoglycan in the CG scaffold resulted in increased the reporter gene 
expression in tenocytes treated with acetylated PEI polyplexes. Findings from this work suggest 
that the electrostatic environment of a gene activated scaffold may prove to be an important 
design parameter to consider in order to enhance the efficiency of cationic polymer based gene 
therapy for tissue engineering applications. 
Shifting from a focus on materials for addressing cell behavior critical for later stages of wound 
healing such as proliferation and cell-mediated matrix remodeling, Chapter 4 describes a new 
class of collagen biomaterial that uses bioinspired changes in composition to alter the 
inflammatory phase of wound repair. Influenced by the scarless wound healing seen in fetal 
tissues, this study incorporated materials from the fetal wound environment (hyaluronic acid and 
amniotic membrane matrix) into the established collagen-based scaffolds. These fetal wound 
inspired components, particularly the collagen-amniotic membrane scaffold composite, induced 
increased metabolic activity in equine tenocytes even after a pro-inflammatory challenge with 
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interleukin 1 beta. These scaffolds also supported downregulated pro-inflammatory gene 
expression profiles in these cells in response to inflammatory challenge. 
Following the promise seen in the ability of collagen-amniotic membrane (AM) scaffolds to 
temper the inflammatory response in a fibroblast cell population, Chapter 5 outlines work that 
examined the mode of AM incorporation into the scaffold and resultant cellular response in 
mesenchymal stem cells that are a key element of immunomodulatory responses seen in vivo. 
AM matrix was either directly incorporated into the collagen scaffold during fabrication to form 
a C:AM composite scaffold, or the intact AM membrane was introduced as a membrane-based 
wrap around a conventional CG scaffold to create a core-shell composite biomaterial. The 
fabrication of these scaffolds allowed for microstructural anisotropy to mimic the aligned ECM 
of the tendon. After culturing the MSC-seeded scaffolds in pro-inflammatory conditions, the 
genes associated with MSC immunomodulation remained unchanged across all scaffold groups 
(including the control) although pro-inflammatory genes were downregulated in the AM 
scaffolds. Additional work needs to be done to further understand the role of AM scaffolds in 
influencing progenitor cell behavior in vitro, but these findings suggest the effects of AM within 
the collagen biomaterial may be realized via modulation of the biochemical (not structural) 
microenvironment of the scaffold. 
Macrophages are critical components in the transition between each phase of the wound healing 
cascade (inflammation, proliferation, remodeling) due to their phenotypic plasticity. The work of 
Chapter 6 probes the effect of anti-inflammatory matrix (AM) containing scaffolds in vitro and 
in vivo by monitoring macrophage phenotype. The results indicate that while the scaffolds do not 
support a M1 (pro-inflammatory) phenotype in vitro, there is some upregulation of M1 
associated genes at early time points in vivo. The presence of a M2 (pro-healing, anti-
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inflammatory) associated macrophage phenotype is much more dominant in in vitro culture. 
Ongoing work will address questions of macrophage response under inflammatory conditions 
and more extensive characterization of macrophage phenotype in vivo. 
7.2 Future Directions 
By limiting the need for covalent chemistries or delivery vehicles and reducing the required 
dosage of growth factors necessary in cell culture media or for diffusive pre-loading, the use of 
charged-based growth factor sequestration has the potential to enhance the in vitro study and in 
vivo application of biomaterials. This work demonstrated the effects of GAG sequestration with 
just one growth factor, in just one type of scaffold. Future work could apply this technique to 
other scaffolds for other tissues, such as a mineralized collagen scaffold for bone, and evaluate 
its effectiveness in sequestering different growth factors, singly or in combination. 
The potential for future work in the area of 3D, anti-inflammatory biomaterials that use the 
amniotic membrane is vast. Work going forward would benefit from a detailed characterization 
of the amniotic membrane outside of the CG scaffold platform. This could include verification of 
processing (decellularization, in particular), a full analysis of its composition (matrix and growth 
factors/cytokines), and evaluation of the cellular response to the amnion as a 2D substrate (in the 
form of a control in in vitro experiments). As mentioned previously, further work in monitoring 
macrophage response in the CG scaffolds should include some sort of inflammatory challenge 
(by using M1 macrophages or applying inflammatory cytokines to the media) to study the 
influence of the scaffolds on the kinetics of the phenotypic switch to M2 macrophages. 
Additionally, due to the complex nature of the native immune response and importance of 
cellular signaling as part of wound resolution, characterizing the effect of the CG scaffold in a 
co-culture environment (MSCs and macrophages, macrophages and fibroblasts) would advance 
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the understanding of the role it could play in tissue regeneration. Of course, as this work is 
intended for clinical applications, further study in in vivo animal models should be carried out. 
7.3 Final Thoughts 
The compositional changes implemented here offer a path forward in the development of 
bioactive, three-dimensional, collagen-based scaffolds for tissue regeneration. By addressing 
concerns at multiple levels of the wound healing cascade, this thesis provides a unique look at 
material design for reducing inflammation or enhancing growth factor activity for a range of 
functions. The idea of instructive signals changing the kinetics of the wound healing cascade 
offers an exciting glimpse into the future of tissue engineering where this emerging subfield 
presents significant potential for clinical success.  
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APPENDIX A: SCAFFOLD FABRICATION PROTOCOLS 
 
A.1 Protocol for CG suspension preparation 
Reference: [51, 69] 
Reagents 
• Purified fibrillar collagen (Collagen Matrix) or collagen from bovine tendon (Sigma-Aldrich 
C9879); stored at 4ºC 
• Chondroitin sulfate sodium salt from shark cartilage (Sigma-Aldrich C4384); stored at 4ºC 
• Heparin sodium salt from porcine intestinal mucosa (Sigma-Aldrich H4784 or H3149); stored 
at 4ºC 
• Hyaluronic acid from Streptococcus equi (Sigma-Aldrich 53747); stored at -20ºC 
• Glacial acetic acid (Sigma-Aldrich 71251) 
• Ethylene glycol (VWR BDH1125-4LP) 
• Deionized water 
 
Equipment and Supplies 
• Recirculating chiller (Fisher Isotemp Model 900) 
• Rotor-stator (IKA 0593400) with large head attachment 
• Disperser (IKA 3565001) 
• Jacketed beaker (Ace Glass 5340-110) 
• Freeze-dryer (VirTis Genesis) 
• Dual range balance (Mettler Toledo XS105)  
• Beakers 
• Parafilm 
• Spatula 
 
Procedure 
*This procedure describes how to make 300 mL of 0.5% CG suspension at an 11:1 
collagen:glycosaminoglycan ratio. Scale collagen and GAG content appropriately to create 
different volumes and ratios of suspension. 
1. Fill recirculating chiller with a 50/50 mix of ethylene glycol and deionized water, making sure 
that the cooling coils are completely immersed in the liquid. Set the recirculating chiller to 4ºC. 
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2. Attach recirculating chiller to jacketed beaker so that the coolant enters at the jacketed 
beaker’s base and exits at the beaker’s top. Allow for the temperature to equilibrate to 4ºC, about 
30 minutes. Maintaining this temperature is important, as it will prevent the collagen from 
denaturing during the blending process. 
3. Prepare a 0.05 M solution of acetic acid by adding 0.87 mL of glacial acetic acid to 300 mL of 
deionized water. 
4. Weigh 1.5 g of collagen and add to the jacketed beaker. 
5. Pour 250 mL of the 0.05 M acetic acid into the jacketed beaker. 
6. Assemble the rotor-stator and attach it to the disperser. Lower the rotor-stator into the 
suspension. The rotor-stator should be vertical and off-centered in the beaker for optimal 
blending. 
7. Blend the suspension at 10,000 rpm at 4ºC until smooth, approximately 5 minutes. The height 
of the rotor-stator may need to be adjusted during the blending process: If the rotor-stator is 
positioned too high, the holes on its side will be visible; if it is too low, the suspension will 
bubble excessively. Periodically check to see if the rotor-stator is clogged with collagen; remove 
clogs with a spatula as needed. 
8. Add 50 mL of 0.05 M acetic acid to a 50 mL centrifuge tube. Weigh out 0.133 g of 
chondroitin sulfate, heparin, or hyaluronic acid (GAG) and add to a 50 mL centrifuge tube. 
Vortex until the GAG is fully dissolved. Let the GAG solution rest in the refrigerator (4ºC) for at 
least 10 minutes. 
9. Add the GAG solution drop-wise to the collagen suspension while it is being mixed at 10,000 
rpm at 4ºC. Periodically manually stir in any GAG that remains on the surface of the suspension 
using a spatula. It may be necessary to stop and unclog the rotor-stator with a spatula during this 
process. 
10. Once all of the GAG solution has been added, blend at 10,000 rpm at 4ºC until smooth, 
approximately 10 minutes. Periodically check to ensure the rotor-stator is lowered to the correct 
depth, as the suspension will gradually become less viscous and creep up the sides of the 
jacketed beaker. Periodically check to see if the rotor-stator is clogged; remove clogs with a 
spatula as needed. 
11. Store the suspension overnight at 4ºC. 
12. Degas the suspension to remove any air bubbles prior to use. It is recommended to degas 
approximately 20 mL at a time, until the solution starts to boil. To minimize suspension loss 
during the degassing process, cover the beaker with slit Parafilm. 
13. Store the suspension at 4ºC. Periodically check the CG suspension; if not homogenous, re-
blend at 4ºC. 
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A.2 Amniotic membrane isolation 
Reference: [294, 295] 
Reagents 
• Calcium and Magnesium Free Hank’s Balanced Salt Solution (CMF-HBSS) (Fisher Scientific 
SH3003103) 
• Penicillin, Streptomycin, Amphotericin B (Anti-anti) (ThermoFisher 15140122) 
• Phosphate buffered solution (PBS) (Fisher Scientific BW17516F12) 
• Thermolysin (Sigma-Aldrich T7902) 
• 70% ethanol solution 
• 10% bleach solution 
• Dish soap 
 
Equipment and Supplies 
• Disposable-Blade Dissection Handles (Size 3, 4.87 inches) (Fisher Scientific 08-913-5) 
• Disposable blades (Blade size: 15; Length: 1.375 in. (3.5cm)) (Fisher Scientific 08-916-5D) 
• Scissors (Fisher Scientific 8681) 
• Forceps (Fisher Scientific 08-875) 
• Spatula (Fisher Scientific 14-373) 
• Sterilization pouches (3.5" x 9") (Fisher Scientific 01-812-51) 
• 6 Beakers (VWR 13912-240) 
• Petri dishes (Fisher Scientific 08-757-14) 
• Stainless-Steel Utility Tray (Fisher Scientific 13-361 C) 
• Nalgene Jars (250 mL) (Sigma-Aldrich Z380245-1PAK) 
• Nalgene Jars (1000 mL) (Sigma-Aldrich Z380261-1PAK) 
• Transport container (e.g. small cooler) with biohazard stickers 
• Aluminum foil 
• Autoclave tape 
• Kimwipes 
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Procedure 
 Prior to a collection, prepare the following and store in the Biomedical Research Center 
(BRC) at Carle Foundation Hospital: 
1. Put knife handles, scissors, forceps, and spatulas in individual sterilization pouches. Cover 
glass beakers with foil and secure with autoclave tape. Loosen lids of Nalgene jars (disengage 
threads to prevent melting them closed) and secure lids with autoclave tape. Autoclave all these 
materials in a secondary container on a gravity cycle that reaches a temperature of 121°C for at 
least 30 minutes. 
2. Prepare at least 2 bottles of CMF-HBSS solution with 10% Anti-anti solution. Store in cold 
room at Carle so collection coordinator can use it to keep placenta wet while in storage. 
 Once a placenta is being stored in the Carle Biomedical Research Center cold room: 
1. Make a fresh solution of thermolysin (125 μg/mL) in PBS (approximately 100 mL). Sterile 
filter. 
2. Do all isolation procedures in a biosafety cabinet. Spray metal utility tray with 70% ethanol, 
dry with Kimwipe. Move placenta from collection container to tray. 
3. With scissors, remove the umbilical cord from the placenta. Place cord in collection container. 
Wash blood off surface of placenta with HBSS. 
4. Pull amniotic membrane (AM) free from placenta with forceps. Scrape with spatula, if 
necessary. Place AM in beaker with ~250 mL of HBSS.  
5. Wash AM in a total of three (3) rounds of fresh HBSS (using 3 separate beakers works well). 
Depending on the size and state of the matrix, cutting the membrane into smaller pieces and 
manually scraping blood and the spongy layer away may be required for appropriate cleaning. 
6. If the membrane hasn’t been cut yet, cut now into pieces that will each fit into a large petri 
dish. This usually results in ~4 pieces.  
7. Transfer all placenta waste and liquids back into collection container. Place container in 
biohazard waste bin. Add 10% bleach solution to tray and let soak during next steps. 
8. Cover AM with ~25 mL of thermolysin solution. Shake petri dishes occasionally over this 20 
minute decellularization step. 
9. Setup three (3) beakers with ~250 mL of PBS. After decellularization, vigorously rinse AM 
pieces, moving to a fresh beaker of PBS for a total of three (3) washes. 
10. Store AM pieces in PBS in small Nalgene jars. Label with AM collection details and 
biohazard stickers. Place small Nalgene jars into larger Nalgene jars for secondary containment. 
Label as biohazard and as “exempted biological material.” 
11. Wash already bleached metal tray. Bleach all beakers and instruments and then wash with 
soap and water. Bleach hood for 10 minutes with 10% bleach. Wipe then spray with 70% 
ethanol. Transport AM to RAL lab using DRS approved procedures 
(https://www.drs.illinois.edu/Programs/BiologicalMaterialTransport). Store at 4°C.  
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A.3 Amniotic membrane drying protocol 
Reference: [230] 
Reagents 
• Cell Grade Sterile Water 
 
Equipment and Supplies 
• Forceps (Fisher Scientific 08-875) 
• Spatula (Fisher Scientific 14-373) 
• T-75 cell culture flasks (ThermoFisher Scientific 12-565-349) 
• Petri dishes (Fisher Scientific 08-757-14) 
• 5 x 5 inch aluminum pans for freeze drying 
• Parafilm 
 
Procedure 
1. Following AM isolation (described in A.2.) store AM in PBS at 4°C for 24-48 hours. In this 
time the spongy layer will swell. 
2. Remove AM from storage container and place in a large Petri dish. Using a spatula, scrape the 
spongy layer from surface of the membrane.  
3. Place AM with ~35 mL of sterile cell grade water in a T-75 culture flask. Wash under shaking 
for 30 minutes. 
4. Repeat steps 2-3 twice more to thoroughly remove the spongy layer and wash the PBS salts 
from the membrane. 
5. Transfer AM piece(s) to metal pans for freeze drying. Add ~20 mL of sterile cell grade water 
and spread the membrane out into a single layer. Cover pan with slit Parafilm.  
6. Freeze dry the membrane using the “-40°C amnion protocol.” 
7. Store dried amnion in foil pouch in desiccator.  
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A.4 C:AM suspension preparation protocol 
Reference: [230] 
Reagents 
• Purified fibrillar collagen (Collagen Matrix); stored at 4ºC 
• Dried amniotic membrane sheet (prepared as described in A.2. and A.3.) 
• Glacial acetic acid (Sigma-Aldrich 71251) 
• Ethylene glycol (VWR BDH1125-4LP) 
• Deionized water 
 
Equipment and Supplies 
• Recirculating chiller (Fisher Isotemp Model 900) 
• Rotor-stator (IKA 0593400) with large head attachment 
• Small dispersing element (IKA) 
• Disperser (IKA 3565001) 
• Jacketed beaker (Ace Glass 5340-105) 
• 100 mL Nalgene jar 
• 50 mL conical tube 
• Freeze-dryer (VirTis Genesis) 
• Dual range balance (Mettler Toledo XS105)  
• Beakers 
• Parafilm 
• Spatula 
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Procedure 
*This procedure describes how to make 150 mL of 0.5% C:AM suspension at an 5:1 
collagen:amniotic membrane ratio. It accounts for the collagen mass of the AM membrane and 
makes the total dry mass equivalent to CG suspensions outlined in A.1. This has been the most 
successful concentration and ratio throughout this project. Batch sizes of 50 mL have also been 
used by putting a small Nalgene in the jacketed beaker and surrounding it with Kimwipes and 
water. 
1. Fill recirculating chiller with a 50/50 mix of ethylene glycol and deionized water, making sure 
that the cooling coils are completely immersed in the liquid. Set the recirculating chiller to 4ºC. 
2. Attach recirculating chiller to jacketed beaker so that the coolant enters at the jacketed 
beaker’s base and exits at the beaker’s top. Allow for the temperature to equilibrate to 4ºC, about 
30 minutes. Maintaining this temperature is important, as it will prevent the collagen from 
denaturing during the blending process. 
3. Prepare a 0.05 M solution of acetic acid by adding 0.435mL of glacial acetic acid to 150 mL 
of deionized water. 
4. Weigh out 0.136 g of dry amniotic membrane. Using a mortar and pestle, grind into smaller 
pieces. Add up to 5 mL of acetic acid solution while grinding. 
5. Transfer amniotic membrane to 50 mL conical tube. Bring final volume to 25 mL with acetic 
acid solution. Use small dispersing element to homogenize amniotic membrane further. Store 
solution at 4°C until needed. 
6. Weigh 0.68 g of collagen and add to the jacketed beaker. 
7. Pour remaining 0.05 M acetic acid into the jacketed beaker. 
8. Assemble the rotor-stator and attach it to the disperser. Lower the rotor-stator into the 
suspension. The rotor-stator should be vertical and off-centered in the beaker for optimal 
blending. 
9. Blend the suspension at 10,000 rpm at 4ºC until smooth, approximately 5 minutes. The height 
of the rotor-stator may need to be adjusted during the blending process: If the rotor-stator is 
positioned too high, the holes on its side will be visible; if it is too low, the suspension will 
bubble excessively. Periodically check to see if the rotor-stator is clogged with collagen; remove 
clogs with a spatula as needed. 
10. Add the AM solution drop-wise to the collagen suspension while it is being mixed at 10,000 
rpm at 4ºC. Periodically manually stir in any GAG that remains on the surface of the suspension 
using a spatula. It may be necessary to stop and unclog the rotor-stator with a spatula during this 
process. 
11. Once all of the GAG solution has been added, blend at 10,000 rpm at 4ºC until smooth, 
approximately 10 minutes. Periodically check to ensure the rotor-stator is lowered to the correct 
depth, as the suspension will gradually become less viscous and creep up the sides of the 
jacketed beaker. Periodically check to see if the rotor-stator is clogged; remove clogs with a 
spatula as needed. 
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12. Store the suspension overnight at 4ºC. 
13. Degas the suspension to remove any air bubbles prior to use. It is recommended to degas 
approximately 20 mL at a time, until the solution starts to boil. To minimize suspension loss 
during the degassing process, cover the beaker with slit Parafilm. 
14. Store the suspension at 4ºC. Periodically check the CG suspension; if not homogenous, re-
blend at 4ºC. 
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A.5 Aligned CG scaffold fabrication protocol 
Reference: [61, 251]  
Reagents  
• CG suspension; store at 4°C  
• Welch DirecTorr Gold synthetic pump oil (Fisher 01-184-105)  
 
Supplies and equipment  
• Freeze-dryer (VirTis Genesis)  
• PTFE-copper freeze-drying mold  
• Beakers  
• Parafilm  
• Aluminum foil  
 
Procedure  
*This procedure describes the fabrication of aligned scaffolds (with and without amniotic 
membrane shells). Check that oil is clean (not yellow) before and after each freeze-dryer run, 
replacing when necessary. 
1. Degas CG suspension in Parafilm-covered beaker by pulling vacuum inside freeze-dryer to 
remove all air bubbles. Make sure the condenser is at least -50°C or cooler before degassing. 
2. Begin to cool freeze-dryer shelves by running 'Tf = xx C shelf cool' program where xx is the 
desired freezing temperature (-10, -40, or -60°C).  
3. If making scaffold-membrane composites, cut amniotic membranes to size, roll, and place in 
PTFE-copper freeze-drying mold holes.  
4. Pipette ~ 1 mL (8 mm diameter holes) or ~550 μL (6 mm diameter holes) of suspension into 
each hole in PTFE-copper freeze-drying mold. 
5. Cancel shelf cool program and place freeze-dryer mold on the pre-cooled shelf. Shut the 
freeze-dryer door and run program 'Aligned Tf = xx' where xx is the desired freezing temperature 
(-10, -40, or -60°C).   
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A.6 Isotropic CG scaffold fabrication protocol 
Reference: [69]  
Reagents  
• CG suspension; store at 4°C  
• Welch DirecTorr Gold synthetic pump oil (Fisher 01-184-105)  
Supplies and equipment  
• Freeze-dryer (VirTis Genesis)  
• Aluminum, polysulfone tray molds (3x3” or 5x5”)  
• Polysulfone cylindrical molds (10 mm diameter x 10 mm height) 
• Beakers  
• Parafilm  
• Aluminum foil  
Procedure  
*This procedure describes the fabrication of 4 mm tall scaffold sheets and 10 mm diameter 
isotropic scaffolds. Check that oil is clean (clear, not yellowed) before and after each freeze-
dryer run, replacing when necessary. It is easiest to replace the oil just after a run, when the oil is 
still warm.  
1. Degas the CG suspension in a beaker (covered in Parafilm with small slits) by pulling vacuum 
inside freeze-dryer. Degas just to the boiling point to remove all air bubbles. Make sure the 
condenser is at least -50°C or cooler before degassing. 
2. Add 24.2 mL of CG suspension to a 3x3” tray mold or 67.2 mL to a 5x5” mold. Ensure that 
the suspension reaches the corners and push any bubbles or unblended collagen to the edge using 
tweezers. To make cylindrical scaffolds, pipette ~800 μL of CG suspension into each mold. 
3. Place molds in freeze dryer and run program at desired freezing temperature. 
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A.7 DHT crosslinking protocol 
Reference: [51, 248] 
Supplies and equipment 
• Sterile air filter (Millipore SLGP033RS) 
• Vacuum oven (Welch Vacuum, Fisher 13-262-52) 
• Welch DirecTorr Gold synthetic pump oil (Fisher 01-184-105) 
 
Procedure 
*Note: Periodically check vacuum pump oil levels. Change oil at least once every 6-12 months. 
Change sterile air filter on ‘Purge’ line regularly. 
1. Turn on vacuum oven and set the temperature to 105ºC. 
2. Once vacuum oven has reached temperature set point, place scaffolds in opened aluminum 
pouches carefully inside the oven. Close the oven door. 
3. Close the ‘Purge’ valve, located on the lower right face of the vacuum oven. Completely open 
the ‘Vacuum’ valve. 
4. Turn on the vacuum pump and make sure vacuum is pulled to a sufficiently low level (<1 in 
Hg). Allow scaffolds to crosslink for 24 hours. 
5. After crosslinking is complete, turn off the vacuum pump, close the 'Vacuum' valve, open the 
'Purge' valve, then carefully remove scaffolds from the oven. Quickly seal the aluminum 
pouches, taking care to ensure that the aluminum pouches are sufficiently “puffed” so that the 
scaffolds will not be crushed during storage. Store sealed pouches with scaffolds (now sterile) in 
desiccator until time of use. 
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A.8 EDC crosslinking protocol 
Reference: [248, 251] 
Reagents 
• 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDAC, Sigma-Aldrich 
E7750); Store at -20oC 
• N-hydroxysulfosuccinimide (NHS, Sigma-Aldrich H7377); Store in desiccator 
• Sterile phosphate-buffered saline (PBS) 
• Sterile water 
• 100% ethanol 
 
Supplies and equipment 
• 6-well plates (Fisher 08-772-1B) 
• 50 mL centrifuge tubes 
• Razor blades  
• Biopsy punches (6 mm) 
• Syringe and syringe filter 
• MTS 2/4 digital microtiter shaker (IKA 3208001) 
• Dual range balance (Mettler Toledo XS105) 
 
Procedure 
* Note: all steps should be performed in the laminar flow hood unless otherwise noted. 
1. Cut scaffolds to be crosslinked to size using a razor blade or biopsy punch. 
2. Transfer scaffold pieces to sterile centrifuge tube, remove from laminar flow hood, and weigh 
pieces on dual range balance. 
3. Hydrate pieces in 100% ethanol overnight. 
4. Rinse pieces several times in PBS and then let soak in PBS for 24 h before crosslinking. 
5. Determine the EDAC and NHS concentrations to be used in crosslinking solution. The sample 
calculations in this protocol are done with a 5:2:1 EDAC:NHS:COOH molar ratio where COOH 
is carboxylic acid groups in CG material based on a conversion factor of 1.2 mmol COOH per 
gram of collagen [338]. The mass of EDAC and NHS required can be calculated as follows: 





















EDAC
EDAC
COOH
EDAC
collagen
COOH
scaffoldEDAC
mol
g
mol
mol
g
mol
MM
1
7.191
1
5
0012.0  (Equation A.1) 
172 
 
 





















NHS
NHS
COOH
NHS
collagen
COOH
scaffoldNHS
mol
g
mol
mol
g
mol
MM
1
0.116
1
2
0012.0  (Equation A.2) 
 
6. Mix the EDAC and NHS in sterile water. Approximately 0.75 mL of solution will be needed 
per scaffold piece (6-8 mm diameter, 3-5 mm thick).  
7. In the laminar flow hood, sterile filter the solution and add to 6-well plates. 
8. Add scaffolds in crosslinking solution and place well plate on digital microtiter shaker in 
incubator at 37oC. Allow scaffolds to crosslink under moderate shaking for 30-120 min. 
Crosslinking time should be increased for less permeable constructs such as membranes and high 
solids content scaffolds. 
9. Remove EDAC/NHS solution and rinse scaffolds in sterile PBS under moderate shaking for 
10-15 min. 
10. Remove first PBS wash solution and rinse scaffolds in fresh PBS under moderate shaking for 
an additional 30-45 min. Store in fresh sterile PBS at 4°C until use. 
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APPENDIX B: CELL CULTURE AND ASSAY PROTOCOLS 
 
B.1 Tenocyte culture protocol 
Reference: [61, 251, 253] 
Reagents 
• Complete tendon cell media (500 mL); Store at 4oC 
435 mL high glucose DMEM (Fisher SH30022.FS) 
50 mL fetal bovine serum (Invitrogen 16140-071) 
5 mL pen-strep (Invitrogen 15140-122) 
5 mL L-glutamine (Invitrogen 25030-081) 
5 mL amphotericin B solution (MP Biomedical 091672348) 
25 mg ascorbic acid (Wako 014-04801) 
Sterile filter before use 
• DMSO (Fisher D128-500) 
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS)  
• Trypsin-EDTA (Invitrogen 25300-062)  
• Trypan blue (Sigma-Aldrich T8154) 
 
Supplies and equipment 
• Sterile filter 
• Sterile pipettes (5, 10, 25 mL) 
• T75 tissue culture flasks 
• Hausser phase contrast hemocytometer  
• Tabletop centrifuge 
• Optical microscope 
• Water bath (37oC) 
 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted. 
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 Tendon cell thawing procedure 
1. Place complete tendon cell media in water bath and warm to 37oC. 
2. Thaw frozen cell vials in 37oC water bath for about 2 min. 
3. Transfer the thawed cells and freezing media to a 15 mL centrifuge tube. Add complete 
tendon cell media until the cerulean effect has dissipated, then bring the volume up to 10 mL. 
4. Gently re-suspend the cells in the diluted media and pellet the cells at 1000 rpm for 7 min. 
5. Aspirate off the media supernatant and add a total of 5-10 mL of media to the conical tubes 
depending on desired dilution for counting. 
6. Mix the 10 μL cell suspension aliquot with 10 μL of Trypan blue. Pipette several times to mix 
the stain and cell suspension. 
7. Place a cover slip on the hemocytometer and pipette 10 μL of the stain/cell suspension into the 
hemocytometer. 
8. Cell counts are performed in as many of the nine separate regions of the hemocytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue). 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume) 
9. Seed the cells at the required density (usually 10,000-50,000 cells/cm2). Use around 10-12 mL 
media for a 100 mm dish, 12-14 mL for a T75, or 7-8 mL for a T25. 
10. Place the flask(s) into the incubator. Check the confluence every 24 h and feed cells every 72 
h. 
 
 Tendon cell feeding procedure 
1. Warm complete tendon cell media and sterile PBS in water bath to 37oC. 
2. When the media and PBS are warm, wipe them dry with paper towel and spray with 70% 
ethanol before placing in the sterile hood.  
3. Remove all old media from each flask, taking care not to scrape the cells with the pipette tip. 
4. Add 12-14 mL of complete tendon cell media. Return the flasks to the incubator and repeat 
every 72 h. 
 
 Tendon cell passaging procedure 
1. Warm complete tendon cell media, sterile PBS, and 3 mL trypsin-EDTA per T75 flask to be 
passaged in water bath to 37oC.  
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2. When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray with 
70% ethanol before placing in the sterile hood. 
3. Remove all old media from each flask, taking care not to scrape the cells with the pipette tip. 
4. Add 10 mL of PBS per flask and leave the PBS in the flask to rinse the cells for 30 s. Swirl 
gently to remove any excess media from the cells. 
5. Remove the PBS and add 3 mL of trypsin per flask. Return the flasks to the incubator for 6 
min to allow for the cells to detach from the tissue culture plastic (allow the cells to sit for 3-4 
additional min in the incubator if they do not detach after 6 min). Slap flasks a few times to 
detach cells. 
6. Add 6 mL of complete tendon cell media to each flask to neutralize the trypsin and to flush 
cells off of the tissue culture plastic. 
7. Remove the trypsin, additional media, and cells from the flask and put into a conical tube. 
Remove a 10 μL cell suspension aliquot for counting. Centrifuge the cells at 1000 rpm for 7 min. 
8. While cells are spinning down, mix the 10 μL cell suspension aliquot with 10 μL of Trypan 
blue. Pipette several times to mix the stain and cell suspension. 
9. Place a cover slip on the hemocytometer and pipette 10 L of the stain/cell suspension into 
the hemocytometer. 
10. Cell counts are performed in as many of the nine separate regions of the hemocytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue). 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume) 
11. Aspirate off the media supernatant and add new media to dilute cells to desired 
concentration. 
12. Seed the cells at the required density (usually 10,000-50,000 cells/cm2). Use around 10-12 
mL media for a 100 mm dish, 12-14 mL for a T75, or 7-8 mL for a T25. 
13. Place the flask(s) into the incubator. Check the confluence every 24 h and feed cells every 72 
h. 
 
 Tendon cell freezing procedure 
1. Grow cells to confluence and replace media the day before freezing. 
2. Warm complete tendon cell media, sterile PBS, and 3 mL trypsin-EDTA per T75 flask to be 
passaged in water bath to 37oC. 
3. When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray with 
70% ethanol before placing in the sterile hood. 
4. Remove all old media from each flask, taking care not to scrape the cells with the pipette tip. 
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5. Add 10 mL of PBS per flask and leave the PBS in the flask to rinse the cells for 30 s. Swirl 
gently to remove any excess media from the cells. 
6. Remove the PBS and add 3 mL of trypsin per flask. Return the flasks to the incubator for 6 
min to allow for the cells to detach from the tissue culture plastic (allow the cells to sit for 3-4 
additional min in the incubator if they do not detach after 6 min). Slap flasks a few times to 
detach cells. 
7. Add 6 mL of complete tendon cell media to each flask to neutralize the trypsin and to flush 
cells off of the tissue culture plastic. 
8. Remove the trypsin, additional media, and cells from the flask and put into a conical tube. 
Remove a 10 μL cell suspension aliquot for counting. Centrifuge the cells at 1000 rpm for 7 min. 
9. While cells are spinning down, mix the 10 μL cell suspension aliquot with 10 μL of Trypan 
blue. Pipette several times to mix the stain and cell suspension. 
10. Place a cover slip on the hemocytometer and pipette 10 μL of the stain/cell suspension into 
the hemocytometer. 
11. Cell counts are performed in as many of the nine separate regions of the hemocytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue). 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume) 
12. Aspirate off the media supernatant and calculate volume of freezing media needed to re-
suspend 1-3 x 106 cells per mL (freezing media: 50% DMEM, 40% FBS, 10% DMSO). 
13. Aliquot cells into 1 mL cryogenic tubes and place in -20°C freezer for 1 h. 
14. Place cryogenic tubes in -80oC freezer. Cells can be stored here for up to 6 months. For 
longer-term storage, keep cells at -80oC for at least 24 h and then carefully move to liquid 
nitrogen storage in IGB. 
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B.2 hMSC culture protocol  
Reference: [88] 
Reagents  
• Complete hMSC media (500 mL); store at 4°C  
445 mL low glucose DMEM (SCS Media Facility); store at 4°C  
50 mL MSC-validated fetal bovine serum (Invitrogen 12662-029); store at -20°C  
5 mL antibiotic-antimyotic (Invitrogen 15140-122); store at -20°C  
• Trypsin-EDTA (Invitrogen 25300-062); store at -20°C  
• Trypan blue (Sigma-Aldrich T8154)  
• DMSO (Fisher D128-500)  
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS)  
 
Supplies and equipment  
• Hausser phase contrast hemacytometer (Fisher 02-671-5)  
• Tabletop centrifuge (VWR 53513-812)  
• Optical microscope (Leica Microsystems DMIL LED)  
• Water bath (37°C, Fisher 15-474-35)  
• Sterile filters  
• Sterile pipettes (5, 10, 25 mL)  
• T75 tissue culture flasks  
 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted. 
 
 MSC thawing procedure  
1. Place complete MSC media in water bath and warm to 37°C. 
2. Thaw frozen cell vials in 37°C water bath for about 2 min. 
3. Transfer the thawed cells and freezing media to a 15 mL centrifuge tube. Add complete MSC 
media until the cerulean effect has dissipated, then bring the volume up to 9 mL. 
4. Remove a 10 μL cell suspension aliquot for counting. Gently re-suspend the cells in the 
diluted media and pellet the cells at 600 g for 5 min. 
5. While cells are spinning down, mix the 10 μL cell suspension aliquot with 10 μL of Trypan 
blue. Pipette several times to mix the stain and cell suspension. 
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6. Place a cover slip on the hemacytometer and pipette 10 μL of the stain/cell suspension into the 
hemacytometer. 
7. Cell counts are performed in as many of the nine separate regions of the hemacytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue).  
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume) 
8. Seed the cells at the required density (usually 5,000-6,000 cells/cm2). Use around 10-12 mL 
media for a 100 mm dish, 12-14 mL for a T75, or 7-8 mL for a T25. 
9. Place the flask(s) into the incubator. Check the confluence every 24 h and feed every 3 days. 
Cells are usually confluent after 7-9 days. Do not use past passage 6.  
 
 MSC feeding procedure  
1. Warm complete MSC or lineage-specific induction media in water bath to 37°C. 
2. When the media is warm, wipe dry with paper towel and spray with 70% ethanol before 
placing in the sterile hood. 
3. Remove all old media from each flask or well plate, taking care not to scrape the cells with the 
pipette tip. 
4. Add appropriate volume of media. Return the flasks or well plates to the incubator and feed 
every 3 days. Adjust volume of media accordingly for different sized containers. 
 
 MSC passaging procedure  
1. Warm complete MSC media, sterile PBS, and 3 mL trypsin-EDTA per T75 flask to be 
passaged in water bath to 37°C. 
2. When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray with 
70% ethanol before placing in the sterile hood. 
3. Remove all old media from each T75 flask, taking care not to scrape the cells with the pipette 
tip. 
4. Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. 
Swirl gently to remove any excess media from the cells. Adjust volumes of PBS, media, and 
trypsin accordingly for different sized flasks. 
5. Remove the PBS and add 3 mL of trypsin per T75 flask. Return the flasks to the incubator for 
6 min to allow for the cells to detach from the tissue culture plastic (allow the cells to sit for 3-4 
additional min in the incubator if they do not detach after 6 min). Slap flasks a few times to 
detach cells. 
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6. Add 6 mL of complete MSC media to each flask to neutralize the trypsin and to flush cells off 
of the tissue culture plastic. 
7. Remove the trypsin, additional media, and cells from the flask and put into a conical tube. 
Remove a 10 μL cell suspension aliquot for counting. Centrifuge the cells at 600 g for 5 min. 
8. While cells are spinning down, mix the 10 μL cell suspension aliquot with 10 μL of Trypan 
blue. Pipette several times to mix the stain and cell suspension. 
9. Place a cover slip on the hemacytometer and pipette 10 μL of the stain/cell suspension into the 
hemacytometer. 
10. Cell counts are performed in as many of the nine separate regions of the hemacytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue).  
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume) 
11. Aspirate off the media supernatant and add new media to dilute cells to desired 
concentration. 
12. Seed the cells at the required density (usually 5,000-6,000 cells/cm2). Use around 10-12 mL 
media for a 100 mm dish, 12-14 mL for a T75, or 7-8 mL for a T25. 
13. Place the flask(s) into the incubator. Check the confluence every 24 h and feed cells every 3 
days. 
 
 MSC freezing procedure  
1. Grow cells to confluence and replace media the day before freezing. 
2. Warm complete MSC media, sterile PBS, and 3 mL trypsin-EDTA per T75 flask to be 
passaged in water bath to 37°C. 
3. When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray with 
70% ethanol before placing in the sterile hood. 
4. Remove all old media from each flask, taking care not to scrape the cells with the pipette tip. 
5. Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. 
Swirl gently to remove any excess media from the cells. Adjust volumes of PBS, media, and 
trypsin accordingly for different sized flasks. 
6. Remove the PBS and add 3 mL of trypsin per T75 flask. Return the flasks to the incubator for 
6 min to allow for the cells to detach from the tissue culture plastic (allow the cells to sit for 3-4 
additional min in the incubator if they do not detach after 6 min). Slap flasks a few times to 
detach cells. 
7. Add 6 mL of complete tenocyte media to each flask to neutralize the trypsin and to flush cells 
off of the tissue culture plastic. 
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8. Remove the trypsin, additional media, and cells from the flask and put into a conical tube. 
Remove a 10 μL cell suspension aliquot for counting. Centrifuge the cells at 600 g for 5 min. 
9. While cells are spinning down, mix the 10 μL cell suspension aliquot with 10 μL of Trypan 
blue. Pipette several times to mix the stain and cell suspension. Place a cover slip on the 
hemacytometer and pipette 10 μL of the stain/cell suspension into the hemacytometer. 
10. Cell counts are performed in as many of the nine separate regions of the hemacytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan blue). 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume) 
11. Aspirate off the media supernatant and calculate volume of freezing media needed to re-
suspend 1-10 x 106 cells per mL (freezing media: 50% complete MSC media, 40% FBS, 10% 
DMSO). 
12. Aliquot cells into 1 mL cryogenic tubes and place in -20°C freezer for 1 h. 
13. Place cryogenic tubes in -80°C freezer. Cells can be stored here for up to 6 months. For 
longer-term storage, keep cells at -80°C for at least 24 h and then carefully move to liquid 
nitrogen storage in IGB. 
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B.3 THP-1 culture protocol 
Reference: [326, 339]; Discussions with Kara Spiller (Drexel) 
Reagents  
• THP-1 cells (ATCC TIB-202) 
• Complete growth medium: 
Heat Inactivated RPMI-1640 (ATCC 30-2001) 
10% Heat Inactivated Fetal Bovine Serum (FBS) (ATCC 30-2020) 
1% Penicillin-Streptomycin (P/S) (Invitrogen 15140-122) 
(New 500ml bottle of media + 50ml FBS + 5ml P/S) 
 
Supplies and equipment  
 Hausser phase contrast hemacytometer (Fisher 02-671-5)  
 Tabletop centrifuge (VWR 53513-812)  
 Optical microscope (Leica Microsystems DMIL LED)  
 Water bath (37°C, Fisher 15-474-35)  
 T25 tissue culture flasks 
 T75 tissue culture flasks  
 
Procedure 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted. 
1. Thaw frozen cells in 37°C water bath by swirling gently. Transfer cells to a 15 ml tube, add 9 
mL of media, spin at ~130 rcf for 5 min. 
2. Remove supernatant and resuspend in 5 mL of HI-RPMI. 
3. Count cells using a hemacytometer (as described in B.1. and B.2.) 
4. Bring cell suspension to a concentration of 3x105 cell/mL. Add 2.5 mL of cell suspension in 
T25 cell culture flasks. Check daily to ensure cells are not adhering and to do a maintenance cell 
count. Renew media every 2-3 days. 
5. Subculture when cells reach a concentration of 8x105 cell/mL by adding fresh media or 
replacing media. Cultures can be established by centrifugation and subsequent resuspension at of 
3x105 cell/mL. Eventually, it will be necessary to culture in larger (T75) culture flasks. Do not 
allow the cell concentration to exceed of 1x106 cell/mL. 
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B.4 THP-1 differentiation and polarization protocol 
Reference: [326, 339]; Discussions with Kara Spiller (Drexel) 
Reagents  
• THP-1 cells (ATCC TIB-202) 
• Cytokines: LPS (Sigma L4391); IFN-γ, IL-4, IL-13, IL-10 (ProSpec; human recombinant) 
• Complete growth medium: 
Heat Inactivated RPMI-1640 (ATCC 30-2001) 
10% Heat Inactivated Fetal Bovine Serum (FBS) (ATCC 30-2020) 
1% Penicillin-Streptomycin (P/S) (Invitrogen 15140-122) 
(New 500ml bottle of media + 50ml FBS + 5ml P/S) 
• Phorbol 12-myristate-13-acetate (PMA) (Sigma P1585) 
• Accutase solution (Sigma A6964) 
 
Supplies and equipment  
 Hausser phase contrast hemacytometer (Fisher 02-671-5)  
 Tabletop centrifuge (VWR 53513-812)  
 Optical microscope (Leica Microsystems DMIL LED)  
 Water bath (37°C, Fisher 15-474-35)  
 Ultra-low attachment 6-well plates (Fisher 07-200-601) 
 Ultra-low attachment T-75 tissue culture flasks (ThermoFisher Scientific 12-565-349) 
 
1. Prepare PMA by creating a 1mg/mL solution in 100% ethanol. Divide into 50 μL aliquots and 
freeze at -20°C for future use. 
*Warning: PMA is a carcinogen. Handle and dispose of appropriately. Protect from light. 
2. To differentiate cells into macrophages, add 2 µL of PMA stock solution (100 µg/ml) for 
every 1 ml of media. This step can be performed after transferring the cells to the well or by 
mixing the cells and the PMA in a 50 mL centrifuge tube and then transferring to the appropriate 
culture flask. 
3. Resuspend cells at concentration of 1x106 cell/mL (assume 25% differentiation efficiency) 
and plate in ULA culture containers (2 mL per 6 well plate or 10 mL per T75 flask). Label the 
plates with “Caution contains PMA – Carcinogen”. 
4. Incubate the plates under standard cell culture conditions (37˚C and 5% CO2) for 3 days. 
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5. Collect media/cells in a 50ml centrifuge tube through a combination of treatment with 
accutase and cell scraping. Centrifuge and resuspend in fresh media to wash the PMA from the 
cells. Now the cells are M0 and can be used for 2D (concentration guidelines below) or 3D 
culture. 
*Dispose of PMA-contaminated media through DRS waste management.  
 
Well 
Plate 
Surface 
area 
Cells/well Vfinal/well Stock (Cellls/ml) 
T25Flask 25 cm2 2.5 x106 2.5 ml 1.0 x106 cells/ml 
6 9.8 cm2 1.0x106 2 ml 0.5x106 cells/ml 
12 3.8 cm2 0.4x106 1 ml 0.4x106 cells/ml 
24 2.0 cm2 0.2x106  0.5 ml 0.4x106 cells/ml 
96 0.32 cm2 0.3x105 200 µl 0.1x106 cells/ml 
 
6. To polarize M0 macrophages to different phenotypes, add complete growth medium and add 
cytokines as follows. Incubate under standard conditions for 48 hours. 
*Note: Always include a control where no cytokines are added and cells are cultured under 
similar conditions. 
 
M0 M1 M2a M2c 
Just media 
   
100ng/ml IFNy 
100ng/ml LPS 
40ng/ml IL-4 
20ng/ml IL-13 
40ng/ml IL-10 
 NOTE: No MSCF is needed for these cells since the PMA is what differentiates the 
THP-1 monocytes into macrophages. 
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B.5 Cell seeding on CG scaffolds protocol 
Reference: [61, 251] 
Reagents 
• Complete media for specific cell type; store at 4ºC 
• Trypsin-EDTA (Invitrogen 25300-062); store at -20ºC 
• Trypan blue (Sigma-Aldrich T8154) 
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS) 
 
Supplies and equipment 
• Ultra-low attachment 6-well plates (Fisher 07-200-601) 
• Hausser phase contrast hemacytometer (Fisher 02-671-5) 
• Tabletop centrifuge (VWR 53513-812) 
• Optical microscope (Leica Microsystems DMIL LED) 
• Water bath (37ºC, Fisher 15-474-35) 
• Sterile pipettes (5, 10, 25 mL) 
• Kimwipes 
 
Procedure 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted. 
1. Soak scaffolds overnight in the media to be used for seeding (0.5 mL per scaffold). 
2. Warm complete media, sterile PBS, and 3 mL trypsin-EDTA per T75 flask in water bath to 
37ºC. 
3. When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray with 
70% ethanol before placing in the sterile hood. 
4. Remove all old media from each flask, taking care not to scrape the cells with the pipette tip. 
5. Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. 
Swirl gently to remove any excess media from the cells. Adjust volumes of PBS, media, and 
trypsin accordingly for different sized flasks. 
6. Remove the PBS and add 3 mL of trypsin per flask. Return the flasks to the incubator for 6 
min to allow for the cells to detach from the tissue culture plastic. Tap flasks until cells 
detach. 
7. Add 6 mL of complete cell media to each flask to neutralize the trypsin and to flush cells off 
of the tissue culture plastic. 
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8. Remove the trypsinized cell solution from the flask and put into a conical tube. Centrifuge the 
cells at 1000 rpm for 7 min (tenocytes), 600 g for 5 min (hMSC), or 130 g for 5 min 
(macrophages; follow B.4. protocol prior to this step). 
9. Resuspend the cell pellet in a small volume of media. 
10. Mix the 10 μL cell suspension aliquot with 10 μL of Trypan blue (90 μL for macrophages). 
Pipette several times to mix the stain and cell suspension. 
11. Place a cover slip on the hemacytometer and pipette 10 μL of the stain/cell suspension into 
the hemacytometer. 
12. Cell counts are performed in as many of the nine separate regions per side of the 
hemacytometer as is feasible (Typically four corners and center). Average number of cells 
per region is used to calculate the total cell population. For this calculation, the dilution 
factor is 2 (for tenocytes and hMSCs) or 10 (for macrophages). 
13. Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume) 
14. Add additional media to dilute cells to desired concentration (usually 5 x 105 for tenocytes, 1 
x 105 for hMSCs, and ~8 x 105 for macrophages) per 20 μL. 
15. Carefully remove excess media from scaffolds with a Kimwipe and place 3-4 scaffold pieces 
in each well of Ultra-low attachment 6-well plates. Do not overdry scaffolds as this will lead 
to reduced viability. 
16. Add 10 μL of cell suspension to each scaffold piece. Place scaffolds in incubator for 15 mins. 
Remove scaffolds from incubator, flip over, add additional 10 μL of cell suspension to the 
other side of each scaffold, and return to incubator for 2 h to allow for cell attachment. 
17. Carefully add 5-6 mL complete media per well to each well. Change media every 3 days over 
the course of the experiment. 
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B.6 alamarBlue metabolic activity protocol 
Reference: [61, 251, 340] 
 
Reagents 
• Complete cell media for cell type of interest (described in B.1.-B.3.); Store at 4°C 
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS) 
• alamarBlue (Invitrogen DAL1100) 
 
Supplies and equipment 
• 24-well plates (Fisher 08-772-1) 
• 96-well plates 
• MTS 2/4 digital microtiter shaker (IKA 3208001) 
• Water bath (37°C) 
• Fluorescent spectrophotometer (Varian) 
 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted. The 
volumes of reagents used are correct for 8 mm diameter, 5 mm thick scaffold pieces. 
 
Procedure 
1. Warm media, sterile PBS, and alamarBlue in water bath to 37°C.  
2. Before starting an experiment, generate a standard curve with a known number of cells. Do at 
least eight sample points: one well with just media, one well with media and alamarBlue, and 
then six wells with media, alamarBlue, and a different number of cells (usually ranging 25-300% 
of the number of cells seeded in the scaffolds). 
3. Add media and cell suspension in different ratios to each well so that the total volume is 900 
μL. Two wells should not have any cells. 
4. Add 100 μL alamarBlue to each well except for one without cells. Incubate at 37°C under 
gentle (~50 rpm) shaking for 2-4 h. During this time, healthy cells convert the active ingredient 
in alamarBlue (resazurin) to the highly fluorescent resorufin. Make sure not to incubate cells too 
long or all of the resazurin will be reduced to resorufin. 
5. After incubation, pipette 100 μL in triplicate from each sample well into a 96-well plate. 
6. Measure fluorescence (excitation: 570 nm, emission: 585 nm) on the spectrophotometer. Use 
the 'Kinetics' program in the Cary Eclipse software to read plate '96 well clear.' 
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7. For measuring cell metabolic activity on scaffolds, pipette 900 μL media into each well (one 
well for each scaffold piece plus two control wells). Add 100 μL alamarBlue to each well except 
for one control well. 
8. Remove scaffolds to be assayed and rinse in warm, sterile PBS to remove excess media and 
unattached/dead cells. Add scaffolds to experimental wells and incubate at 37oC under gentle 
(~50 rpm) shaking for 2-4 h. The incubation time should be identical to the time used to make 
the standard curve. 
9. After incubation, pipette 100 μL L in triplicate from each sample well into a 96-well plate. 
10. Measure fluorescence (excitation: 570 nm, emission: 585 nm) on the spectrophotometer. Use 
the 'Kinetics' program in the Cary Eclipse software to read plate '96 well clear.' Fluorescent 
intensity can be extrapolated on standard curve to give metabolic activity. 
11. This assay is non-destructive so scaffolds can continue to be cultured for longer times.  
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B.7 Hoechst DNA quantification protocol 
Reference: [61, 251, 341]  
Reagents 
• Hoechst dye buffer (500 mL); store at 4ºC for up to 3 months 
400 mL deionized water 
58.44 g sodium chloride (RAL storeroom) 
0.605 g Tris base (RAL storeroom) 
0.185 g disodium EDTA (Sigma-Aldrich E5134) 
Adjust pH to 7.4, bring total volume to 500 mL, sterile filter before use 
• Papain buffer (100 mL); store at 4ºC 
100 mLsterile phosphate-buffered saline without Ca2+ or Mg2+ PBS 
1 mL 0.5 M EDTA (pH = 8.0, Sigma-Aldrich EDS); store at 4ºC 
79 mg cysteine-HCl (Sigma-Aldrich 00320) 
• Hoechst 33258 dye solution (1 mL); store at 4ºC for up to 6 months 
1 mL sterile water 
1 mg Hoechst 33258 dye (Invitrogen H1398); store at 4ºC 
• Papain from Carica papaya (Sigma-Aldrich 76218); store at -20ºC 
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS) 
 
Supplies and equipment 
• 96-well plates (Fisher 12-565-369) 
• Vortex (Fisher 02-215-365) 
• Water bath (60ºC, Fisher 15-460-2SQ) 
• Fluorescence spectrophotometer (Tecan, Room 104 RAL) 
• Microcentrifuge tubes (1.5 mL) 
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Procedure 
 
*Note: steps 1-2 should be performed in the laminar flow hood. 
 
 Standard Curve Procedure 
1. At the beginning of each experiment, a standard curve should be generated with a known 
number of cells. Make up active papain enzyme solution by dissolving 2.4 mg papain in 1mL 
papain buffer in the 60ºC water bath. 
2. In 1.5 mL microcentrifuge tube, spin down 100 μL of cell solution (5 times cell seeding 
volume) for 3 min at 12000 rpm. 
3. Remove supernatant and add 300 μL papain enzyme solution to tube. Pipette to resuspend 
cells. Allow to digest for 24 h in the 60ºC water bath. 
4. After 24 h, vortex cell lysate thoroughly. 
5. Prepare 1 mL of digest by dissolving 2.4 mg papain in 1 mL papain buffer in the 60ºC water 
bath. 
6. Perform half dilutions to prepare standard (5x, 2.5x, 1.25x, 0.625x, 0.3125x cells seeded plus 
control). Label tubes for 2.5-.3125x points and add 150 μL of papain enzyme solution to each 
tube. Starting with the 2.5x sample, add 150 μL from the next higher concentration tube to the 
tube and vortex (150 μL from 5x into 2.5x, then 150 μL from x into 1.25x, etc.). 
7. Prepare Hoechst working dye solution by adding 0.5 μL dye solution to 5 mL Hoechst dye 
buffer. Vortex thoroughly. Prepare a second set of microcentrifuge tubes. To each tube add 600 
μL of dye solution and 30 μL of corresponding cell lysate for a total volume of 630 μL. Vortex 
thoroughly. The Hoechst dye fluorescently binds to double-stranded DNA from the lysed cells, 
allowing quantification of DNA and thus cell number. 
8. Pipette 190 μL from each tube in triplicate into a black 96-well plate. 
9. Measure fluorescence (excitation: 360 nm, emission: 465 nm) on the spectrophotometer in 
RAL 104. Use the ‘DNA F200’ program and remember to reserve the F200 machine on the 
Google Calendar prior to use. For each data point, adjust the fluorescence reading by subtracting 
the reading from the blank control. The standard curve is created by plotting cell number as a 
function of adjusted fluorescent intensity. 
 
 Cell Quantification Procedure 
 
*Note: step 2 should be performed in the laminar flow hood. 
 
1. For measuring cell number on scaffolds, pipette 300 μL of papain enzyme solution into 
microcentrifuge tubes (one for each scaffold plus controls: one tube containing a blank scaffold 
with no seeded cells as a background control). 
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2. Remove scaffolds to be assayed and rinse in warm, sterile PBS to remove excess media and 
unattached/dead cells. Add scaffolds to microcentrifuge tubes and incubate in 60ºC water bath 
for 24 h. Vortex occasionally to facilitate digestion of scaffold. 
3. After incubation, pipette 600 μL Hoechst working dye solution into new set of 
microcentrifuge tubes. 
4. Remove samples from water bath and vortex thoroughly. Add 30 μL from each tube to its 
corresponding tube containing working dye solution. Vortex thoroughly. 
5. Pipette 190 μL from each tube in triplicate from each sample well into a 96-well plate. 
6. Measure fluorescence (excitation: 360 nm, emission: 465 nm) on the spectrophotometer in 
RAL 104. Use the ‘DNA F200’ program and remember to reserve the F200 machine on the 
Google Calendar prior to use. For each data point, adjust the fluorescence reading by subtracting 
the reading from the background control. Adjusted fluorescent intensity can be extrapolated on 
the standard curve to give a cell number.   
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B.8 RNA isolation and quantification protocol 
Reference: [60, 342] 
Reagents  
• RNeasy Plant Mini Kit (Qiagen 74904)  
• β-mercaptoethanol (Sigma M7522-100ML)  
• 70% ethanol (use RNase free water when making solution)  
• Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS)  
• RNase-free water  
• Ice  
 
Supplies and equipment  
• 2 mL RNase free non-graduated microcentrifuge tubes  
• RNase free pipette tips  
• Ice bucket  
• Kimwipes  
• Microcentrifuge  
 
Procedure  
 Reagent prep (before starting) 
1. Lysis buffer: Add 10 μL β-mercaptoethanol (14.3 M) per 1 mL of Buffer RLT supplied with 
Qiagen kit. This solution can be stored at room temperature for 1 month.  
2. Buffer RPE: Add 4 volumes of 100% ethanol to the bottle of Buffer RPE supplied with 
Qiagen kit.  
 
 RNA Extraction  
*Note: All steps are performed at room temperature. Work quickly; limit the number of samples 
for RNA extraction to 18-24 in each sitting. RNase free tips should be used throughout. 
1. Label one microcentrifuge tube for each sample.  
2. Put some ice (2nd floor RAL) in an ice bucket.  
3. Wash scaffolds in PBS three times, cut in half with razor blade, and then place in labeled 
tubes. 
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4. Add ~ 500 μL of ice-cold lysis buffer to each tube and keep on ice for ~ 5 min, shaking tubes 
periodically to help the buffer infiltrate the scaffolds. Scale amount of lysis buffer appropriately. 
5. Pipette lysate into a labeled QIAShredder column. Place scaffold pieces in column as well. 
Spin at 14,000 rpm for 2.5 min. 
6. Add equal volume of 70% ethanol to each sample and mix by pipetting up and down. 
7. Add half of the lysate + ethanol to labeled RNeasy column (with 2-mL collection tube). 
8. Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
9. Add the remaining lysate + ethanol to the column. 
10. Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
11. Add 700 μL Buffer RW1 to the column. 
12. Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
13. Pipet 500 μL Buffer RPE into the column. 
14. Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
15. Add another 500 μL Buffer RPE into the column. 
16. Centrifuge at 12,000 rpm for 2.5 min. Discard flow-through and place the column in a new 2 
mL collection tube (supplied with kit). 
17. Centrifuge at 12,000 rpm for 2.0 min. 
18. Transfer the column to a new labeled, 1.5-mL collection tube. 
19. Pipet 30 μL RNase-free water into the column and wait 5 min. 
20. Centrifuge the RNeasy column at 12,000 rpm for 1.5 min. 
21. Store RNA at -80°C for later use or put on ice if directly proceeding to quantification, reverse 
transcription, and RT-PCR. 
22. If quantifying RNA, use 2 μL water to blank the NanoDrop Lite (set to the RNA menu). 
Quantify RNA by pipetting 2 μL of each sample onto pedestal and pushing the ‘sample’ button. 
Clean platform with a Kimwipe between each sample. 
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B.9 RNA reverse transcription protocol 
Reference: [60, 342] 
Reagents: 
• QuantiTect Reverse Transcription Kit (Qiagen 205313) 
• RNA samples 
• Ice 
 
Supplies and equipment 
• BIO-RAD S1000 ThermoCycler 
• Ice bucket 
• 200 μL microcentrifuge tubes 
 
Procedure 
1. Label PCR tubes for number of reactions needed and defrost reverse transcription kit 
components on ice if needed. Keep kit components and RNA samples on ice. Turn on 
thermocycler so it can warm up.  
2. Label 200 μL conical tubes with sample identifiers (1 per sample). 
3. Calculate the volume of RNA sample required for a 10 μL reaction (typically 10 ng of cDNA 
will be desired per well for subsequent RT-PCR experiment): 
𝑉𝑜𝑙 𝑜𝑓 𝑅𝑁𝐴 =  
10 𝑛𝑔 ∗ # 𝑜𝑓 𝑝𝑟𝑖𝑚𝑒𝑟 𝑠𝑒𝑡𝑠 ∗ # 𝑜𝑓 𝑟𝑒𝑝𝑒𝑎𝑡𝑠 ∗ 1.10
[𝑅𝑁𝐴]
 
*Note: 1.10 is for 10% excess. 
4. Calculate the amount of water needed for each reaction (RNA+water = 6uL total volume) 
Note: If the total RNA volume necessary is above 6 μL, use only 6 μL. 
5. Pipette the required amount of water into each 200 μL conical tube. 
6. Add 1 μL of gDNA wipeout and mix (vortex or pipette) each conical tube. 
7. Add required RNA volumes to each tube, mix, and close lids. 
8. Load samples into thermocycler. Close lid with extra quarter turn of tightness. 
9. Run the ‘CAV1’ program. Change volume to 10 μL. This will begin by incubating the 
samples at 42°C for 2 min.  
10. While the first step is running, prepare reaction buffer. Note that the RT buffer (green tubes) 
and the Primer Mix (purple tubes) can be combined in one tube. If you do this, place a check 
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mark on the lid of the green tube. Combine 2.5 μL of RT buffer/primer mix with 0.5 μL reverse 
transcriptase (red tubes) per sample (make enough for at least n+2 reactions) into a single tube 
and vortex well. 
11. Pipet 3 μL of reaction buffer mix into each PCR tube once the 2 min initial incubation is 
complete. Close tubes, lid, and then press enter to skip to the next step, which is a 15 min 
incubation at 42°C followed by 95°C incubation for 3 min. 
12. When cycle is complete, remove samples and store at -20°C.  
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B.10 PCR protocol 
Reference: [60, 342] 
Reagents  
• QuantiTect SYBR Green Kit (Qiagen 204145); store at -20°C although individual kit aliquots 
may be stored at 4°C once opened.  
• Primers (Integrated DNA Technologies)  
Dilute to 30 μM in TE buffer (pH = 8.0)  
Aliquot and store at -20°C or keep at 4°C  
• Ice  
• DNase removal buffer  
 
Supplies and equipment  
• Rainier multi-pipettes  
• 384-well plates (Invitrogen 4309849)  
• Plate covers (Invitrogen 4311971)  
• Sealing tool  
• Rainier pipette tips (VWR)  
• RNase-free PCR tubes (500 μL, CLSL stockroom)  
• Ice bucket  
• Vortex (Fisher 02-215-365)  
• Applied Biosystems 7900HT Fast Real-Time PCR system (Applied Biosystems)  
• Sequence Detection Systems software v2.4 (Applied Biosystems)  
 
Procedure  
 
*Note: keep PCR area as clean as possible and remember to wipe down area with DNase 
removal buffer following each plate prep. Remember to reserve time on the PCR system on the 
IGB website (each plate takes 1 h 55 min to run). 
 
1. Diagram plate layout and determine the amount of water, SYBR green, and primers you will 
need. Master mix 1 consists of SYBR green and primers and is added at 5.2 μL per well for 10 
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μL reactions. Master mix 2 is RNase-free water and cDNA and is added at 4.8 μL per well for 10 
μL reactions. Make up 10% excess reagent for each mix. 
2. Make up master mix 1 (V = 5.2μL * # of cDNA samples * # of replicates*110%;) for each 
primer set. Each replicate for a 10 μL reaction requires 5 μL of SYBR green, 0.1 μL forward 
primer, 0.1 μL of reverse primer. Mix primers before pipetting. 
3. Make up master mix 2 (V = 4.8μL*# of genes * # of replicates * 110%) for each sample. 
4. Vortex each tube of master mix 1 thoroughly and pipet into wells. 
5. Vortex each tube of master mix 2 thoroughly and pipet into wells. 
6. Place cover on plate. Make sure the plate is sealed tightly on all edges with the sealing tool. 
7. Keep plate protected from light at 4°C until ready to analyze. 
8. Transport to IGB 124A and set up plate on PCR machine. Follow instructions obtained during 
training on machine, making sure to add extra stage to determining product melting point. SYBR 
green dye non-specifically binds to all DNA, so the melting curve must be obtained to confirm 
the presence of a single product. 
9. Analyze results using the Sequence Detection Systems software to obtain Ct values. For 
multiple plates, make sure the threshold is set at the same number for each primer pair. Calculate 
fold changes in expression using the delta-delta Ct method. 
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